US20120040101A1 - Techniques to improve polyurethane membranes for implantable glucose sensors - Google Patents
Techniques to improve polyurethane membranes for implantable glucose sensors Download PDFInfo
- Publication number
- US20120040101A1 US20120040101A1 US13/283,397 US201113283397A US2012040101A1 US 20120040101 A1 US20120040101 A1 US 20120040101A1 US 201113283397 A US201113283397 A US 201113283397A US 2012040101 A1 US2012040101 A1 US 2012040101A1
- Authority
- US
- United States
- Prior art keywords
- polymer
- membrane
- glucose
- solution
- hydrophilic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000012528 membrane Substances 0.000 title claims abstract description 184
- 239000008103 glucose Substances 0.000 title claims abstract description 134
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title claims abstract description 130
- 238000000034 method Methods 0.000 title claims description 45
- 229920002635 polyurethane Polymers 0.000 title claims description 29
- 239000004814 polyurethane Substances 0.000 title claims description 29
- 229920000642 polymer Polymers 0.000 claims abstract description 101
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 44
- 239000011159 matrix material Substances 0.000 claims abstract description 36
- 239000012491 analyte Substances 0.000 claims description 37
- 239000000203 mixture Substances 0.000 claims description 37
- 238000009792 diffusion process Methods 0.000 claims description 30
- 229920001577 copolymer Polymers 0.000 claims description 19
- 230000035699 permeability Effects 0.000 claims description 19
- 238000006243 chemical reaction Methods 0.000 claims description 11
- 229920001480 hydrophilic copolymer Polymers 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 9
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 8
- 229920001519 homopolymer Polymers 0.000 claims description 7
- 229920001296 polysiloxane Polymers 0.000 claims description 5
- 239000004952 Polyamide Substances 0.000 claims description 4
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 229920002647 polyamide Polymers 0.000 claims description 4
- 229920000728 polyester Polymers 0.000 claims description 4
- 229920000570 polyether Polymers 0.000 claims description 4
- -1 polysiloxane Polymers 0.000 claims description 4
- 229920002554 vinyl polymer Polymers 0.000 claims description 4
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 3
- 230000037361 pathway Effects 0.000 claims description 2
- 239000000178 monomer Substances 0.000 claims 4
- 239000004721 Polyphenylene oxide Substances 0.000 claims 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 42
- 239000001301 oxygen Substances 0.000 abstract description 42
- 229910052760 oxygen Inorganic materials 0.000 abstract description 42
- 230000032258 transport Effects 0.000 abstract description 9
- 230000001105 regulatory effect Effects 0.000 abstract description 4
- 230000006377 glucose transport Effects 0.000 abstract description 2
- 238000000576 coating method Methods 0.000 description 31
- 102000004190 Enzymes Human genes 0.000 description 30
- 108090000790 Enzymes Proteins 0.000 description 30
- 239000011248 coating agent Substances 0.000 description 30
- 229940088598 enzyme Drugs 0.000 description 30
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 24
- 239000000243 solution Substances 0.000 description 20
- 229920001400 block copolymer Polymers 0.000 description 15
- 239000000463 material Substances 0.000 description 15
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 13
- 210000001124 body fluid Anatomy 0.000 description 13
- 239000010839 body fluid Substances 0.000 description 13
- 238000005259 measurement Methods 0.000 description 11
- 235000019420 glucose oxidase Nutrition 0.000 description 10
- 108010015776 Glucose oxidase Proteins 0.000 description 8
- 239000004366 Glucose oxidase Substances 0.000 description 8
- 229940116332 glucose oxidase Drugs 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 230000008859 change Effects 0.000 description 6
- 125000005442 diisocyanate group Chemical group 0.000 description 6
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 5
- 239000013060 biological fluid Substances 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 238000005266 casting Methods 0.000 description 4
- 239000007795 chemical reaction product Substances 0.000 description 4
- 230000001276 controlling effect Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000036571 hydration Effects 0.000 description 4
- 238000006703 hydration reaction Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000002736 nonionic surfactant Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000000376 reactant Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 108010093096 Immobilized Enzymes Proteins 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 229920001600 hydrophobic polymer Polymers 0.000 description 3
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000006482 condensation reaction Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000006059 cover glass Substances 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 150000002009 diols Chemical class 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000012208 gluconic acid Nutrition 0.000 description 2
- 239000000174 gluconic acid Substances 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000012035 limiting reagent Substances 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 229920003226 polyurethane urea Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000004970 Chain extender Substances 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 108010015133 Galactose oxidase Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- NXGQWVKSKOYDIA-UHFFFAOYSA-N O=O.OO Chemical compound O=O.OO NXGQWVKSKOYDIA-UHFFFAOYSA-N 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010092464 Urate Oxidase Proteins 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000003487 electrochemical reaction Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 229920000592 inorganic polymer Polymers 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000000879 optical micrograph Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000006395 oxidase reaction Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000005702 oxyalkylene group Chemical group 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002959 polymer blend Polymers 0.000 description 1
- 229920005597 polymer membrane Polymers 0.000 description 1
- 239000002952 polymeric resin Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 229920013730 reactive polymer Polymers 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1486—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using enzyme electrodes, e.g. with immobilised oxidase
- A61B5/14865—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using enzyme electrodes, e.g. with immobilised oxidase invasive, e.g. introduced into the body by a catheter or needle or using implanted sensors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1468—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means
- A61B5/1473—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means invasive, e.g. introduced into the body by a catheter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1486—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using enzyme electrodes, e.g. with immobilised oxidase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/12—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D69/00—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor
- B01D69/14—Dynamic membranes
- B01D69/141—Heterogeneous membranes, e.g. containing dispersed material; Mixed matrix membranes
- B01D69/1411—Heterogeneous membranes, e.g. containing dispersed material; Mixed matrix membranes containing dispersed material in a continuous matrix
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D71/00—Semi-permeable membranes for separation processes or apparatus characterised by the material; Manufacturing processes specially adapted therefor
- B01D71/06—Organic material
- B01D71/54—Polyureas; Polyurethanes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D71/00—Semi-permeable membranes for separation processes or apparatus characterised by the material; Manufacturing processes specially adapted therefor
- B01D71/06—Organic material
- B01D71/76—Macromolecular material not specifically provided for in a single one of groups B01D71/08 - B01D71/74
- B01D71/80—Block polymers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D3/00—Pretreatment of surfaces to which liquids or other fluent materials are to be applied; After-treatment of applied coatings, e.g. intermediate treating of an applied coating preparatory to subsequent applications of liquids or other fluent materials
- B05D3/007—After-treatment
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D5/00—Processes for applying liquids or other fluent materials to surfaces to obtain special surface effects, finishes or structures
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/001—Enzyme electrodes
- C12Q1/002—Electrode membranes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/001—Enzyme electrodes
- C12Q1/005—Enzyme electrodes involving specific analytes or enzymes
- C12Q1/006—Enzyme electrodes involving specific analytes or enzymes for glucose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2562/00—Details of sensors; Constructional details of sensor housings or probes; Accessories for sensors
- A61B2562/02—Details of sensors specially adapted for in-vivo measurements
- A61B2562/028—Microscale sensors, e.g. electromechanical sensors [MEMS]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2562/00—Details of sensors; Constructional details of sensor housings or probes; Accessories for sensors
- A61B2562/12—Manufacturing methods specially adapted for producing sensors for in-vivo measurements
- A61B2562/125—Manufacturing methods specially adapted for producing sensors for in-vivo measurements characterised by the manufacture of electrodes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/31504—Composite [nonstructural laminate]
- Y10T428/31551—Of polyamidoester [polyurethane, polyisocyanate, polycarbamate, etc.]
Definitions
- the present invention relates generally to membranes for use in combination with implantable devices for evaluating an analyte in a body fluid. More particularly, the invention relates to membranes for controlling the diffusion of glucose therethrough to a glucose sensor.
- a biosensor is a device that uses biological recognition properties for the selective analysis of various analytes or biomolecules. Generally, the sensor will produce a signal that is quantitatively related to the concentration of the analyte.
- a great deal of research has been directed toward the development of a glucose sensor that would function in vivo to monitor a patient's blood glucose level. Such a glucose sensor is useful in the treatment of diabetes mellitus.
- an implantable glucose sensor that would continuously monitor the patient's blood glucose level would provide a physician with more accurate information in order to develop optimal therapy.
- One type of glucose sensor is the amperometric electrochemical glucose sensor.
- an electrochemical glucose sensor employs the use of a glucose oxidase enzyme to catalyze the reaction between glucose and oxygen and subsequently generate an electrical signal.
- the reaction catalyzed by glucose oxidase yields gluconic acid and hydrogen peroxide as shown in the reaction below (equation 1):
- the current measured by the sensor is generated by the oxidation of the hydrogen peroxide at a platinum working electrode.
- the hydrogen peroxide is stoichiometrically related to the amount of glucose that reacts with the enzyme.
- the ultimate current is also proportional to the amount of glucose that reacts with the enzyme.
- the current will be proportional to the oxygen concentration, not the glucose concentration.
- glucose must be the limiting reagent, i.e., the oxygen concentration must be in excess for all potential glucose concentrations. Unfortunately, this requirement is not easily achieved.
- U.S. Pat. No. 5,322,063 to Allen et al. teaches that various compositions of hydrophilic polyurethanes can be used in order to control the ratios of the diffusion coefficients of oxygen to glucose in an implantable glucose sensor.
- various polyurethane compositions were synthesized that were capable of absorbing from 10 to 50% of their dry weight of water.
- the polyurethanes were rendered hydrophilic by incorporating polyethyleneoxide as their soft segment diols.
- One disadvantage of this invention is that the primary backbone structure of the polyurethane is sufficiently different so that more than one casting solvent may be required to fabricate the membranes. This reduces the ease with which the membranes may be manufactured and may further reduce the reproducibility of the membrane.
- U.S. Pat. Nos. 5,777,060 and 5,882,494, each to Van Antwerp also disclose homogeneous membranes having hydrophilic domains dispersed throughout a hydrophobic matrix to reduce the amount of glucose diffusion to the working electrode of a biosensor.
- U.S. Pat. No. 5,882,494 to Van Antwerp discloses a membrane including the reaction products of a diisocyanate, a hydrophilic diol or diamine, and a silicone material.
- polymeric membranes that can be prepared from (a) a diisocyanate, (b) a hydrophilic polymer, (c) a siloxane polymer having functional groups at the chain termini, and optionally (d) a chain extender.
- Polymerization of these membranes typically requires heating of the reaction mixture for periods of time from 1 to 4 hours, depending on whether polymerization of the reactants is carried out in bulk or in a solvent system. Therefore, it would be beneficial to provide a method of preparing a homogenous membrane from commercial polymers.
- one skilled in the art cannot simply change the polymer composition and be able to predict the oxygen to glucose permeability ratios. Therefore, a large number of polymers would need to be synthesized and coating or casting techniques optimized before a desired specific oxygen to glucose permeability ratio could be obtained.
- a further membrane is disclosed in U.S. Pat. No. 6,200,772 B1 to Vadgama et al. that has hydrophilic domains dispersed substantially throughout a hydrophobic matrix for limiting the amount of glucose diffusing to a working electrode.
- the patent describes a sensor device that includes a membrane comprised of modified polyurethane that is substantially non-porous and incorporates a non-ionic surfactant as a modifier.
- the non-ionic surfactant is disclosed as preferably including a poly-oxyalkylene chain, such as one derived from multiple units of poly-oxyethylene groups.
- the non-ionic surfactant may be incorporated into the polyurethane by admixture or through compounding to distribute it throughout the polyurethane.
- the non-ionic surfactant is, according to the specification, preferably incorporated into the polyurethane by allowing it to react chemically with the polyurethane so that it becomes chemically bound into its molecular structure. Like most reactive polymer resins, complete reaction of the surfactant into the polyurethane may never occur. Therefore, a disadvantage of this membrane is that it can leach the surfactant over time and cause irritation at the implant site or change its permeability to glucose.
- PCT Application WO 92/13271 discloses an implantable fluid measuring device for determining the presence and the amounts of substances in a biological fluid that includes a membrane for limiting the amount of a substance that passes therethrough.
- this application discloses a membrane including a blend of two substantially similar polyurethane urea copolymers, one having a glucose permeability that is somewhat higher than preferred and the other having a glucose permeability that is somewhat lower than preferred.
- FIG. 1 shows a photomicrograph at 200 ⁇ magnification of a prior art cast polymer blend following hydration.
- a disadvantage of the prior art membranes is that, upon thermodynamic separation from the hydrophobic portions, the hydrophilic components form undesirable structures that appear circular 1 and elliptical 2 when viewed with a light microscope when the membrane 3 is hydrated, but not when it is dry. These hydrated structures can be detected by photomicroscopy under magnifications in the range of between 200 ⁇ -400 ⁇ , for example. They have been shown by the present inventors to be non-uniform in their dimensions throughout the membrane, with some being of the same size and same order of dimensions as the electrode size.
- a continuous path 16 by which glucose may traverse along the hydrophilic segments 10 that are dispersed in hydrophobic sections 12 of the membrane.
- glucose is able to traverse a fairly continuous path along assembled hydrophilic segments 10 from the side 18 of the membrane in contact with the body fluid containing glucose to the sensing side 20 proximal to sensor 22 , where an electrode 24 is placed at position 26 where glucose diffusion occurs adjacent surface 20 .
- glucose diffusion occurs along hydrophilic segments 10 that comprise a hydrated structure 28 having a size and overall dimensions x that are of the same order of magnitude as electrode 24 . Therefore, glucose diffusion would be substantially constant across the dimension adjacent electrode 24 , but the number of glucose diffusion paths would be limited.
- electrode 30 is located at position 34 , which is adjacent to a locally high concentration of a hydrophobic region 12 of prior art membrane 14 .
- glucose diffusion cannot adequately occur, or is severely limited across the dimension adjacent the electrode surface. Consequently, one would expect that the locally high concentration of the hydrophobic regions adjacent to working electrode 30 would limit the ability of the sensing device to obtain accurate glucose measurements.
- FIG. 2C shows another cross-section of prior art membrane 14 .
- glucose is able to traverse a fairly continuous path 36 from side 18 to side 20 proximal to the sensing device.
- electrode 38 is located at position 40 such that glucose diffusion is variable across the dimension adjacent the electrical surface.
- most of the electrode surface is associated with a locally high concentration of hydrophobic region and a small portion is associated with hydrophilic segments 10 along glucose diffusion path 36 .
- glucose diffusing along path 36 a would not be associated with the electrode.
- the large non-uniform structures of the prior art membranes can limit the number of glucose diffusion paths and the ability of the sensing device to obtain accurate glucose measurements.
- the present invention provides an implantable membrane for controlling the diffusion of an analyte therethrough to a biosensor with which it is associated.
- the membrane of the present invention satisfies a need in the art by providing a homogenous membrane with both hydrophilic and hydrophobic regions to control the diffusion of glucose and oxygen to a biosensor, the membrane being fabricated easily and reproducibly from commercially available materials.
- the invention provides a biocompatible membrane that regulates the transport of analytes that includes: (a) a matrix including a first polymer; and (b) a second polymer dispersed throughout the matrix, wherein the second polymer forms a network of microdomains which when hydrated are not observable using photomicroscopy at 400 ⁇ magnification or less.
- a polymeric membrane for regulation of glucose and oxygen in a subcutaneous glucose measuring device that includes: (a) a matrix including a first polymer; and (b) a second polymer dispersed throughout the matrix, wherein the second polymer forms a network of microdomains which are not photomicroscopically observable when hydrated at 400 ⁇ magnification or less.
- Yet another aspect of the present invention is directed to a polymeric membrane for regulating the transport of analytes, the membrane including at least one block copolymer AB, wherein B forms a network of microdomains which are not photomicroscopically observable when hydrated at 400 ⁇ magnification or less.
- a membrane and sensor combination the sensor being adapted for evaluating an analyte within a body fluid
- the membrane having: (a) a matrix including a first polymer; and (b) a second polymer dispersed throughout the matrix, wherein the second polymer forms a network of microdomains which are not photomicroscopically observable when hydrated at 400 ⁇ magnification or less.
- the invention further provides an implantable device for measuring an analyte in a hydrophilic body fluid, including: (a) a polymeric membrane having (i) a matrix including a first polymer; and (ii) a second polymer dispersed throughout the matrix, wherein the second polymer forms a network of microdomains which are not photomicroscopically observable when hydrated at 400 ⁇ magnification or less; and (b) a proximal layer of enzyme reactive with the analyte.
- a method for preparing an implantable membrane according to the invention including the steps of: (a) forming a composition including a dispersion of a second polymer within a matrix of a first polymer, the dispersion forming a network of microdomains which are not photomicroscopically observable when hydrated at 400 ⁇ magnification or less; (b) maintaining the composition at a temperature sufficient to maintain the first polymer and the second polymer substantially soluble; (c) applying the composition at this temperature to a substrate to form a film thereon; and (d) permitting the resultant film to dry to form the membrane.
- FIG. 1 is a photomicrograph of a cross-section of prior art membrane at 200 ⁇ magnification following hydration with water for two hours.
- FIG. 2A is a schematic representation of a cross-section of a prior art membrane having large hydrated structures dispersed substantially throughout a hydrophobic matrix, the hydrated structures being photomicroscopically observable at 400 ⁇ magnification or less.
- the figure illustrates the positioning of a working electrode relative to a glucose diffusion pathway.
- FIG. 2B is another schematic representation of a cross-section of the prior art membrane of FIG. 2A , where the working electrode is placed in association with a locally high concentration of the hydrophobic matrix.
- FIG. 2C is yet another schematic representation of a cross-section of the prior art membrane of FIG. 2A where glucose diffusion is variable across the dimension adjacent the electrode surface.
- FIG. 3 is a photomicrograph of a cross-section of a membrane of the present invention at 200 ⁇ magnification following hydration with water for two hours.
- FIG. 4 is a schematic representation of a cross-section illustrating one particular form of the membrane of the present invention that shows a network of microdomains which are not photomicroscopically observable at 400 ⁇ or less magnification dispersed through a hydrophobic matrix, where the membrane is positioned in association with a sensor that includes a working electrode.
- FIG. 5 is a schematic representation of a cross-section of the membrane of FIG. 3 in combination with an enzyme containing layer positioned more adjacent to a sensor 50 .
- FIG. 6 is a graph showing sensor output versus the percent of the hydrophobic-hydrophilic copolymer component in the coating blend.
- FIG. 7 is a graph showing the percent standard deviation of the sensor current versus the percent of the hydrophobic-hydrophilic copolymer component in the coating blend.
- analyte refers to a substance or chemical constituent in a biological fluid (e.g. blood or urine) that is intended to be analyzed.
- a preferred analyte for measurement by analyte detecting devices including the membrane of the present invention is glucose.
- sensor refers to the component or region of a device by which an analyte can be evaluated.
- continuous glucose sensing refers to the period in which monitoring of plasma glucose concentration is repeatedly performed over short periods of time, for example, 10 seconds to about every 15 minutes.
- domain refers to regions of the membrane of the present invention that may be layers, uniform or non-uniform gradients (e.g. anisotropic) or provided as portions of the membrane. Furthermore, the region possesses physical properties distinctly different from other portions of the membrane.
- glucose and “accurately” means, for example, 85% of measured glucose values are within the “A” and “B” region of a standard Clarke Error Grid when the sensor measurements are compared to a standard reference measurement. It is understood that like any analytical device, calibration, calibration validation and recalibration are required for the most accurate operation of the device.
- the term “host” refers to humans and other animals.
- the invention will primarily be referred to in terms of assay of glucose and solutions such as blood that tend to contain a large excess of glucose over oxygen.
- the membrane is not limited solely to the assay of glucose in a biological fluid, but may be used for the assay of other compounds.
- the sensor primarily referred to is an electrochemical sensor that directly measures hydrogen peroxide.
- non-electrochemical based sensors that use optical detectors or other suitable detectors may be used to evaluate an analyte.
- Membranes of the prior art have generally been unreliable at limiting the passage of glucose to implantable glucose sensors. This has presented a problem in the past in that the amount of glucose coming into contact with the immobilized enzyme exceeds the amount of oxygen available. As a result, the oxygen concentration is the rate-limiting component of the reaction, rather than the glucose concentration, such that the accuracy of the glucose measurement in the body fluid is compromised.
- a disadvantage of prior art membranes for regulating analyte transport therethrough has been their tendency to form large undesirable structures (see FIG. 1 ) that are observable when the membrane is hydrated.
- these hydrated structures can be detected by photomicroscopy under magnifications in the range of between 200 ⁇ -400 ⁇ , for example. They have been shown by the present inventors to be non-uniform in their dimensions through the membrane, with some being of the same size and same order of dimensions as the electrode size.
- These large structures have been found to be problematic in that they can result in a locally high concentration of either hydrophobic or hydrophilic material in association with the working electrode, which can lead to inaccurate glucose readings. Moreover, they can greatly reduce the number of glucose diffusion paths available.
- the membrane of the present invention seeks to circumvent these problems associated with prior art membranes by providing a reliable homogeneous membrane that regulates the transport of glucose or other analytes therethrough, the membrane having (a) a matrix including a first polymer; and (b) a second polymer dispersed throughout the matrix, wherein the second polymer forms a network of microdomains which when hydrated are not observable using photomicroscopy at 400 ⁇ magnification or less.
- the membrane is substantially free of observable domains.
- FIG. 3 shows a photomicrograph of a cross-section of a membrane 5 according to the present invention following hydration at two hours.
- the membrane is devoid of any undesirable, large elliptical or spherical structures, such as were observable in hydrated prior art membranes at similar magnifications. It is noted that particles 6 in membrane 5 are dust particles.
- glucose permeability and diffusion is related to the ratio of hydrophobic to hydrophilic constituents and their distribution throughout the membrane, with diffusion occurring substantially along assembled hydrophilic segments from the side of the membrane in contact with the host to the sensing side.
- membrane 42 of the present invention in accordance with a particular arrangement, is schematically shown having hydrophilic segments 44 dispersed substantially throughout a hydrophobic matrix 46 and presenting a surface 48 to a hydrophilic body fluid.
- the hydrophilic body fluid contains the sample to be assayed.
- the body fluid contains both glucose and oxygen.
- Membrane 42 restricts the rate at which glucose enters and passes through the membrane and/or may increase the rate at which oxygen enters and passes through membrane 42 .
- hydrophilic segments 44 While not wishing to be bound by any one theory, it is likely that glucose diffuses substantially along hydrophilic segments 44 , but is generally excluded from the hydrophobic matrix 46 . It is noted that while the hydrophilic segments 44 are shown as comprising discrete microdomains in FIG. 4 , small amounts of hydrophobic polymer may be present therein, particularly at the interface with the hydrophobic matrix 46 . Similarly, small amounts of hydrophilic polymer may be present in the hydrophobic matrix 46 , particularly at the interface with hydrophilic segments 44 .
- inventive membrane 42 is shown in combination with a sensor 50 , which is positioned adjacent to the membrane. It is noted that additional membranes or layers may be situated between membrane 42 and sensor 50 , as will be discussed in further detail below. Diffusion of the sample along paths 52 through membrane 42 into association with a working electrode 54 of sensor 50 causes development of a signal that is proportional to the amount of analyte in the sample. Determination of the analyte may be made by calculations based upon similar measurements made on standard solutions containing known concentrations of the analyte.
- one or more electrodes may be used to detect the amount of analyte in the sample and convert that information into a signal; the signal may then be transmitted to electronic circuitry required to process biological information obtained from the host.
- U.S. Pat. Nos. 4,757,022, 5,497,772 and 4,787,398 describe suitable electronic circuitry that may be utilized with implantable devices of the present invention.
- the present invention solves a need in the art by providing a reliable membrane for controlling glucose diffusion therethrough.
- glucose can traverse along hydrophilic segments 44 from the side 48 of the membrane in contact with a body fluid to the side 56 proximal to sensor 50 .
- the hydrophilic microdomains 44 are likely distributed substantially evenly throughout the membrane.
- these microdomains are likely substantially uniform in size throughout the membrane.
- the size and order to dimensions of these microdomains is considerably less than the that of the working electrode 54 of sensor 50 .
- the electrode is in association with a useful amount of both the hydrophobic 46 and hydrophilic 44 regions of the membrane to allow effective control over the amount of glucose diffusing to the electrode.
- the number of paths available for glucose to permeate the membrane and diffuse from side 48 to the sensing side 56 would be greater for the inventive membrane than for prior art membranes. Consequently, more accurate and reproducible glucose readings are attainable across the entire inventive membrane.
- FIG. 5 shows a preferred embodiment of the present invention wherein membrane 42 is used in combination with a proximal membrane layer 58 that comprises an enzyme that is reactive with the analyte.
- a proximal membrane layer 58 that comprises an enzyme that is reactive with the analyte.
- diffusion of the sample from side 48 through the membrane 42 into contact with the immobilized enzyme in layer 58 leads to an enzymatic reaction in which the reaction products may be measured.
- the analyte is glucose.
- the enzyme immobilized in layer 58 is glucose oxidase.
- glucose oxidase catalyzes the conversion of oxygen and glucose to hydrogen peroxide and gluconic acid. Because for each glucose molecule metabolized, there is proportional change in the co-reactant O 2 and the product H 2 O 2 , one can monitor the change in either the co-reactant or the product to determine glucose concentration. With further reference to FIG. 5 , diffusion of the resulting hydrogen peroxide through layer 58 to the sensor 50 , (e.g. electrochemically reactive surfaces), causes the development of an electrical current that can be detected. This enables determination of the glucose by calculations based upon similar measurements made on standard solutions containing known concentrations of glucose.
- the sensor 50 e.g. electrochemically reactive surfaces
- the present invention contemplates the use of a layer impregnated with other oxidases, e.g. galactose oxidase or uricase.
- oxidases e.g. galactose oxidase or uricase.
- the sensor's response must neither be limited by enzyme activity nor cofactor concentration. Because enzymes, including glucose oxidase, are subject to deactivation as a function of ambient conditions, this behavior needs to be accounted for in constructing sensors for long-term use.
- enzyme layer 58 When the membrane of the present invention is combined with an enzyme layer 58 as shown in FIG. 5 , it is the enzyme layer that is located more proximally to the sensor 50 (e.g. electrochemically reactive surfaces). It is noted that enzyme-containing layer 58 must be of sufficient permeability to 1) freely pass glucose to active enzyme and 2) to permit the rapid passage of hydrogen peroxide to the sensor (electrode surface). A failure to permit the rapid passage of glucose to the active enzyme or hydrogen peroxide from the active enzyme to the electrode surface can cause a time delay in the measured signal and thereby lead to inaccurate results.
- the enzyme layer is comprised of aqueous polyurethane-based latex into which the enzyme is immobilized.
- inventive membrane 42 may itself contain immobilized enzymes for promoting a reaction between glucose and oxygen, it is preferred that the enzyme be located in a separate layer, such as layer 58 shown in FIG. 5 .
- a disadvantage of providing enzyme in a layer that is semi-permeable to glucose is that the calibration factors of the sensor may change over time as the working enzyme degrades.
- enzyme is dispersed throughout a membrane freely permeable to glucose (i.e. layer 58 in FIG. 5 )
- such a membrane is likely to yield calibration factors that are more stable over the life of a sensor.
- the first polymer of the membrane includes homopolymer A and the second polymer includes copolymer AB.
- the first polymer includes copolymer AB and the second polymer includes copolymer AB.
- the amount of B in copolymer AB of the first polymer is different than the amount of B in copolymer AB of the second polymer.
- the membrane may be formed from a blend of two AB copolymers, where one of the copolymers contains more of a hydrophilic B polymer component than the blended targeted amount and the other copolymer contains less of a hydrophilic B polymer component than the blended targeted amount.
- the first polymer includes homopolymer A and the second polymer includes homopolymer B.
- the invention also provides a polymeric membrane for regulating the transport of analytes that includes at least one block copolymer AB, wherein B forms a network of microdomains which are not photomicroscopically observable when hydrated at 400 ⁇ magnification or less.
- the ratio of A to B in copolymer AB is 70:30 to 90:10.
- homopolymer A is preferably a hydrophobic A polymer.
- copolymer AB is preferably a hydrophobic-hydrophilic copolymer component that includes the reaction products of a hydrophobic A polymer and a hydrophilic B polymer. Suitable materials for preparing membranes the present invention are described below.
- copolymer AB may be a random or ordered block copolymer.
- the random or ordered block copolymer may be selected from the following: ABA block copolymer, BAB block copolymer, AB random alternating block copolymer, AB regularly alternating block copolymer and combinations thereof.
- the senor, membrane, and methods of the present invention may be used to determine the level of glucose or other analytes in a host.
- the level of glucose is a particularly important measurement for individuals having diabetes in that effective treatment depends on the accuracy of this measurement.
- the invention provides a method of measuring glucose in a biological fluid that includes the steps of: (a) providing (i) a host, and (ii) an implantable device for measuring an analyte in a hydrophilic body fluid, where the device includes a polymeric membrane having a matrix including a first polymer and a second polymer dispersed throughout the matrix, wherein the second polymer forms a network of microdomains which are not photomicroscopically observable when hydrated at 400 ⁇ magnification or less; and a proximal layer of enzyme reactive with the analyte; and (b) implanting the device in the host.
- the device is implanted subcutaneously.
- the invention also provides a method of measuring glucose in a biological fluid that includes the following steps: (a) providing (i) a host, and (ii) an implantable device for measuring an analyte in a hydrophilic body fluid, that includes a polymeric membrane including a matrix including a first polymer and a second polymer dispersed throughout the matrix, wherein the second polymer forms a network of microdomains which are not photomicroscopically observable when hydrated at 400 ⁇ magnification or less; and a proximal layer of enzyme reactive with the analyte, the device being capable of accurate continuous glucose sensing; and (b) implanting the device in the host.
- the implant is placed subcutaneously in the host.
- Glucose sensors that use, for example, glucose oxidase to effect a reaction of glucose and oxygen are known in the art, and are within the skill of one in the art to fabricate (see, for example, U.S. Pat. Nos. 5,165,407, 4,890,620, 5,390,671, 5,391,250, 6,001,067 as well as copending, commonly owned U.S. patent application Ser. No. 09/916,858. It is noted that the present invention does not depend on a particular configuration of the sensor, but is rather dependent on the use of the inventive membrane to cover or encapsulate the sensor elements.
- the glucose concentration as opposed to oxygen concentration, must be the limiting factor.
- oxygen must be present within the membrane in excess of the glucose.
- the oxygen must be in sufficient excess so that it is also available for electrochemical reactions occurring at the amperometric electrode surfaces.
- the inventive membrane is designed so that oxygen can pass readily into and through the membrane and so that a reduced amount of glucose diffuses into and through the membrane into contact with an immobilized glucose oxidase enzyme.
- the inventive membrane allows the ratio of oxygen to glucose to be changed from a concentration ratio in the body fluid of about approximately 50 and 100 parts of glucose to 1 of oxygen to a new ratio in which there is a stoichiometric excess of oxygen in the enzyme layer.
- an implantable glucose sensor system is not limited by the concentration of oxygen present in subcutaneous tissues and can therefore operate under the premise that the glucose oxidase reaction behaves as a 1-substrate (glucose) dependent process.
- the present invention provides a semi-permeable membrane that controls the flux of oxygen and glucose to an underlying enzyme layer, rendering the necessary supply of oxygen in non-rate-limiting excess.
- the membrane of the present invention is a polymer membrane with oxygen-to-glucose permeability ratios of approximately 200:1; as a result, 1-dimensional reactant diffusion is adequate to provide excess oxygen at all reasonable glucose and oxygen concentrations found in a subcutaneous matrix [Rhodes, et al., Anal. Chem., 66: 1520-1529 (1994)].
- a hydrophilic or “water loving” solute such as glucose is readily partitioned into a hydrophilic material, but is generally excluded from a hydrophobic material.
- oxygen can be soluble in both hydrophilic and hydrophobic materials.
- the membrane of the invention is formed from a blend of polymers including (i) a hydrophobic A polymer component; and (ii) a hydrophobic-hydrophilic copolymer component blended with component (i) that forms hydrophilic B domains that control the diffusion of an analyte therethrough, wherein the copolymer component includes a random or ordered block copolymer. Suitable block copolymers are described above. One is able to modify the glucose permeability and the glucose diffusion characteristics of the membrane by simply varying the polymer composition.
- the hydrophobic A polymer is a polyurethane.
- the polyurethane is polyetherurethaneurea.
- a polyurethane is a polymer produced by the condensation reaction of a diisocyanate and a difunctional hydroxyl-containing material.
- a polyurethaneurea is a polymer produced by the condensation reaction of a diisocyanate and a difunctional amine-containing material.
- Preferred diisocyanates include aliphatic diisocyanates containing from 4 to 8 methylene units. Diisocyanates containing cycloaliphatic moieties, may also be useful in the preparation of the polymer and copolymer components of the membrane of the present invention.
- the invention is not limited to the use of polyurethanes as the hydrophobic polymer A component.
- the material that forms the basis of the hydrophobic matrix of the inventive membrane may be any of those known in the art as appropriate for use as membranes in sensor devices and having sufficient permeability to allow relevant compounds to pass through it, for example, to allow an oxygen molecule to pass through the inventive membrane from the sample under examination in order to reach the active enzyme or electrochemical electrodes.
- Examples of materials which may be used to make a non-polyurethane type membrane include vinyl polymers, polyethers, polyesters, polyamides, inorganic polymers such as polysiloxanes and polycarbosiloxanes, natural polymers such as cellulosic and protein based materials and mixtures or combinations thereof.
- the hydrophobic-hydrophilic copolymer component includes the reaction products of a hydrophobic A polymer component and a hydrophilic B polymer component.
- the hydrophilic B polymer component is desirably polyethylene oxide.
- one useful hydrophobic-hydrophilic copolymer component is a polyurethane polymer that includes about 20% hydrophilic polyethyelene oxide.
- the polyethylene oxide portion of the copolymer is thermodynamically driven to separate from the hydrophobic portions of the copolymer and the hydrophobic A polymer component.
- the 20% polyethylene oxide based soft segment portion of the copolymer used to form the final blend controls the water pick-up and subsequent glucose permeability of the membrane of the present invention.
- the polyethylene oxide may have an average molecular weight of from 200 to 3000 with a preferred molecular weight range of 600 to 1500 and preferably constitutes about 20% by weight of the copolymer component used to form the membrane of the present invention.
- the membrane of the present invention has a thickness of about 5 to about 100 microns.
- the membrane of the present invention is constructed of a polyetherurethaneurea/polyetherurethaneurea-block-polyethylene glycol blend and has a thickness of not more than about 100 microns, more preferably not less than about 10 microns, and not more than about 80 microns, and most preferably, not less than about 20 microns, and not more than about 60 microns.
- the membrane of the present invention can be made by casting from solutions, optionally with inclusion of additives to modify the properties and the resulting cast film or to facilitate the casting process.
- the present invention provides a method for preparing the implantable membrane of the invention.
- the method includes the steps of: (a) forming a composition including a dispersion of a second polymer within a matrix of a first polymer, the dispersion forming a network of microdomains which are not photomicroscopically observable when hydrated at 400 ⁇ magnification or less; (b) maintaining the composition at a temperature sufficient to maintain the first polymer and the second polymer substantially soluble; (c) applying the composition at the temperature to a substrate to form a film thereon; and (d) permitting the resultant film to dry to form the membrane.
- the forming step includes forming a mixture or a blend.
- the first polymer is a polyurethane and the second polymer is polyethylene oxide.
- the second polymer may be a random or ordered block copolymer selected from the following: ABA block copolymer, BAB block copolymer, AB random alternating block copolymer, AB regularly alternating block copolymer and combinations thereof.
- the composition comprised of a dispersion of the second polymer within the matrix of a first polymer is heated to a temperature of about 70° C. to maintain the first and second polymers substantially soluble.
- a hydrophobic polymer A component and a hydrophobic-hydrophilic copolymer AB component is desirably exposed to a temperature of about 70° C. to maintain the polymer and copolymers substantially soluble.
- the blend is heated well above room temperature in order to keep the hydrophilic and hydrophobic components soluble with each other and the solvent.
- the invention contemplates permitting the coated film formed on the substrate to dry at a temperature from about 120° C. to about 150° C.
- the elevated temperature further serves to drive the solvent from the coating as quickly as possible. This inhibits the hydrophilic and hydrophobic portions of the membrane from segregating and forming large undesired structures.
- the membrane and sensor combinations of the present invention provide a significant advantage over the prior art in that they provide accurate sensor operation at temperatures from about 30° C. to about 45° C. for a period of time exceeding about 30 days to exceeding about a year.
- the inventive membrane may be cast from a coating solution.
- the coating solution is prepared by placing approximately 281 gm of dimethylacetamide (DMAC) into a 3 L stainless steel bowl to which a solution of polyetherurethaneurea (344 gm of Chronothane H (Cardiotech International, Inc., Woburn, Mass.), 29,750 cp@25% solids in DMAC) is added. To this mixture is added another polyetherurethaneurea (approximately 312 gm, Chronothane 1020 (Cardiotech International, Inc., Woburn, Mass.), 6275 cp@25% solids in DMAC).
- DMAC dimethylacetamide
- the bowl is then fitted to a planetary mixer with a paddle-type blade and the contents are stirred for 30 minutes at room temperature.
- Coatings solutions prepared in this manner are then coated at between room temperature to about 70° C. onto a PET release liner (Douglas Hansen Co., Inc., Minneapolis, Minn.) using a knife-over-roll set at a 0.012 inch gap.
- the film is continuously dried at 120° C. to about 150° C. The final film thickness is approximately 0.0015 inches.
- a 1 ⁇ 4′′ by 1 ⁇ 4′′ piece of membrane is first immersed in deionized water for a minimum of 2 hours at room temperature. After this time, the sample is placed onto a microscope slide along with one drop of water. A glass cover slide is then placed over the membrane and gentle pressure is applied in order to remove excess liquid from underneath the cover glass. In this way, the membrane does not dry during its evaluation.
- the hydrated membrane sample is first observed at 40 ⁇ -magnification using a light microscope (Nikon Eclipse E400). If air bubbles are present on the top or bottom of the film, the cover glass is gently pressed again with a tissue in order to remove them. Magnification is then increased to 200 ⁇ ; and the hydrated membrane is continuously observed while changing the focus from the top to bottom of the film. This is followed by an increase in magnification to 400 ⁇ , with the membrane again being continuously observed while changing the focus from the top to bottom of the film.
- Example 2 further demonstrates that, provided the coating solution is preheated to about 70° C., either a standard) (120°) or elevated (150° C.) drying temperature were sufficient to drive the DMAC solvent from the coated film quickly to further inhibit the hydrophilic and hydrophobic portions of the polyurethane membrane from segregating into large domains.
- the invention was evaluated by performing a coating experiment where standard coating conditions (room temperature coating solution and 120° C. drying temperature of the coated film) were compared to conditions where the coating solution temperature was elevated and/or the drying temperature of the coated film was elevated.
- standard coating conditions room temperature coating solution and 120° C. drying temperature of the coated film
- Membranes prepared under the EE condition described in Example 2 were evaluated for their ability to allow glucose and hydrogen peroxide to get through the membrane to a sensor.
- a series of polyurethane blends of the present invention were generated wherein the percentage of Chronothane H in a coating blend was varied.
- one of these blends (57.5% Chronothane H in coating blend) was prepared under both the EE condition and the SS condition as described in Example 2.
- FIG. 6 shows that the sensor output generated with a series of polyurethane blends of the present invention was dependent upon the percentage of the Chronothane H.
- the sensor output increased as the percentage of Chronothane H in the coating blend increased.
- the percentage of Chronothane H in the coating blend was 57.5%, the sensor output was three times greater for the membrane prepared under the optimized EE coating condition as compared to the non-optimized SS coating condition.
- FIG. 7 demonstrates that, regardless of the percent Chronothane H in the coating blend, an inventive membrane prepared under the EE condition shows a fairly constant percent standard deviation of sensor output. Moreover, a membrane prepared with 57.5% Chronothane H in the coating blend under the SS condition showed a percent standard deviation of sensor output approximately twice that of an EE membrane prepared with the same percentage of Chronothane H in the blend. It is noted that given that the sensor output is a true measure of the amount of glucose getting through the membrane to the sensor, the results indicate that the permeability of glucose and H 2 O 2 is relatively constant throughout a given inventive membrane prepared under optimized coating conditions (i.e., EE conditions). This is important from a manufacturing standpoint.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Veterinary Medicine (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- Medical Informatics (AREA)
- Pathology (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Dispersion Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Composite Materials (AREA)
- Materials Engineering (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention provides an implantable membrane for regulating the transport of analytes therethrough that includes a matrix including a first polymer; and a second polymer dispersed throughout the matrix, wherein the second polymer forms a network of microdomains which when hydrated are not observable using photomicroscopy at 400× magnification or less. In one aspect, the homogeneous membrane of the present invention has hydrophilic domains dispersed substantially throughout a hydrophobic matrix to provide an optimum balance between oxygen and glucose transport to an electrochemical glucose sensor.
Description
- This application is a continuation of U.S. application Ser. No. 11/280,672 filed Nov. 16, 2005, which is a division of U.S. application Ser. No. 10/153,356, filed May 22, 2002, now U.S. Pat. No. 7,226,978, the disclosures which are hereby incorporated by reference in their entirety and are hereby made a portion of this application.
- The present invention relates generally to membranes for use in combination with implantable devices for evaluating an analyte in a body fluid. More particularly, the invention relates to membranes for controlling the diffusion of glucose therethrough to a glucose sensor.
- A biosensor is a device that uses biological recognition properties for the selective analysis of various analytes or biomolecules. Generally, the sensor will produce a signal that is quantitatively related to the concentration of the analyte. In particular, a great deal of research has been directed toward the development of a glucose sensor that would function in vivo to monitor a patient's blood glucose level. Such a glucose sensor is useful in the treatment of diabetes mellitus. In particular, an implantable glucose sensor that would continuously monitor the patient's blood glucose level would provide a physician with more accurate information in order to develop optimal therapy. One type of glucose sensor is the amperometric electrochemical glucose sensor. Typically, an electrochemical glucose sensor employs the use of a glucose oxidase enzyme to catalyze the reaction between glucose and oxygen and subsequently generate an electrical signal. The reaction catalyzed by glucose oxidase yields gluconic acid and hydrogen peroxide as shown in the reaction below (equation 1):
- The hydrogen peroxide reacts electrochemically as shown below in equation 2:
-
H2O2→2H++O2+2e− - The current measured by the sensor is generated by the oxidation of the hydrogen peroxide at a platinum working electrode. According to
equation 1, if there is excess oxygen forequation 1, then the hydrogen peroxide is stoichiometrically related to the amount of glucose that reacts with the enzyme. In this instance, the ultimate current is also proportional to the amount of glucose that reacts with the enzyme. However, if there is insufficient oxygen for all of the glucose to react with the enzyme, then the current will be proportional to the oxygen concentration, not the glucose concentration. For the glucose sensor to be useful, glucose must be the limiting reagent, i.e., the oxygen concentration must be in excess for all potential glucose concentrations. Unfortunately, this requirement is not easily achieved. For example, in the subcutaneous tissue the concentration of oxygen is much less that of glucose. As a consequence, oxygen can become a limiting reactant, giving rise to a problem with oxygen deficit. Attempts have been made to circumvent this problem in order to allow the sensor to continuously operate in an environment with an excess of oxygen. - Several attempts have been made to use membranes of various types in an effort to design a membrane that regulates the transport of oxygen and glucose to the sensing elements of glucose oxidase-based glucose sensors. One approach has been to develop homogenous membranes having hydrophilic domains dispersed substantially throughout a hydrophobic matrix to circumvent the oxygen deficit problem, where glucose diffusion is facilitated by the hydrophilic segments.
- For example, U.S. Pat. No. 5,322,063 to Allen et al. teaches that various compositions of hydrophilic polyurethanes can be used in order to control the ratios of the diffusion coefficients of oxygen to glucose in an implantable glucose sensor. In particular, various polyurethane compositions were synthesized that were capable of absorbing from 10 to 50% of their dry weight of water. The polyurethanes were rendered hydrophilic by incorporating polyethyleneoxide as their soft segment diols. One disadvantage of this invention is that the primary backbone structure of the polyurethane is sufficiently different so that more than one casting solvent may be required to fabricate the membranes. This reduces the ease with which the membranes may be manufactured and may further reduce the reproducibility of the membrane. Furthermore, neither the percent of the polyethyleneoxide soft segment nor the percent water pickup of the polyurethanes disclosed by Allen directly correlate to the oxygen to glucose permeability ratios. Therefore, one skilled in the art cannot simply change the polymer composition and be able to predict the oxygen to glucose permeability ratios. As a result, a large number of polymers would need to be synthesized before a desired specific oxygen to glucose permeability ratio could be obtained.
- U.S. Pat. Nos. 5,777,060 and 5,882,494, each to Van Antwerp, also disclose homogeneous membranes having hydrophilic domains dispersed throughout a hydrophobic matrix to reduce the amount of glucose diffusion to the working electrode of a biosensor. For example, U.S. Pat. No. 5,882,494 to Van Antwerp discloses a membrane including the reaction products of a diisocyanate, a hydrophilic diol or diamine, and a silicone material. In addition, U.S. Pat. No. 5,777,060 to Van Antwerp discloses polymeric membranes that can be prepared from (a) a diisocyanate, (b) a hydrophilic polymer, (c) a siloxane polymer having functional groups at the chain termini, and optionally (d) a chain extender. Polymerization of these membranes typically requires heating of the reaction mixture for periods of time from 1 to 4 hours, depending on whether polymerization of the reactants is carried out in bulk or in a solvent system. Therefore, it would be beneficial to provide a method of preparing a homogenous membrane from commercial polymers. Moreover, as mentioned above, one skilled in the art cannot simply change the polymer composition and be able to predict the oxygen to glucose permeability ratios. Therefore, a large number of polymers would need to be synthesized and coating or casting techniques optimized before a desired specific oxygen to glucose permeability ratio could be obtained.
- A further membrane is disclosed in U.S. Pat. No. 6,200,772 B1 to Vadgama et al. that has hydrophilic domains dispersed substantially throughout a hydrophobic matrix for limiting the amount of glucose diffusing to a working electrode. In particular, the patent describes a sensor device that includes a membrane comprised of modified polyurethane that is substantially non-porous and incorporates a non-ionic surfactant as a modifier. The non-ionic surfactant is disclosed as preferably including a poly-oxyalkylene chain, such as one derived from multiple units of poly-oxyethylene groups. As described, the non-ionic surfactant may be incorporated into the polyurethane by admixture or through compounding to distribute it throughout the polyurethane. The non-ionic surfactant is, according to the specification, preferably incorporated into the polyurethane by allowing it to react chemically with the polyurethane so that it becomes chemically bound into its molecular structure. Like most reactive polymer resins, complete reaction of the surfactant into the polyurethane may never occur. Therefore, a disadvantage of this membrane is that it can leach the surfactant over time and cause irritation at the implant site or change its permeability to glucose.
- PCT Application WO 92/13271 discloses an implantable fluid measuring device for determining the presence and the amounts of substances in a biological fluid that includes a membrane for limiting the amount of a substance that passes therethrough. In particular, this application discloses a membrane including a blend of two substantially similar polyurethane urea copolymers, one having a glucose permeability that is somewhat higher than preferred and the other having a glucose permeability that is somewhat lower than preferred.
- An important factor in obtaining a useful implantable sensor for detection of glucose or other analytes is the need for optimization of materials and methods in order to obtain predictable in vitro and in vivo function. The ability of the sensor to function in a predictable and reliable manner in vitro is dependent on consistent fabrication techniques. Repeatability of fabrication has been a problem associated with prior art membranes that attempt to regulate the transport of analytes to the sensing elements.
- We refer now to
FIG. 1 , which shows a photomicrograph at 200× magnification of a prior art cast polymer blend following hydration. A disadvantage of the prior art membranes is that, upon thermodynamic separation from the hydrophobic portions, the hydrophilic components form undesirable structures that appear circular 1 and elliptical 2 when viewed with a light microscope when themembrane 3 is hydrated, but not when it is dry. These hydrated structures can be detected by photomicroscopy under magnifications in the range of between 200×-400×, for example. They have been shown by the present inventors to be non-uniform in their dimensions throughout the membrane, with some being of the same size and same order of dimensions as the electrode size. It is believed that these large domains present a problem in that they result in a locally high concentration of either hydrophobic or hydrophilic material in association with the electrode. This can result in glucose diffusion being limited or variable across the dimension adjacent the sensing electrode. Moreover, these large hydrated structures can severely limit the number of glucose diffusion paths available. It is noted thatparticles 4 inmembrane 3 are dust particles. - With reference now to a schematic representation of a known
membrane 14 inFIG. 2A , one can consider by way of example acontinuous path 16 by which glucose may traverse along thehydrophilic segments 10 that are dispersed inhydrophobic sections 12 of the membrane. Forpath 16, glucose is able to traverse a fairly continuous path along assembledhydrophilic segments 10 from theside 18 of the membrane in contact with the body fluid containing glucose to thesensing side 20 proximal tosensor 22, where anelectrode 24 is placed atposition 26 where glucose diffusion occursadjacent surface 20. In particular, in that portion of themembrane 14 proximal toposition 26, glucose diffusion occurs alonghydrophilic segments 10 that comprise ahydrated structure 28 having a size and overall dimensions x that are of the same order of magnitude aselectrode 24. Therefore, glucose diffusion would be substantially constant across the dimensionadjacent electrode 24, but the number of glucose diffusion paths would be limited. - Referring now to
FIG. 2B , one can consider an example where glucose traversingprior art membrane 14 fromside 18 in contact with the body fluid to thesensing side 20 cannot adequately reachelectrode 30. In particular,electrode 30 is located atposition 34, which is adjacent to a locally high concentration of ahydrophobic region 12 ofprior art membrane 14. In this instance, glucose diffusion cannot adequately occur, or is severely limited across the dimension adjacent the electrode surface. Consequently, one would expect that the locally high concentration of the hydrophobic regions adjacent to workingelectrode 30 would limit the ability of the sensing device to obtain accurate glucose measurements. The random chance that the membrane could be placed in the 2A configuration as opposed to 2B leads to wide variability in sensor performance. - We also refer to
FIG. 2C , which shows another cross-section ofprior art membrane 14. In this instance, glucose is able to traverse a fairlycontinuous path 36 fromside 18 toside 20 proximal to the sensing device. However,electrode 38 is located atposition 40 such that glucose diffusion is variable across the dimension adjacent the electrical surface. In particular, most of the electrode surface is associated with a locally high concentration of hydrophobic region and a small portion is associated withhydrophilic segments 10 alongglucose diffusion path 36. Furthermore, glucose diffusing alongpath 36 a would not be associated with the electrode. Again, the large non-uniform structures of the prior art membranes can limit the number of glucose diffusion paths and the ability of the sensing device to obtain accurate glucose measurements. - It would be beneficial to form more homogeneous membranes for controlling glucose transport from commercially available polymers that have a similar backbone structure. This would result in a more reproducible membrane. In particular, it is desired that one would be able to predict the resulting glucose permeability of the resulting membrane by simply varying the polymer composition. In this way, the glucose diffusion characteristics of the membrane could be modified, without greatly changing the manufacturing parameters for the membrane. In particular, there is a need for homogeneous membranes having hydrophilic segments dispersed throughout a hydrophobic matrix that are easy to fabricate reproducibly from readily available reagents. Of particular importance would be the development of membranes where the hydrophilic portions were distributed evenly throughout the membrane, and where their size and dimensions were on an order considerably less than the size and dimensions of the electrode of the sensing device to allow the electrode to be in association with a useful amount of both hydrophobic and hydrophilic portions. The ability of the membranes to be synthesized and manufactured in reasonable quantities and at reasonable prices would be a further advantage.
- The present invention provides an implantable membrane for controlling the diffusion of an analyte therethrough to a biosensor with which it is associated. In particular, the membrane of the present invention satisfies a need in the art by providing a homogenous membrane with both hydrophilic and hydrophobic regions to control the diffusion of glucose and oxygen to a biosensor, the membrane being fabricated easily and reproducibly from commercially available materials.
- The invention provides a biocompatible membrane that regulates the transport of analytes that includes: (a) a matrix including a first polymer; and (b) a second polymer dispersed throughout the matrix, wherein the second polymer forms a network of microdomains which when hydrated are not observable using photomicroscopy at 400× magnification or less.
- Further provided by the invention is a polymeric membrane for regulation of glucose and oxygen in a subcutaneous glucose measuring device that includes: (a) a matrix including a first polymer; and (b) a second polymer dispersed throughout the matrix, wherein the second polymer forms a network of microdomains which are not photomicroscopically observable when hydrated at 400× magnification or less.
- Yet another aspect of the present invention is directed to a polymeric membrane for regulating the transport of analytes, the membrane including at least one block copolymer AB, wherein B forms a network of microdomains which are not photomicroscopically observable when hydrated at 400× magnification or less.
- Also provided is a membrane and sensor combination, the sensor being adapted for evaluating an analyte within a body fluid, the membrane having: (a) a matrix including a first polymer; and (b) a second polymer dispersed throughout the matrix, wherein the second polymer forms a network of microdomains which are not photomicroscopically observable when hydrated at 400× magnification or less.
- The invention further provides an implantable device for measuring an analyte in a hydrophilic body fluid, including: (a) a polymeric membrane having (i) a matrix including a first polymer; and (ii) a second polymer dispersed throughout the matrix, wherein the second polymer forms a network of microdomains which are not photomicroscopically observable when hydrated at 400× magnification or less; and (b) a proximal layer of enzyme reactive with the analyte.
- Moreover, a method for preparing an implantable membrane according to the invention is provided, the method including the steps of: (a) forming a composition including a dispersion of a second polymer within a matrix of a first polymer, the dispersion forming a network of microdomains which are not photomicroscopically observable when hydrated at 400× magnification or less; (b) maintaining the composition at a temperature sufficient to maintain the first polymer and the second polymer substantially soluble; (c) applying the composition at this temperature to a substrate to form a film thereon; and (d) permitting the resultant film to dry to form the membrane.
-
FIG. 1 is a photomicrograph of a cross-section of prior art membrane at 200× magnification following hydration with water for two hours. -
FIG. 2A is a schematic representation of a cross-section of a prior art membrane having large hydrated structures dispersed substantially throughout a hydrophobic matrix, the hydrated structures being photomicroscopically observable at 400× magnification or less. The figure illustrates the positioning of a working electrode relative to a glucose diffusion pathway. -
FIG. 2B is another schematic representation of a cross-section of the prior art membrane ofFIG. 2A , where the working electrode is placed in association with a locally high concentration of the hydrophobic matrix. -
FIG. 2C is yet another schematic representation of a cross-section of the prior art membrane ofFIG. 2A where glucose diffusion is variable across the dimension adjacent the electrode surface. -
FIG. 3 is a photomicrograph of a cross-section of a membrane of the present invention at 200× magnification following hydration with water for two hours. -
FIG. 4 is a schematic representation of a cross-section illustrating one particular form of the membrane of the present invention that shows a network of microdomains which are not photomicroscopically observable at 400× or less magnification dispersed through a hydrophobic matrix, where the membrane is positioned in association with a sensor that includes a working electrode. -
FIG. 5 is a schematic representation of a cross-section of the membrane ofFIG. 3 in combination with an enzyme containing layer positioned more adjacent to asensor 50. -
FIG. 6 is a graph showing sensor output versus the percent of the hydrophobic-hydrophilic copolymer component in the coating blend. -
FIG. 7 is a graph showing the percent standard deviation of the sensor current versus the percent of the hydrophobic-hydrophilic copolymer component in the coating blend. - In order to facilitate understanding of the present invention, a number of terms are defined below.
- The term “analyte” refers to a substance or chemical constituent in a biological fluid (e.g. blood or urine) that is intended to be analyzed. A preferred analyte for measurement by analyte detecting devices including the membrane of the present invention is glucose.
- The term “sensor” refers to the component or region of a device by which an analyte can be evaluated.
- By the terms “evaluated”, “monitored”, “analyzed”, and the like, it is meant that an analyte may be detected and/or measured.
- The phrase “continuous glucose sensing” refers to the period in which monitoring of plasma glucose concentration is repeatedly performed over short periods of time, for example, 10 seconds to about every 15 minutes.
- The term “domain” refers to regions of the membrane of the present invention that may be layers, uniform or non-uniform gradients (e.g. anisotropic) or provided as portions of the membrane. Furthermore, the region possesses physical properties distinctly different from other portions of the membrane.
- The terms “accurate” and “accurately” means, for example, 85% of measured glucose values are within the “A” and “B” region of a standard Clarke Error Grid when the sensor measurements are compared to a standard reference measurement. It is understood that like any analytical device, calibration, calibration validation and recalibration are required for the most accurate operation of the device.
- The term “host” refers to humans and other animals.
- In the disclosure that follows, the invention will primarily be referred to in terms of assay of glucose and solutions such as blood that tend to contain a large excess of glucose over oxygen. However, it is well within the contemplation of the present invention that the membrane is not limited solely to the assay of glucose in a biological fluid, but may be used for the assay of other compounds. In addition, the sensor primarily referred to is an electrochemical sensor that directly measures hydrogen peroxide. However, it is well within the contemplation of the present invention that non-electrochemical based sensors that use optical detectors or other suitable detectors may be used to evaluate an analyte.
- Membranes of the prior art have generally been unreliable at limiting the passage of glucose to implantable glucose sensors. This has presented a problem in the past in that the amount of glucose coming into contact with the immobilized enzyme exceeds the amount of oxygen available. As a result, the oxygen concentration is the rate-limiting component of the reaction, rather than the glucose concentration, such that the accuracy of the glucose measurement in the body fluid is compromised.
- As described above, in contrast to the present invention, a disadvantage of prior art membranes for regulating analyte transport therethrough has been their tendency to form large undesirable structures (see
FIG. 1 ) that are observable when the membrane is hydrated. In particular, these hydrated structures can be detected by photomicroscopy under magnifications in the range of between 200×-400×, for example. They have been shown by the present inventors to be non-uniform in their dimensions through the membrane, with some being of the same size and same order of dimensions as the electrode size. These large structures have been found to be problematic in that they can result in a locally high concentration of either hydrophobic or hydrophilic material in association with the working electrode, which can lead to inaccurate glucose readings. Moreover, they can greatly reduce the number of glucose diffusion paths available. - The membrane of the present invention seeks to circumvent these problems associated with prior art membranes by providing a reliable homogeneous membrane that regulates the transport of glucose or other analytes therethrough, the membrane having (a) a matrix including a first polymer; and (b) a second polymer dispersed throughout the matrix, wherein the second polymer forms a network of microdomains which when hydrated are not observable using photomicroscopy at 400× magnification or less. In one embodiment of the invention, the membrane is substantially free of observable domains.
- We refer now to
FIG. 3 , which shows a photomicrograph of a cross-section of amembrane 5 according to the present invention following hydration at two hours. As shown inFIG. 3 , the membrane is devoid of any undesirable, large elliptical or spherical structures, such as were observable in hydrated prior art membranes at similar magnifications. It is noted thatparticles 6 inmembrane 5 are dust particles. - For purposes of the present invention, it is likely that glucose permeability and diffusion is related to the ratio of hydrophobic to hydrophilic constituents and their distribution throughout the membrane, with diffusion occurring substantially along assembled hydrophilic segments from the side of the membrane in contact with the host to the sensing side.
- Referring now to
FIG. 4 ,membrane 42 of the present invention, in accordance with a particular arrangement, is schematically shown havinghydrophilic segments 44 dispersed substantially throughout ahydrophobic matrix 46 and presenting asurface 48 to a hydrophilic body fluid. The hydrophilic body fluid contains the sample to be assayed. In one embodiment, the body fluid contains both glucose and oxygen.Membrane 42 restricts the rate at which glucose enters and passes through the membrane and/or may increase the rate at which oxygen enters and passes throughmembrane 42. - While not wishing to be bound by any one theory, it is likely that glucose diffuses substantially along
hydrophilic segments 44, but is generally excluded from thehydrophobic matrix 46. It is noted that while thehydrophilic segments 44 are shown as comprising discrete microdomains inFIG. 4 , small amounts of hydrophobic polymer may be present therein, particularly at the interface with thehydrophobic matrix 46. Similarly, small amounts of hydrophilic polymer may be present in thehydrophobic matrix 46, particularly at the interface withhydrophilic segments 44. - In the embodiment shown in
FIG. 4 ,inventive membrane 42 is shown in combination with asensor 50, which is positioned adjacent to the membrane. It is noted that additional membranes or layers may be situated betweenmembrane 42 andsensor 50, as will be discussed in further detail below. Diffusion of the sample alongpaths 52 throughmembrane 42 into association with a workingelectrode 54 ofsensor 50 causes development of a signal that is proportional to the amount of analyte in the sample. Determination of the analyte may be made by calculations based upon similar measurements made on standard solutions containing known concentrations of the analyte. For example, one or more electrodes may be used to detect the amount of analyte in the sample and convert that information into a signal; the signal may then be transmitted to electronic circuitry required to process biological information obtained from the host. U.S. Pat. Nos. 4,757,022, 5,497,772 and 4,787,398 describe suitable electronic circuitry that may be utilized with implantable devices of the present invention. - The present invention solves a need in the art by providing a reliable membrane for controlling glucose diffusion therethrough. As shown in
FIG. 4 , glucose can traverse alonghydrophilic segments 44 from theside 48 of the membrane in contact with a body fluid to theside 56 proximal tosensor 50. Thehydrophilic microdomains 44 are likely distributed substantially evenly throughout the membrane. Furthermore, these microdomains are likely substantially uniform in size throughout the membrane. The size and order to dimensions of these microdomains is considerably less than the that of the workingelectrode 54 ofsensor 50. As such, the electrode is in association with a useful amount of both the hydrophobic 46 and hydrophilic 44 regions of the membrane to allow effective control over the amount of glucose diffusing to the electrode. Moreover, as shown inFIG. 4 , the number of paths available for glucose to permeate the membrane and diffuse fromside 48 to thesensing side 56 would be greater for the inventive membrane than for prior art membranes. Consequently, more accurate and reproducible glucose readings are attainable across the entire inventive membrane. -
FIG. 5 shows a preferred embodiment of the present invention whereinmembrane 42 is used in combination with aproximal membrane layer 58 that comprises an enzyme that is reactive with the analyte. In this instance, diffusion of the sample fromside 48 through themembrane 42 into contact with the immobilized enzyme inlayer 58 leads to an enzymatic reaction in which the reaction products may be measured. For example, in one embodiment the analyte is glucose. In a further embodiment, the enzyme immobilized inlayer 58 is glucose oxidase. - As described above, glucose oxidase catalyzes the conversion of oxygen and glucose to hydrogen peroxide and gluconic acid. Because for each glucose molecule metabolized, there is proportional change in the co-reactant O2 and the product H2O2, one can monitor the change in either the co-reactant or the product to determine glucose concentration. With further reference to
FIG. 5 , diffusion of the resulting hydrogen peroxide throughlayer 58 to thesensor 50, (e.g. electrochemically reactive surfaces), causes the development of an electrical current that can be detected. This enables determination of the glucose by calculations based upon similar measurements made on standard solutions containing known concentrations of glucose. - In addition to glucose oxidase, the present invention contemplates the use of a layer impregnated with other oxidases, e.g. galactose oxidase or uricase. For an enzyme-based electrochemical glucose sensor to perform well, the sensor's response must neither be limited by enzyme activity nor cofactor concentration. Because enzymes, including glucose oxidase, are subject to deactivation as a function of ambient conditions, this behavior needs to be accounted for in constructing sensors for long-term use.
- When the membrane of the present invention is combined with an
enzyme layer 58 as shown inFIG. 5 , it is the enzyme layer that is located more proximally to the sensor 50 (e.g. electrochemically reactive surfaces). It is noted that enzyme-containinglayer 58 must be of sufficient permeability to 1) freely pass glucose to active enzyme and 2) to permit the rapid passage of hydrogen peroxide to the sensor (electrode surface). A failure to permit the rapid passage of glucose to the active enzyme or hydrogen peroxide from the active enzyme to the electrode surface can cause a time delay in the measured signal and thereby lead to inaccurate results. - Preferably, the enzyme layer is comprised of aqueous polyurethane-based latex into which the enzyme is immobilized.
- It is noted that while the
inventive membrane 42 may itself contain immobilized enzymes for promoting a reaction between glucose and oxygen, it is preferred that the enzyme be located in a separate layer, such aslayer 58 shown inFIG. 5 . As described above, it is known that enzyme actively reacting with glucose is more susceptible to irreversible inactivation. Therefore, a disadvantage of providing enzyme in a layer that is semi-permeable to glucose, is that the calibration factors of the sensor may change over time as the working enzyme degrades. In contrast, when enzyme is dispersed throughout a membrane freely permeable to glucose (i.e.layer 58 inFIG. 5 ), such a membrane is likely to yield calibration factors that are more stable over the life of a sensor. - In one preferred embodiment of the invention, the first polymer of the membrane includes homopolymer A and the second polymer includes copolymer AB.
- In another embodiment, the first polymer includes copolymer AB and the second polymer includes copolymer AB. Preferably, the amount of B in copolymer AB of the first polymer is different than the amount of B in copolymer AB of the second polymer. In particular, the membrane may be formed from a blend of two AB copolymers, where one of the copolymers contains more of a hydrophilic B polymer component than the blended targeted amount and the other copolymer contains less of a hydrophilic B polymer component than the blended targeted amount.
- In yet another embodiment of the invention, the first polymer includes homopolymer A and the second polymer includes homopolymer B.
- As described above, the invention also provides a polymeric membrane for regulating the transport of analytes that includes at least one block copolymer AB, wherein B forms a network of microdomains which are not photomicroscopically observable when hydrated at 400× magnification or less. In one embodiment, the ratio of A to B in copolymer AB is 70:30 to 90:10.
- For each of the inventive embodiments herein described, homopolymer A is preferably a hydrophobic A polymer. Moreover, copolymer AB is preferably a hydrophobic-hydrophilic copolymer component that includes the reaction products of a hydrophobic A polymer and a hydrophilic B polymer. Suitable materials for preparing membranes the present invention are described below.
- For purposes of the present invention, copolymer AB may be a random or ordered block copolymer. Specifically, the random or ordered block copolymer may be selected from the following: ABA block copolymer, BAB block copolymer, AB random alternating block copolymer, AB regularly alternating block copolymer and combinations thereof.
- In a preferred embodiment, the sensor, membrane, and methods of the present invention may be used to determine the level of glucose or other analytes in a host. The level of glucose is a particularly important measurement for individuals having diabetes in that effective treatment depends on the accuracy of this measurement.
- In particular, the invention provides a method of measuring glucose in a biological fluid that includes the steps of: (a) providing (i) a host, and (ii) an implantable device for measuring an analyte in a hydrophilic body fluid, where the device includes a polymeric membrane having a matrix including a first polymer and a second polymer dispersed throughout the matrix, wherein the second polymer forms a network of microdomains which are not photomicroscopically observable when hydrated at 400× magnification or less; and a proximal layer of enzyme reactive with the analyte; and (b) implanting the device in the host. In one embodiment, the device is implanted subcutaneously.
- The invention also provides a method of measuring glucose in a biological fluid that includes the following steps: (a) providing (i) a host, and (ii) an implantable device for measuring an analyte in a hydrophilic body fluid, that includes a polymeric membrane including a matrix including a first polymer and a second polymer dispersed throughout the matrix, wherein the second polymer forms a network of microdomains which are not photomicroscopically observable when hydrated at 400× magnification or less; and a proximal layer of enzyme reactive with the analyte, the device being capable of accurate continuous glucose sensing; and (b) implanting the device in the host. Desirably, the implant is placed subcutaneously in the host.
- Glucose sensors that use, for example, glucose oxidase to effect a reaction of glucose and oxygen are known in the art, and are within the skill of one in the art to fabricate (see, for example, U.S. Pat. Nos. 5,165,407, 4,890,620, 5,390,671, 5,391,250, 6,001,067 as well as copending, commonly owned U.S. patent application Ser. No. 09/916,858. It is noted that the present invention does not depend on a particular configuration of the sensor, but is rather dependent on the use of the inventive membrane to cover or encapsulate the sensor elements.
- For the electrochemical glucose sensor to provide useful results, the glucose concentration, as opposed to oxygen concentration, must be the limiting factor. In order to make the system sensitive to glucose concentration, oxygen must be present within the membrane in excess of the glucose. In addition, the oxygen must be in sufficient excess so that it is also available for electrochemical reactions occurring at the amperometric electrode surfaces. In a preferred embodiment, the inventive membrane is designed so that oxygen can pass readily into and through the membrane and so that a reduced amount of glucose diffuses into and through the membrane into contact with an immobilized glucose oxidase enzyme. The inventive membrane allows the ratio of oxygen to glucose to be changed from a concentration ratio in the body fluid of about approximately 50 and 100 parts of glucose to 1 of oxygen to a new ratio in which there is a stoichiometric excess of oxygen in the enzyme layer. Through the use of the inventive membrane, an implantable glucose sensor system is not limited by the concentration of oxygen present in subcutaneous tissues and can therefore operate under the premise that the glucose oxidase reaction behaves as a 1-substrate (glucose) dependent process.
- The present invention provides a semi-permeable membrane that controls the flux of oxygen and glucose to an underlying enzyme layer, rendering the necessary supply of oxygen in non-rate-limiting excess. As a result, the upper limit of linearity of glucose measurement is extended to a much higher value than that which could be achieved without the membrane of the present invention. In particular, in one embodiment the membrane of the present invention is a polymer membrane with oxygen-to-glucose permeability ratios of approximately 200:1; as a result, 1-dimensional reactant diffusion is adequate to provide excess oxygen at all reasonable glucose and oxygen concentrations found in a subcutaneous matrix [Rhodes, et al., Anal. Chem., 66: 1520-1529 (1994)].
- A hydrophilic or “water loving” solute such as glucose is readily partitioned into a hydrophilic material, but is generally excluded from a hydrophobic material. However, oxygen can be soluble in both hydrophilic and hydrophobic materials. These factors affect entry and transport of components in the inventive membrane. The hydrophobic portions of the inventive membrane hinder the rate of entry of glucose into the membrane, and therefore to the proximal enzyme layer while providing access of oxygen through both the hydrophilic and hydrophobic portions to the underlying enzyme.
- In one preferred embodiment, the membrane of the invention is formed from a blend of polymers including (i) a hydrophobic A polymer component; and (ii) a hydrophobic-hydrophilic copolymer component blended with component (i) that forms hydrophilic B domains that control the diffusion of an analyte therethrough, wherein the copolymer component includes a random or ordered block copolymer. Suitable block copolymers are described above. One is able to modify the glucose permeability and the glucose diffusion characteristics of the membrane by simply varying the polymer composition.
- In one preferred embodiment, the hydrophobic A polymer is a polyurethane. In a most preferred embodiment, the polyurethane is polyetherurethaneurea. A polyurethane is a polymer produced by the condensation reaction of a diisocyanate and a difunctional hydroxyl-containing material. A polyurethaneurea is a polymer produced by the condensation reaction of a diisocyanate and a difunctional amine-containing material. Preferred diisocyanates include aliphatic diisocyanates containing from 4 to 8 methylene units. Diisocyanates containing cycloaliphatic moieties, may also be useful in the preparation of the polymer and copolymer components of the membrane of the present invention. The invention is not limited to the use of polyurethanes as the hydrophobic polymer A component. The material that forms the basis of the hydrophobic matrix of the inventive membrane may be any of those known in the art as appropriate for use as membranes in sensor devices and having sufficient permeability to allow relevant compounds to pass through it, for example, to allow an oxygen molecule to pass through the inventive membrane from the sample under examination in order to reach the active enzyme or electrochemical electrodes. Examples of materials which may be used to make a non-polyurethane type membrane include vinyl polymers, polyethers, polyesters, polyamides, inorganic polymers such as polysiloxanes and polycarbosiloxanes, natural polymers such as cellulosic and protein based materials and mixtures or combinations thereof.
- As described above, the hydrophobic-hydrophilic copolymer component includes the reaction products of a hydrophobic A polymer component and a hydrophilic B polymer component. The hydrophilic B polymer component is desirably polyethylene oxide. For example, one useful hydrophobic-hydrophilic copolymer component is a polyurethane polymer that includes about 20% hydrophilic polyethyelene oxide. The polyethylene oxide portion of the copolymer is thermodynamically driven to separate from the hydrophobic portions of the copolymer and the hydrophobic A polymer component. The 20% polyethylene oxide based soft segment portion of the copolymer used to form the final blend controls the water pick-up and subsequent glucose permeability of the membrane of the present invention.
- The polyethylene oxide may have an average molecular weight of from 200 to 3000 with a preferred molecular weight range of 600 to 1500 and preferably constitutes about 20% by weight of the copolymer component used to form the membrane of the present invention.
- It is desired that the membrane of the present invention have a thickness of about 5 to about 100 microns. In preferred embodiments, the membrane of the present invention is constructed of a polyetherurethaneurea/polyetherurethaneurea-block-polyethylene glycol blend and has a thickness of not more than about 100 microns, more preferably not less than about 10 microns, and not more than about 80 microns, and most preferably, not less than about 20 microns, and not more than about 60 microns.
- The membrane of the present invention can be made by casting from solutions, optionally with inclusion of additives to modify the properties and the resulting cast film or to facilitate the casting process.
- The present invention provides a method for preparing the implantable membrane of the invention. The method includes the steps of: (a) forming a composition including a dispersion of a second polymer within a matrix of a first polymer, the dispersion forming a network of microdomains which are not photomicroscopically observable when hydrated at 400× magnification or less; (b) maintaining the composition at a temperature sufficient to maintain the first polymer and the second polymer substantially soluble; (c) applying the composition at the temperature to a substrate to form a film thereon; and (d) permitting the resultant film to dry to form the membrane. In one embodiment, the forming step includes forming a mixture or a blend. As described above, in preferred embodiments, the first polymer is a polyurethane and the second polymer is polyethylene oxide. In general, the second polymer may be a random or ordered block copolymer selected from the following: ABA block copolymer, BAB block copolymer, AB random alternating block copolymer, AB regularly alternating block copolymer and combinations thereof.
- In one embodiment, the composition comprised of a dispersion of the second polymer within the matrix of a first polymer is heated to a temperature of about 70° C. to maintain the first and second polymers substantially soluble. For example, the combination of a hydrophobic polymer A component and a hydrophobic-hydrophilic copolymer AB component is desirably exposed to a temperature of about 70° C. to maintain the polymer and copolymers substantially soluble. In particular, the blend is heated well above room temperature in order to keep the hydrophilic and hydrophobic components soluble with each other and the solvent.
- The invention contemplates permitting the coated film formed on the substrate to dry at a temperature from about 120° C. to about 150° C. The elevated temperature further serves to drive the solvent from the coating as quickly as possible. This inhibits the hydrophilic and hydrophobic portions of the membrane from segregating and forming large undesired structures.
- The membrane and sensor combinations of the present invention provide a significant advantage over the prior art in that they provide accurate sensor operation at temperatures from about 30° C. to about 45° C. for a period of time exceeding about 30 days to exceeding about a year.
- The inventive membrane may be cast from a coating solution. The coating solution is prepared by placing approximately 281 gm of dimethylacetamide (DMAC) into a 3 L stainless steel bowl to which a solution of polyetherurethaneurea (344 gm of Chronothane H (Cardiotech International, Inc., Woburn, Mass.), 29,750 cp@25% solids in DMAC) is added. To this mixture is added another polyetherurethaneurea (approximately 312 gm, Chronothane 1020 (Cardiotech International, Inc., Woburn, Mass.), 6275 cp@25% solids in DMAC). The bowl is then fitted to a planetary mixer with a paddle-type blade and the contents are stirred for 30 minutes at room temperature. Coatings solutions prepared in this manner are then coated at between room temperature to about 70° C. onto a PET release liner (Douglas Hansen Co., Inc., Minneapolis, Minn.) using a knife-over-roll set at a 0.012 inch gap. The film is continuously dried at 120° C. to about 150° C. The final film thickness is approximately 0.0015 inches.
- A ¼″ by ¼″ piece of membrane is first immersed in deionized water for a minimum of 2 hours at room temperature. After this time, the sample is placed onto a microscope slide along with one drop of water. A glass cover slide is then placed over the membrane and gentle pressure is applied in order to remove excess liquid from underneath the cover glass. In this way, the membrane does not dry during its evaluation. The hydrated membrane sample is first observed at 40×-magnification using a light microscope (Nikon Eclipse E400). If air bubbles are present on the top or bottom of the film, the cover glass is gently pressed again with a tissue in order to remove them. Magnification is then increased to 200×; and the hydrated membrane is continuously observed while changing the focus from the top to bottom of the film. This is followed by an increase in magnification to 400×, with the membrane again being continuously observed while changing the focus from the top to bottom of the film.
- Based on the results of an optical micrograph of a sample membrane prepared by using a room temperature coating solution and drying of the coated film at 120° C., the micrograph being captured as described above, it was noticed that both circular and elliptical domains were present throughout the hydrated section of membrane. At the same magnification, the domains were not observable in dry membrane. Giving that in an electrochemical sensor, the electrodes included therein are typically of the same size and same order of dimensions as the observed circular and elliptical domains, such domains are not desired. These domains present a problem in that they result in a locally high concentration of either hydrophilic or hydrophobic material in association with the electrodes.
- This example demonstrates that preheating the coating solution to a temperature of 70° C. prior to coating eliminates the presence of both the circular and elliptical domains that were present throughout the hydrated cross-section of a membrane prepared using a room temperature coating solution and drying of the coated film at 120° C. Example 2 further demonstrates that, provided the coating solution is preheated to about 70° C., either a standard) (120°) or elevated (150° C.) drying temperature were sufficient to drive the DMAC solvent from the coated film quickly to further inhibit the hydrophilic and hydrophobic portions of the polyurethane membrane from segregating into large domains.
- In particular, the invention was evaluated by performing a coating experiment where standard coating conditions (room temperature coating solution and 120° C. drying temperature of the coated film) were compared to conditions where the coating solution temperature was elevated and/or the drying temperature of the coated film was elevated. Four experimental conditions were run as follows:
- SS-room temperature solution and standard (120° C.) oven temperature.
- SE-room temperature solution and elevated (150° C.) oven temperature.
- ES-preheated (70° C.) solution and standard (120° C.) oven temperature.
- EE-preheated (70° C.) solution and elevated (150° C.) oven temperature.
- Samples of each of the four membranes listed above were then hydrated for 2 hours, and then observed under the microscope. Performance specifications were achieved when the micrograph of the membrane prepared under a given condition showed an absence of circular and/or elliptical domains that result in an undesirable, discontinuous hydrophilic and hydrophobic membrane structure. Table 1 below summarizes these results where (+) indicates a membrane meeting desired performance specifications and (−) is indicative of a membrane showing the undesirable circular and/or elliptical domains. In summary, for both the ES and EE conditions, where the coating solution was preheated to 70° C. prior to coating on a substrate, no hydrated domains were observed at a 200× magnification. Furthermore, regardless of the drying temperature used for the coated film, when the coating solution was not preheated (conditions SS and SE), the hydrated structures were observed. Therefore, it is likely that preheating the coating solution effectively inhibits the hydrophilic and hydrophobic segments of the polyurethane from segregating into large domains.
-
TABLE 1 Coating Condition Result SS − SE − ES (Inventive) + EE (Inventive) + - Evaluation of the Inventive Membranes for their Permeabilit to Glucose and H2O2
- Membranes prepared under the EE condition described in Example 2 were evaluated for their ability to allow glucose and hydrogen peroxide to get through the membrane to a sensor. In particular, a series of polyurethane blends of the present invention were generated wherein the percentage of Chronothane H in a coating blend was varied. Furthermore, one of these blends (57.5% Chronothane H in coating blend) was prepared under both the EE condition and the SS condition as described in Example 2.
FIG. 6 shows that the sensor output generated with a series of polyurethane blends of the present invention was dependent upon the percentage of the Chronothane H. In particular, the sensor output increased as the percentage of Chronothane H in the coating blend increased. With further reference toFIG. 6 , when the percentage of Chronothane H in the coating blend was 57.5%, the sensor output was three times greater for the membrane prepared under the optimized EE coating condition as compared to the non-optimized SS coating condition. - Furthermore,
FIG. 7 demonstrates that, regardless of the percent Chronothane H in the coating blend, an inventive membrane prepared under the EE condition shows a fairly constant percent standard deviation of sensor output. Moreover, a membrane prepared with 57.5% Chronothane H in the coating blend under the SS condition showed a percent standard deviation of sensor output approximately twice that of an EE membrane prepared with the same percentage of Chronothane H in the blend. It is noted that given that the sensor output is a true measure of the amount of glucose getting through the membrane to the sensor, the results indicate that the permeability of glucose and H2O2 is relatively constant throughout a given inventive membrane prepared under optimized coating conditions (i.e., EE conditions). This is important from a manufacturing standpoint. - Having described the particular, preferred embodiments of the invention herein, it should be appreciated that modifications may be made therethrough without departing from the contemplated scope of the invention. The true scope of the invention is set forth in the claims appended hereto.
Claims (27)
1. A method for fabricating a device for measuring a concentration of an analyte, the method comprising:
providing a sensor mechanism configured to measure an analyte or a product of a reaction associated with the analyte;
forming a solution comprising a blend of a first polymer and a second polymer, wherein a segment of the first polymer and a segment of the second polymer are both formed of a same monomer unit;
maintaining the solution at a temperature sufficient to maintain solubility of the first polymer and the second polymer;
applying the solution to the sensor mechanism;
forming a film from the solution at the temperature; and
drying the film to form a membrane.
2. The method of claim 1 , wherein the monomer unit is selected from the group consisting of a polyurethane, a vinyl polymer, a polyether, a polyester, a polyamide, a polysiloxane, and a polycarbosiloxane.
3. The method of claim 1 , wherein the second polymer is a hydrophobic-hydrophilic co-polymer comprising a hydrophobic segment and a hydrophilic segment.
4. The method of claim 1 , wherein the second polymer comprises a polyurethane segment.
5. The method of claim 1 , wherein the membrane has a thickness of from about 5 microns to about 100 microns.
6. The method of claim 1 , wherein the analyte is glucose.
7. The method of claim 6 , wherein the membrane has an oxygen-to-glucose permeability ratio of approximately 200:1.
8. The method of claim 1 , wherein maintaining the solution at a temperature comprises heating the solution to a temperature of at least about 70° C.
9. The method of claim 1 , wherein the first polymer is a homopolymer.
10. A method for fabricating a device for measuring a concentration of an analyte, the method comprising:
providing a sensor mechanism configured to measure an analyte or a product of a reaction associated with the analyte;
forming a solution comprising a blend of a first polymer and a second polymer, wherein the first polymer is a hydrophilic polymer comprising a hydrophilic segment, wherein the second polymer is a hydrophobic-hydrophilic co-polymer comprising a hydrophobic segment and a hydrophilic segment, and wherein the hydrophilic segment of the first polymer and the hydrophilic segment of the second polymer are both formed of a same block; and
applying the solution to the sensor mechanism.
11. The method of claim 10 , further comprising:
maintaining the solution at a temperature sufficient to maintain solubility of the first polymer and the second polymer.
12. The method of claim 11 , wherein maintaining the solution at a temperature comprises heating the solution to a temperature of at least about 70° C.
13. The method of claim 11 , further comprising:
forming a film from the solution at the temperature; and
drying the film to form a membrane.
14. The method of claim 13 , wherein the membrane has a thickness of from about 5 microns to about 100 microns.
15. The method of claim 10 , wherein the second polymer comprises at least one block selected from the group consisting of a polyurethane, a vinyl polymer, a polyether, a polyester, a polyamide, a polysiloxane, a polycarbosiloxane, a polyethylene oxide, and copolymers thereof.
16. The method of claim 10 , wherein the analyte is glucose.
17. The method of claim 16 , wherein the membrane has an oxygen-to-glucose permeability ratio of approximately 200:1.
18. The method of claim 10 , wherein the first polymer is a homopolymer.
19. A method for fabricating a device for measuring a concentration of an analyte, the method comprising:
providing a sensor mechanism configured to measure an analyte or a product of a reaction associated with the analyte;
forming a solution comprising a matrix comprising a first polymer, wherein the solution further comprises a second polymer dispersed throughout the matrix, wherein the first polymer forms a network of hydrophilic microdomains throughout the matrix to create a pathway for analyte diffusion across a membrane, and wherein a segment of the first polymer and a segment of the second polymer are both formed of a same monomer unit;
maintaining the solution at a temperature sufficient to maintain solubility of the first polymer and the second polymer;
applying the solution to the sensor mechanism;
forming a film from the solution at the temperature; and
drying the film to form the membrane.
20. The method of claim 19 , wherein the monomer unit is selected from the group consisting of a polyurethane, a vinyl polymer, a polyether, a polyester, a polyamide, a polysiloxane, and a polycarbosiloxane.
21. The method of claim 19 , wherein the second polymer is a hydrophobic-hydrophilic co-polymer comprising a hydrophobic segment and a hydrophilic segment.
22. The method of claim 19 , wherein the second polymer comprises a polyurethane segment.
23. The method of claim 19 , wherein the membrane has a thickness of from about 5 microns to about 100 microns.
24. The method of claim 19 , wherein the analyte is glucose.
25. The method of claim 24 , wherein the membrane has an oxygen-to-glucose permeability ratio of approximately 200:1.
26. The method of claim 19 , wherein maintaining the solution at a temperature comprises heating the solution to a temperature of at least about 70° C.
27. The method of claim 19 , wherein the first polymer is a homopolymer.
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/283,397 US20120040101A1 (en) | 2002-05-22 | 2011-10-27 | Techniques to improve polyurethane membranes for implantable glucose sensors |
US13/631,780 US8865249B2 (en) | 2002-05-22 | 2012-09-28 | Techniques to improve polyurethane membranes for implantable glucose sensors |
US14/482,458 US9179869B2 (en) | 2002-05-22 | 2014-09-10 | Techniques to improve polyurethane membranes for implantable glucose sensors |
US14/875,539 US9801574B2 (en) | 2002-05-22 | 2015-10-05 | Techniques to improve polyurethane membranes for implantable glucose sensors |
US15/716,998 US10154807B2 (en) | 2002-05-22 | 2017-09-27 | Techniques to improve polyurethane membranes for implantable glucose sensors |
US16/185,957 US20190083018A1 (en) | 2002-05-22 | 2018-11-09 | Techniques to improve polyurethane membranes for implantable glucose sensors |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/153,356 US7226978B2 (en) | 2002-05-22 | 2002-05-22 | Techniques to improve polyurethane membranes for implantable glucose sensors |
US11/280,672 US8050731B2 (en) | 2002-05-22 | 2005-11-16 | Techniques to improve polyurethane membranes for implantable glucose sensors |
US13/283,397 US20120040101A1 (en) | 2002-05-22 | 2011-10-27 | Techniques to improve polyurethane membranes for implantable glucose sensors |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/280,672 Continuation US8050731B2 (en) | 2002-05-22 | 2005-11-16 | Techniques to improve polyurethane membranes for implantable glucose sensors |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/631,780 Continuation US8865249B2 (en) | 2002-05-22 | 2012-09-28 | Techniques to improve polyurethane membranes for implantable glucose sensors |
Publications (1)
Publication Number | Publication Date |
---|---|
US20120040101A1 true US20120040101A1 (en) | 2012-02-16 |
Family
ID=29548646
Family Applications (10)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/153,356 Expired - Lifetime US7226978B2 (en) | 2002-05-22 | 2002-05-22 | Techniques to improve polyurethane membranes for implantable glucose sensors |
US11/280,672 Active 2024-11-12 US8050731B2 (en) | 2002-05-22 | 2005-11-16 | Techniques to improve polyurethane membranes for implantable glucose sensors |
US11/280,102 Abandoned US20060068208A1 (en) | 2002-05-22 | 2005-11-16 | Techniques to improve polyurethane membranes for implantable glucose sensors |
US12/688,737 Expired - Lifetime US8053018B2 (en) | 2002-05-22 | 2010-01-15 | Techniques to improve polyurethane membranes for implantable glucose sensors |
US13/283,397 Abandoned US20120040101A1 (en) | 2002-05-22 | 2011-10-27 | Techniques to improve polyurethane membranes for implantable glucose sensors |
US13/631,780 Expired - Lifetime US8865249B2 (en) | 2002-05-22 | 2012-09-28 | Techniques to improve polyurethane membranes for implantable glucose sensors |
US14/482,458 Expired - Lifetime US9179869B2 (en) | 2002-05-22 | 2014-09-10 | Techniques to improve polyurethane membranes for implantable glucose sensors |
US14/875,539 Expired - Lifetime US9801574B2 (en) | 2002-05-22 | 2015-10-05 | Techniques to improve polyurethane membranes for implantable glucose sensors |
US15/716,998 Expired - Lifetime US10154807B2 (en) | 2002-05-22 | 2017-09-27 | Techniques to improve polyurethane membranes for implantable glucose sensors |
US16/185,957 Abandoned US20190083018A1 (en) | 2002-05-22 | 2018-11-09 | Techniques to improve polyurethane membranes for implantable glucose sensors |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/153,356 Expired - Lifetime US7226978B2 (en) | 2002-05-22 | 2002-05-22 | Techniques to improve polyurethane membranes for implantable glucose sensors |
US11/280,672 Active 2024-11-12 US8050731B2 (en) | 2002-05-22 | 2005-11-16 | Techniques to improve polyurethane membranes for implantable glucose sensors |
US11/280,102 Abandoned US20060068208A1 (en) | 2002-05-22 | 2005-11-16 | Techniques to improve polyurethane membranes for implantable glucose sensors |
US12/688,737 Expired - Lifetime US8053018B2 (en) | 2002-05-22 | 2010-01-15 | Techniques to improve polyurethane membranes for implantable glucose sensors |
Family Applications After (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/631,780 Expired - Lifetime US8865249B2 (en) | 2002-05-22 | 2012-09-28 | Techniques to improve polyurethane membranes for implantable glucose sensors |
US14/482,458 Expired - Lifetime US9179869B2 (en) | 2002-05-22 | 2014-09-10 | Techniques to improve polyurethane membranes for implantable glucose sensors |
US14/875,539 Expired - Lifetime US9801574B2 (en) | 2002-05-22 | 2015-10-05 | Techniques to improve polyurethane membranes for implantable glucose sensors |
US15/716,998 Expired - Lifetime US10154807B2 (en) | 2002-05-22 | 2017-09-27 | Techniques to improve polyurethane membranes for implantable glucose sensors |
US16/185,957 Abandoned US20190083018A1 (en) | 2002-05-22 | 2018-11-09 | Techniques to improve polyurethane membranes for implantable glucose sensors |
Country Status (5)
Country | Link |
---|---|
US (10) | US7226978B2 (en) |
EP (1) | EP1506307A1 (en) |
JP (1) | JP4317519B2 (en) |
AU (1) | AU2003229330A1 (en) |
WO (1) | WO2003100083A1 (en) |
Cited By (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110054275A1 (en) * | 2009-08-31 | 2011-03-03 | Abbott Diabetes Care Inc. | Mounting Unit Having a Sensor and Associated Circuitry |
US8497777B2 (en) | 2009-04-15 | 2013-07-30 | Abbott Diabetes Care Inc. | Analyte monitoring system having an alert |
US8514086B2 (en) | 2009-08-31 | 2013-08-20 | Abbott Diabetes Care Inc. | Displays for a medical device |
US8512243B2 (en) | 2005-09-30 | 2013-08-20 | Abbott Diabetes Care Inc. | Integrated introducer and transmitter assembly and methods of use |
US8545403B2 (en) | 2005-12-28 | 2013-10-01 | Abbott Diabetes Care Inc. | Medical device insertion |
WO2013152090A2 (en) | 2012-04-04 | 2013-10-10 | Dexcom, Inc. | Transcutaneous analyte sensors, applicators therefor, and associated methods |
US8602991B2 (en) | 2005-08-30 | 2013-12-10 | Abbott Diabetes Care Inc. | Analyte sensor introducer and methods of use |
WO2013184566A2 (en) | 2012-06-05 | 2013-12-12 | Dexcom, Inc. | Systems and methods for processing analyte data and generating reports |
US8613703B2 (en) | 2007-05-31 | 2013-12-24 | Abbott Diabetes Care Inc. | Insertion devices and methods |
WO2014004460A1 (en) | 2012-06-29 | 2014-01-03 | Dexcom, Inc. | Use of sensor redundancy to detect sensor failures |
WO2014011488A2 (en) | 2012-07-09 | 2014-01-16 | Dexcom, Inc. | Systems and methods for leveraging smartphone features in continuous glucose monitoring |
WO2014052080A1 (en) | 2012-09-28 | 2014-04-03 | Dexcom, Inc. | Zwitterion surface modifications for continuous sensors |
US8718739B2 (en) | 2008-03-28 | 2014-05-06 | Abbott Diabetes Care Inc. | Analyte sensor calibration management |
US8764657B2 (en) | 2010-03-24 | 2014-07-01 | Abbott Diabetes Care Inc. | Medical device inserters and processes of inserting and using medical devices |
WO2014158405A2 (en) | 2013-03-14 | 2014-10-02 | Dexcom, Inc. | Systems and methods for processing and transmitting sensor data |
WO2014158327A2 (en) | 2013-03-14 | 2014-10-02 | Dexcom, Inc. | Advanced calibration for analyte sensors |
US8852101B2 (en) | 2005-12-28 | 2014-10-07 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor insertion |
US8862198B2 (en) | 2006-09-10 | 2014-10-14 | Abbott Diabetes Care Inc. | Method and system for providing an integrated analyte sensor insertion device and data processing unit |
US8865249B2 (en) | 2002-05-22 | 2014-10-21 | Dexcom, Inc. | Techniques to improve polyurethane membranes for implantable glucose sensors |
WO2015156966A1 (en) | 2014-04-10 | 2015-10-15 | Dexcom, Inc. | Sensors for continuous analyte monitoring, and related methods |
US9259175B2 (en) | 2006-10-23 | 2016-02-16 | Abbott Diabetes Care, Inc. | Flexible patch for fluid delivery and monitoring body analytes |
US9310230B2 (en) | 2009-04-29 | 2016-04-12 | Abbott Diabetes Care Inc. | Method and system for providing real time analyte sensor calibration with retrospective backfill |
US9339217B2 (en) | 2011-11-25 | 2016-05-17 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods of use |
US9351669B2 (en) | 2009-09-30 | 2016-05-31 | Abbott Diabetes Care Inc. | Interconnect for on-body analyte monitoring device |
US9398882B2 (en) | 2005-09-30 | 2016-07-26 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor and data processing device |
US9402544B2 (en) | 2009-02-03 | 2016-08-02 | Abbott Diabetes Care Inc. | Analyte sensor and apparatus for insertion of the sensor |
US9402570B2 (en) | 2011-12-11 | 2016-08-02 | Abbott Diabetes Care Inc. | Analyte sensor devices, connections, and methods |
US9521968B2 (en) | 2005-09-30 | 2016-12-20 | Abbott Diabetes Care Inc. | Analyte sensor retention mechanism and methods of use |
US9572534B2 (en) | 2010-06-29 | 2017-02-21 | Abbott Diabetes Care Inc. | Devices, systems and methods for on-skin or on-body mounting of medical devices |
US9743862B2 (en) | 2011-03-31 | 2017-08-29 | Abbott Diabetes Care Inc. | Systems and methods for transcutaneously implanting medical devices |
US9788771B2 (en) | 2006-10-23 | 2017-10-17 | Abbott Diabetes Care Inc. | Variable speed sensor insertion devices and methods of use |
US9980670B2 (en) | 2002-11-05 | 2018-05-29 | Abbott Diabetes Care Inc. | Sensor inserter assembly |
US10028680B2 (en) | 2006-04-28 | 2018-07-24 | Abbott Diabetes Care Inc. | Introducer assembly and methods of use |
US10194863B2 (en) | 2005-09-30 | 2019-02-05 | Abbott Diabetes Care Inc. | Integrated transmitter unit and sensor introducer mechanism and methods of use |
US10213139B2 (en) | 2015-05-14 | 2019-02-26 | Abbott Diabetes Care Inc. | Systems, devices, and methods for assembling an applicator and sensor control device |
US10226207B2 (en) | 2004-12-29 | 2019-03-12 | Abbott Diabetes Care Inc. | Sensor inserter having introducer |
US10561349B2 (en) | 2016-03-31 | 2020-02-18 | Dexcom, Inc. | Systems and methods for display device and sensor electronics unit communication |
EP3654348A1 (en) | 2012-11-07 | 2020-05-20 | Dexcom, Inc. | Systems and methods for managing glycemic variability |
US10674944B2 (en) | 2015-05-14 | 2020-06-09 | Abbott Diabetes Care Inc. | Compact medical device inserters and related systems and methods |
USD902408S1 (en) | 2003-11-05 | 2020-11-17 | Abbott Diabetes Care Inc. | Analyte sensor control unit |
US10860687B2 (en) | 2012-12-31 | 2020-12-08 | Dexcom, Inc. | Remote monitoring of analyte measurements |
US10856736B2 (en) | 2012-12-31 | 2020-12-08 | Dexcom, Inc. | Remote monitoring of analyte measurements |
US10874338B2 (en) | 2010-06-29 | 2020-12-29 | Abbott Diabetes Care Inc. | Devices, systems and methods for on-skin or on-body mounting of medical devices |
US10932672B2 (en) | 2015-12-28 | 2021-03-02 | Dexcom, Inc. | Systems and methods for remote and host monitoring communications |
US10985804B2 (en) | 2013-03-14 | 2021-04-20 | Dexcom, Inc. | Systems and methods for processing and transmitting sensor data |
USD924406S1 (en) | 2010-02-01 | 2021-07-06 | Abbott Diabetes Care Inc. | Analyte sensor inserter |
US11071478B2 (en) | 2017-01-23 | 2021-07-27 | Abbott Diabetes Care Inc. | Systems, devices and methods for analyte sensor insertion |
US11112377B2 (en) | 2015-12-30 | 2021-09-07 | Dexcom, Inc. | Enzyme immobilized adhesive layer for analyte sensors |
EP3925522A1 (en) | 2017-06-23 | 2021-12-22 | Dexcom, Inc. | Transcutaneous analyte sensors, applicators therefor, and associated methods |
US11298058B2 (en) | 2005-12-28 | 2022-04-12 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor insertion |
US11331022B2 (en) | 2017-10-24 | 2022-05-17 | Dexcom, Inc. | Pre-connected analyte sensors |
US11350862B2 (en) | 2017-10-24 | 2022-06-07 | Dexcom, Inc. | Pre-connected analyte sensors |
USD961778S1 (en) | 2006-02-28 | 2022-08-23 | Abbott Diabetes Care Inc. | Analyte sensor device |
EP4046571A1 (en) | 2015-10-21 | 2022-08-24 | Dexcom, Inc. | Transcutaneous analyte sensors, applicators therefor, and associated methods |
USD962446S1 (en) | 2009-08-31 | 2022-08-30 | Abbott Diabetes Care, Inc. | Analyte sensor device |
USD982762S1 (en) | 2020-12-21 | 2023-04-04 | Abbott Diabetes Care Inc. | Analyte sensor inserter |
USD1002852S1 (en) | 2019-06-06 | 2023-10-24 | Abbott Diabetes Care Inc. | Analyte sensor device |
US11892426B2 (en) | 2012-06-29 | 2024-02-06 | Dexcom, Inc. | Devices, systems, and methods to compensate for effects of temperature on implantable sensors |
US11896371B2 (en) | 2012-09-26 | 2024-02-13 | Abbott Diabetes Care Inc. | Method and apparatus for improving lag correction during in vivo measurement of analyte concentration with analyte concentration variability and range data |
US11998329B2 (en) | 2013-03-15 | 2024-06-04 | Dexcom, Inc. | Membrane for continuous analyte sensors |
USD1036676S1 (en) | 2018-06-22 | 2024-07-23 | Dexcom, Inc. | Wearable medical monitoring device |
US12125588B2 (en) | 2021-04-28 | 2024-10-22 | Dexcom Inc. | Systems and methods for processing and transmitting sensor data |
Families Citing this family (334)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5593852A (en) * | 1993-12-02 | 1997-01-14 | Heller; Adam | Subcutaneous glucose electrode |
US7192450B2 (en) | 2003-05-21 | 2007-03-20 | Dexcom, Inc. | Porous membranes for use with implantable devices |
US7885697B2 (en) | 2004-07-13 | 2011-02-08 | Dexcom, Inc. | Transcutaneous analyte sensor |
US20050033132A1 (en) | 1997-03-04 | 2005-02-10 | Shults Mark C. | Analyte measuring device |
US8527026B2 (en) | 1997-03-04 | 2013-09-03 | Dexcom, Inc. | Device and method for determining analyte levels |
US6001067A (en) | 1997-03-04 | 1999-12-14 | Shults; Mark C. | Device and method for determining analyte levels |
US9155496B2 (en) * | 1997-03-04 | 2015-10-13 | Dexcom, Inc. | Low oxygen in vivo analyte sensor |
US6036924A (en) | 1997-12-04 | 2000-03-14 | Hewlett-Packard Company | Cassette of lancet cartridges for sampling blood |
US6134461A (en) | 1998-03-04 | 2000-10-17 | E. Heller & Company | Electrochemical analyte |
US6391005B1 (en) | 1998-03-30 | 2002-05-21 | Agilent Technologies, Inc. | Apparatus and method for penetration with shaft having a sensor for sensing penetration depth |
US8974386B2 (en) | 1998-04-30 | 2015-03-10 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US6175752B1 (en) | 1998-04-30 | 2001-01-16 | Therasense, Inc. | Analyte monitoring device and methods of use |
US8480580B2 (en) | 1998-04-30 | 2013-07-09 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8346337B2 (en) | 1998-04-30 | 2013-01-01 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8465425B2 (en) | 1998-04-30 | 2013-06-18 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9066695B2 (en) | 1998-04-30 | 2015-06-30 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US6949816B2 (en) | 2003-04-21 | 2005-09-27 | Motorola, Inc. | Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same |
US8688188B2 (en) | 1998-04-30 | 2014-04-01 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8641644B2 (en) | 2000-11-21 | 2014-02-04 | Sanofi-Aventis Deutschland Gmbh | Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means |
US6560471B1 (en) | 2001-01-02 | 2003-05-06 | Therasense, Inc. | Analyte monitoring device and methods of use |
US7041468B2 (en) | 2001-04-02 | 2006-05-09 | Therasense, Inc. | Blood glucose tracking apparatus and methods |
US9226699B2 (en) | 2002-04-19 | 2016-01-05 | Sanofi-Aventis Deutschland Gmbh | Body fluid sampling module with a continuous compression tissue interface surface |
AU2002348683A1 (en) | 2001-06-12 | 2002-12-23 | Pelikan Technologies, Inc. | Method and apparatus for lancet launching device integrated onto a blood-sampling cartridge |
ES2336081T3 (en) | 2001-06-12 | 2010-04-08 | Pelikan Technologies Inc. | SELF-OPTIMIZATION PUNCTURE DEVICE WITH MEANS OF ADAPTATION TO TEMPORARY VARIATIONS IN CUTANEOUS PROPERTIES. |
US7041068B2 (en) | 2001-06-12 | 2006-05-09 | Pelikan Technologies, Inc. | Sampling module device and method |
US9427532B2 (en) | 2001-06-12 | 2016-08-30 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
DE60239132D1 (en) | 2001-06-12 | 2011-03-24 | Pelikan Technologies Inc | APPARATUS FOR INCREASING THE SUCCESS RATE IN RESPECT OF BLOOD EXPLOITATION OBTAINED BY A FINGERSTICK |
US9795747B2 (en) | 2010-06-02 | 2017-10-24 | Sanofi-Aventis Deutschland Gmbh | Methods and apparatus for lancet actuation |
EP1395185B1 (en) | 2001-06-12 | 2010-10-27 | Pelikan Technologies Inc. | Electric lancet actuator |
EP1404232B1 (en) | 2001-06-12 | 2009-12-02 | Pelikan Technologies Inc. | Blood sampling apparatus and method |
US7981056B2 (en) | 2002-04-19 | 2011-07-19 | Pelikan Technologies, Inc. | Methods and apparatus for lancet actuation |
US8337419B2 (en) | 2002-04-19 | 2012-12-25 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US20030032874A1 (en) | 2001-07-27 | 2003-02-13 | Dexcom, Inc. | Sensor head for use with implantable devices |
US6702857B2 (en) | 2001-07-27 | 2004-03-09 | Dexcom, Inc. | Membrane for use with implantable devices |
US9247901B2 (en) | 2003-08-22 | 2016-02-02 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US8364229B2 (en) | 2003-07-25 | 2013-01-29 | Dexcom, Inc. | Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise |
US7613491B2 (en) | 2002-05-22 | 2009-11-03 | Dexcom, Inc. | Silicone based membranes for use in implantable glucose sensors |
US9282925B2 (en) | 2002-02-12 | 2016-03-15 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US8010174B2 (en) | 2003-08-22 | 2011-08-30 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US8260393B2 (en) | 2003-07-25 | 2012-09-04 | Dexcom, Inc. | Systems and methods for replacing signal data artifacts in a glucose sensor data stream |
US7901362B2 (en) | 2002-04-19 | 2011-03-08 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7547287B2 (en) | 2002-04-19 | 2009-06-16 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US8360992B2 (en) | 2002-04-19 | 2013-01-29 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US7491178B2 (en) | 2002-04-19 | 2009-02-17 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7909778B2 (en) | 2002-04-19 | 2011-03-22 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US8267870B2 (en) | 2002-04-19 | 2012-09-18 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for body fluid sampling with hybrid actuation |
US7232451B2 (en) | 2002-04-19 | 2007-06-19 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US8702624B2 (en) | 2006-09-29 | 2014-04-22 | Sanofi-Aventis Deutschland Gmbh | Analyte measurement device with a single shot actuator |
US7371247B2 (en) | 2002-04-19 | 2008-05-13 | Pelikan Technologies, Inc | Method and apparatus for penetrating tissue |
US7892183B2 (en) | 2002-04-19 | 2011-02-22 | Pelikan Technologies, Inc. | Method and apparatus for body fluid sampling and analyte sensing |
US7331931B2 (en) | 2002-04-19 | 2008-02-19 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US9248267B2 (en) | 2002-04-19 | 2016-02-02 | Sanofi-Aventis Deustchland Gmbh | Tissue penetration device |
US7291117B2 (en) | 2002-04-19 | 2007-11-06 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7297122B2 (en) | 2002-04-19 | 2007-11-20 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US8579831B2 (en) | 2002-04-19 | 2013-11-12 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US8784335B2 (en) | 2002-04-19 | 2014-07-22 | Sanofi-Aventis Deutschland Gmbh | Body fluid sampling device with a capacitive sensor |
US7229458B2 (en) | 2002-04-19 | 2007-06-12 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7976476B2 (en) | 2002-04-19 | 2011-07-12 | Pelikan Technologies, Inc. | Device and method for variable speed lancet |
US7717863B2 (en) | 2002-04-19 | 2010-05-18 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7175642B2 (en) | 2002-04-19 | 2007-02-13 | Pelikan Technologies, Inc. | Methods and apparatus for lancet actuation |
US9795334B2 (en) | 2002-04-19 | 2017-10-24 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US8221334B2 (en) | 2002-04-19 | 2012-07-17 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US7892185B2 (en) | 2002-04-19 | 2011-02-22 | Pelikan Technologies, Inc. | Method and apparatus for body fluid sampling and analyte sensing |
US7226461B2 (en) | 2002-04-19 | 2007-06-05 | Pelikan Technologies, Inc. | Method and apparatus for a multi-use body fluid sampling device with sterility barrier release |
US9314194B2 (en) | 2002-04-19 | 2016-04-19 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US7674232B2 (en) | 2002-04-19 | 2010-03-09 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7648468B2 (en) | 2002-04-19 | 2010-01-19 | Pelikon Technologies, Inc. | Method and apparatus for penetrating tissue |
US7727181B2 (en) * | 2002-10-09 | 2010-06-01 | Abbott Diabetes Care Inc. | Fluid delivery device with autocalibration |
EP2383470A1 (en) | 2002-10-09 | 2011-11-02 | Abbott Diabetes Care Inc. | Plunger pump actuated by a shape memory element |
US7993108B2 (en) | 2002-10-09 | 2011-08-09 | Abbott Diabetes Care Inc. | Variable volume, shape memory actuated insulin dispensing pump |
US7842234B2 (en) | 2002-12-02 | 2010-11-30 | Epocal Inc. | Diagnostic devices incorporating fluidics and methods of manufacture |
US7767068B2 (en) * | 2002-12-02 | 2010-08-03 | Epocal Inc. | Heterogeneous membrane electrodes |
US8574895B2 (en) | 2002-12-30 | 2013-11-05 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus using optical techniques to measure analyte levels |
US8771183B2 (en) | 2004-02-17 | 2014-07-08 | Abbott Diabetes Care Inc. | Method and system for providing data communication in continuous glucose monitoring and management system |
AU2003303597A1 (en) | 2002-12-31 | 2004-07-29 | Therasense, Inc. | Continuous glucose monitoring system and methods of use |
US7587287B2 (en) | 2003-04-04 | 2009-09-08 | Abbott Diabetes Care Inc. | Method and system for transferring analyte test data |
US7134999B2 (en) | 2003-04-04 | 2006-11-14 | Dexcom, Inc. | Optimized sensor geometry for an implantable glucose sensor |
US7679407B2 (en) | 2003-04-28 | 2010-03-16 | Abbott Diabetes Care Inc. | Method and apparatus for providing peak detection circuitry for data communication systems |
US7875293B2 (en) | 2003-05-21 | 2011-01-25 | Dexcom, Inc. | Biointerface membranes incorporating bioactive agents |
EP1628567B1 (en) | 2003-05-30 | 2010-08-04 | Pelikan Technologies Inc. | Method and apparatus for fluid injection |
US7850621B2 (en) | 2003-06-06 | 2010-12-14 | Pelikan Technologies, Inc. | Method and apparatus for body fluid sampling and analyte sensing |
US8066639B2 (en) | 2003-06-10 | 2011-11-29 | Abbott Diabetes Care Inc. | Glucose measuring device for use in personal area network |
US8460243B2 (en) | 2003-06-10 | 2013-06-11 | Abbott Diabetes Care Inc. | Glucose measuring module and insulin pump combination |
WO2006001797A1 (en) | 2004-06-14 | 2006-01-05 | Pelikan Technologies, Inc. | Low pain penetrating |
US8071028B2 (en) | 2003-06-12 | 2011-12-06 | Abbott Diabetes Care Inc. | Method and apparatus for providing power management in data communication systems |
US7722536B2 (en) | 2003-07-15 | 2010-05-25 | Abbott Diabetes Care Inc. | Glucose measuring device integrated into a holster for a personal area network device |
US8282549B2 (en) | 2003-12-09 | 2012-10-09 | Dexcom, Inc. | Signal processing for continuous analyte sensor |
EP1648298A4 (en) | 2003-07-25 | 2010-01-13 | Dexcom Inc | Oxygen enhancing membrane systems for implantable devices |
US9763609B2 (en) * | 2003-07-25 | 2017-09-19 | Dexcom, Inc. | Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise |
US20080119703A1 (en) | 2006-10-04 | 2008-05-22 | Mark Brister | Analyte sensor |
US8060173B2 (en) | 2003-08-01 | 2011-11-15 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US20190357827A1 (en) | 2003-08-01 | 2019-11-28 | Dexcom, Inc. | Analyte sensor |
US8275437B2 (en) | 2003-08-01 | 2012-09-25 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8886273B2 (en) | 2003-08-01 | 2014-11-11 | Dexcom, Inc. | Analyte sensor |
US7591801B2 (en) | 2004-02-26 | 2009-09-22 | Dexcom, Inc. | Integrated delivery device for continuous glucose sensor |
US7959569B2 (en) | 2003-08-01 | 2011-06-14 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US7774145B2 (en) | 2003-08-01 | 2010-08-10 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8761856B2 (en) | 2003-08-01 | 2014-06-24 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US8788006B2 (en) | 2003-08-01 | 2014-07-22 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US8160669B2 (en) | 2003-08-01 | 2012-04-17 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8369919B2 (en) | 2003-08-01 | 2013-02-05 | Dexcom, Inc. | Systems and methods for processing sensor data |
US7920906B2 (en) | 2005-03-10 | 2011-04-05 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US20140121989A1 (en) | 2003-08-22 | 2014-05-01 | Dexcom, Inc. | Systems and methods for processing analyte sensor data |
WO2005033659A2 (en) | 2003-09-29 | 2005-04-14 | Pelikan Technologies, Inc. | Method and apparatus for an improved sample capture device |
US9351680B2 (en) | 2003-10-14 | 2016-05-31 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for a variable user interface |
US7299082B2 (en) | 2003-10-31 | 2007-11-20 | Abbott Diabetes Care, Inc. | Method of calibrating an analyte-measurement device, and associated methods, devices and systems |
US9247900B2 (en) | 2004-07-13 | 2016-02-02 | Dexcom, Inc. | Analyte sensor |
US8364231B2 (en) | 2006-10-04 | 2013-01-29 | Dexcom, Inc. | Analyte sensor |
EP1706026B1 (en) | 2003-12-31 | 2017-03-01 | Sanofi-Aventis Deutschland GmbH | Method and apparatus for improving fluidic flow and sample capture |
US7822454B1 (en) | 2005-01-03 | 2010-10-26 | Pelikan Technologies, Inc. | Fluid sampling device with improved analyte detecting member configuration |
US8165651B2 (en) | 2004-02-09 | 2012-04-24 | Abbott Diabetes Care Inc. | Analyte sensor, and associated system and method employing a catalytic agent |
US7699964B2 (en) | 2004-02-09 | 2010-04-20 | Abbott Diabetes Care Inc. | Membrane suitable for use in an analyte sensor, analyte sensor, and associated method |
US8277713B2 (en) | 2004-05-03 | 2012-10-02 | Dexcom, Inc. | Implantable analyte sensor |
GB0411162D0 (en) * | 2004-05-19 | 2004-06-23 | Precisense As | Optical sensor for in vivo detection of analyte |
EP1751546A2 (en) | 2004-05-20 | 2007-02-14 | Albatros Technologies GmbH & Co. KG | Printable hydrogel for biosensors |
US9775553B2 (en) | 2004-06-03 | 2017-10-03 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for a fluid sampling device |
WO2005120365A1 (en) | 2004-06-03 | 2005-12-22 | Pelikan Technologies, Inc. | Method and apparatus for a fluid sampling device |
CA3090413C (en) * | 2004-06-04 | 2023-10-10 | Abbott Diabetes Care Inc. | Glucose monitoring and graphical representations in a data management system |
US8565848B2 (en) | 2004-07-13 | 2013-10-22 | Dexcom, Inc. | Transcutaneous analyte sensor |
US7640048B2 (en) | 2004-07-13 | 2009-12-29 | Dexcom, Inc. | Analyte sensor |
EP3718479B1 (en) | 2004-07-13 | 2021-12-15 | Dexcom, Inc. | Transcutaneous analyte sensor |
US7905833B2 (en) | 2004-07-13 | 2011-03-15 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8452368B2 (en) | 2004-07-13 | 2013-05-28 | Dexcom, Inc. | Transcutaneous analyte sensor |
EP1784249A2 (en) * | 2004-08-16 | 2007-05-16 | Novo Nordisk A/S | Multiphase biocompatible semi-permeable membrane for biosensors |
US8097725B2 (en) | 2004-12-03 | 2012-01-17 | Roche Diagnostics Operations, Inc. | Luminescent indicator dye and optical sensor |
US20090082693A1 (en) * | 2004-12-29 | 2009-03-26 | Therasense, Inc. | Method and apparatus for providing temperature sensor module in a data communication system |
US9636450B2 (en) | 2007-02-19 | 2017-05-02 | Udo Hoss | Pump system modular components for delivering medication and analyte sensing at seperate insertion sites |
US8571624B2 (en) | 2004-12-29 | 2013-10-29 | Abbott Diabetes Care Inc. | Method and apparatus for mounting a data transmission device in a communication system |
US8652831B2 (en) | 2004-12-30 | 2014-02-18 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for analyte measurement test time |
US7545272B2 (en) | 2005-02-08 | 2009-06-09 | Therasense, Inc. | RF tag on test strips, test strip vials and boxes |
WO2006102412A2 (en) | 2005-03-21 | 2006-09-28 | Abbott Diabetes Care, Inc. | Method and system for providing integrated medication infusion and analyte monitoring system |
US8744546B2 (en) | 2005-05-05 | 2014-06-03 | Dexcom, Inc. | Cellulosic-based resistance domain for an analyte sensor |
CA2606440A1 (en) * | 2005-04-29 | 2006-11-09 | University Of Rochester | Ultrathin porous nanoscale membranes, methods of making, and uses thereof |
US8112240B2 (en) | 2005-04-29 | 2012-02-07 | Abbott Diabetes Care Inc. | Method and apparatus for providing leak detection in data monitoring and management systems |
WO2006119252A2 (en) * | 2005-04-29 | 2006-11-09 | University Of Rochester | Ultrathin nanoscale membranes, methods of making, and uses thereof |
WO2006122554A2 (en) | 2005-05-17 | 2006-11-23 | Radiometer Medical Aps | Enzyme sensor with a cover membrane layer covered by a hydrophilic polymer |
US7768408B2 (en) | 2005-05-17 | 2010-08-03 | Abbott Diabetes Care Inc. | Method and system for providing data management in data monitoring system |
US7620437B2 (en) | 2005-06-03 | 2009-11-17 | Abbott Diabetes Care Inc. | Method and apparatus for providing rechargeable power in data monitoring and management systems |
DE102005037979B4 (en) * | 2005-08-11 | 2011-01-05 | Jürgen Prof. Dr. Heinze | Sensor with multiphase, segmented polymer network |
WO2007027691A1 (en) | 2005-08-31 | 2007-03-08 | University Of Virginia Patent Foundation | Improving the accuracy of continuous glucose sensors |
US7756561B2 (en) | 2005-09-30 | 2010-07-13 | Abbott Diabetes Care Inc. | Method and apparatus for providing rechargeable power in data monitoring and management systems |
US8880138B2 (en) | 2005-09-30 | 2014-11-04 | Abbott Diabetes Care Inc. | Device for channeling fluid and methods of use |
US7583190B2 (en) | 2005-10-31 | 2009-09-01 | Abbott Diabetes Care Inc. | Method and apparatus for providing data communication in data monitoring and management systems |
US7766829B2 (en) | 2005-11-04 | 2010-08-03 | Abbott Diabetes Care Inc. | Method and system for providing basal profile modification in analyte monitoring and management systems |
EP1792563A1 (en) * | 2005-12-02 | 2007-06-06 | F.Hoffmann-La Roche Ag | Analysis system comprising an OLED display element |
JP2009518494A (en) * | 2005-12-09 | 2009-05-07 | カウンスィル オブ サイエンティフィック アンド インダストリアル リサーチ | Melt transurethane process for producing polyurethane |
US8160670B2 (en) | 2005-12-28 | 2012-04-17 | Abbott Diabetes Care Inc. | Analyte monitoring: stabilizer for subcutaneous glucose sensor with incorporated antiglycolytic agent |
US8353881B2 (en) | 2005-12-28 | 2013-01-15 | Abbott Diabetes Care Inc. | Infusion sets for the delivery of a therapeutic substance to a patient |
US8515518B2 (en) | 2005-12-28 | 2013-08-20 | Abbott Diabetes Care Inc. | Analyte monitoring |
US9757061B2 (en) | 2006-01-17 | 2017-09-12 | Dexcom, Inc. | Low oxygen in vivo analyte sensor |
EP4372096A3 (en) | 2006-01-17 | 2024-08-21 | DexCom, Inc. | Low oxygen in vivo analyte sensor |
US7736310B2 (en) | 2006-01-30 | 2010-06-15 | Abbott Diabetes Care Inc. | On-body medical device securement |
US8344966B2 (en) | 2006-01-31 | 2013-01-01 | Abbott Diabetes Care Inc. | Method and system for providing a fault tolerant display unit in an electronic device |
EP3756537B1 (en) | 2006-02-22 | 2023-08-02 | DexCom, Inc. | Analyte sensor |
US7981034B2 (en) | 2006-02-28 | 2011-07-19 | Abbott Diabetes Care Inc. | Smart messages and alerts for an infusion delivery and management system |
US7826879B2 (en) | 2006-02-28 | 2010-11-02 | Abbott Diabetes Care Inc. | Analyte sensors and methods of use |
US7885698B2 (en) | 2006-02-28 | 2011-02-08 | Abbott Diabetes Care Inc. | Method and system for providing continuous calibration of implantable analyte sensors |
EP4218548A1 (en) | 2006-03-09 | 2023-08-02 | Dexcom, Inc. | Systems and methods for processing analyte sensor data |
EP1991110B1 (en) | 2006-03-09 | 2018-11-07 | DexCom, Inc. | Systems and methods for processing analyte sensor data |
US8119394B2 (en) * | 2006-03-14 | 2012-02-21 | University Of Rochester | Cell culture devices having ultrathin porous membrane and uses thereof |
US9675290B2 (en) | 2012-10-30 | 2017-06-13 | Abbott Diabetes Care Inc. | Sensitivity calibration of in vivo sensors used to measure analyte concentration |
US7618369B2 (en) | 2006-10-02 | 2009-11-17 | Abbott Diabetes Care Inc. | Method and system for dynamically updating calibration parameters for an analyte sensor |
US9326709B2 (en) | 2010-03-10 | 2016-05-03 | Abbott Diabetes Care Inc. | Systems, devices and methods for managing glucose levels |
US8224415B2 (en) | 2009-01-29 | 2012-07-17 | Abbott Diabetes Care Inc. | Method and device for providing offset model based calibration for analyte sensor |
US9392969B2 (en) | 2008-08-31 | 2016-07-19 | Abbott Diabetes Care Inc. | Closed loop control and signal attenuation detection |
US7620438B2 (en) | 2006-03-31 | 2009-11-17 | Abbott Diabetes Care Inc. | Method and system for powering an electronic device |
US8473022B2 (en) | 2008-01-31 | 2013-06-25 | Abbott Diabetes Care Inc. | Analyte sensor with time lag compensation |
US8140312B2 (en) | 2007-05-14 | 2012-03-20 | Abbott Diabetes Care Inc. | Method and system for determining analyte levels |
US8219173B2 (en) | 2008-09-30 | 2012-07-10 | Abbott Diabetes Care Inc. | Optimizing analyte sensor calibration |
US7653425B2 (en) | 2006-08-09 | 2010-01-26 | Abbott Diabetes Care Inc. | Method and system for providing calibration of an analyte sensor in an analyte monitoring system |
US8478557B2 (en) | 2009-07-31 | 2013-07-02 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte monitoring system calibration accuracy |
US7630748B2 (en) | 2006-10-25 | 2009-12-08 | Abbott Diabetes Care Inc. | Method and system for providing analyte monitoring |
US8374668B1 (en) | 2007-10-23 | 2013-02-12 | Abbott Diabetes Care Inc. | Analyte sensor with lag compensation |
US7801582B2 (en) | 2006-03-31 | 2010-09-21 | Abbott Diabetes Care Inc. | Analyte monitoring and management system and methods therefor |
US8226891B2 (en) | 2006-03-31 | 2012-07-24 | Abbott Diabetes Care Inc. | Analyte monitoring devices and methods therefor |
WO2007120381A2 (en) | 2006-04-14 | 2007-10-25 | Dexcom, Inc. | Analyte sensor |
US20080071157A1 (en) | 2006-06-07 | 2008-03-20 | Abbott Diabetes Care, Inc. | Analyte monitoring system and method |
US9119582B2 (en) | 2006-06-30 | 2015-09-01 | Abbott Diabetes Care, Inc. | Integrated analyte sensor and infusion device and methods therefor |
US8206296B2 (en) | 2006-08-07 | 2012-06-26 | Abbott Diabetes Care Inc. | Method and system for providing integrated analyte monitoring and infusion system therapy management |
US8932216B2 (en) | 2006-08-07 | 2015-01-13 | Abbott Diabetes Care Inc. | Method and system for providing data management in integrated analyte monitoring and infusion system |
US7871456B2 (en) * | 2006-08-10 | 2011-01-18 | The Regents Of The University Of California | Membranes with controlled permeability to polar and apolar molecules in solution and methods of making same |
WO2008018879A1 (en) * | 2006-08-10 | 2008-02-14 | The Regents Of The University Of California | Membranes with controlled permeability to polar and apolar molecules in solution and methods of making same |
EP1892877B1 (en) * | 2006-08-25 | 2008-12-03 | Alcatel Lucent | Digital signal receiver with Q-monitor |
US20080069858A1 (en) * | 2006-09-20 | 2008-03-20 | Boston Scientific Scimed, Inc. | Medical devices having biodegradable polymeric regions with overlying hard, thin layers |
EP2077762B8 (en) * | 2006-10-18 | 2014-09-17 | Maquet Critical Care AB | Microdialysis catheter and a method of making a microdialysis catheter |
US8135548B2 (en) | 2006-10-26 | 2012-03-13 | Abbott Diabetes Care Inc. | Method, system and computer program product for real-time detection of sensitivity decline in analyte sensors |
US8579853B2 (en) | 2006-10-31 | 2013-11-12 | Abbott Diabetes Care Inc. | Infusion devices and methods |
US20080199894A1 (en) | 2007-02-15 | 2008-08-21 | Abbott Diabetes Care, Inc. | Device and method for automatic data acquisition and/or detection |
US8121857B2 (en) | 2007-02-15 | 2012-02-21 | Abbott Diabetes Care Inc. | Device and method for automatic data acquisition and/or detection |
US8732188B2 (en) | 2007-02-18 | 2014-05-20 | Abbott Diabetes Care Inc. | Method and system for providing contextual based medication dosage determination |
US8930203B2 (en) | 2007-02-18 | 2015-01-06 | Abbott Diabetes Care Inc. | Multi-function analyte test device and methods therefor |
US8123686B2 (en) | 2007-03-01 | 2012-02-28 | Abbott Diabetes Care Inc. | Method and apparatus for providing rolling data in communication systems |
CA2681412A1 (en) | 2007-03-26 | 2008-10-02 | Dexcom, Inc. | Analyte sensor |
WO2009096992A1 (en) | 2007-04-14 | 2009-08-06 | Abbott Diabetes Care, Inc. | Method and apparatus for providing data processing and control in medical communication system |
US9204827B2 (en) | 2007-04-14 | 2015-12-08 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in medical communication system |
CA2683721C (en) | 2007-04-14 | 2017-05-23 | Abbott Diabetes Care Inc. | Method and apparatus for providing dynamic multi-stage signal amplification in a medical device |
US8140142B2 (en) | 2007-04-14 | 2012-03-20 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in medical communication system |
ES2784736T3 (en) | 2007-04-14 | 2020-09-30 | Abbott Diabetes Care Inc | Procedure and apparatus for providing data processing and control in a medical communication system |
US9008743B2 (en) | 2007-04-14 | 2015-04-14 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in medical communication system |
US8461985B2 (en) | 2007-05-08 | 2013-06-11 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
US7928850B2 (en) | 2007-05-08 | 2011-04-19 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
US8665091B2 (en) | 2007-05-08 | 2014-03-04 | Abbott Diabetes Care Inc. | Method and device for determining elapsed sensor life |
US8456301B2 (en) | 2007-05-08 | 2013-06-04 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
US8600681B2 (en) | 2007-05-14 | 2013-12-03 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US8444560B2 (en) | 2007-05-14 | 2013-05-21 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US8239166B2 (en) | 2007-05-14 | 2012-08-07 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US8560038B2 (en) | 2007-05-14 | 2013-10-15 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US9125548B2 (en) | 2007-05-14 | 2015-09-08 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US8103471B2 (en) | 2007-05-14 | 2012-01-24 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US7996158B2 (en) | 2007-05-14 | 2011-08-09 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US8260558B2 (en) | 2007-05-14 | 2012-09-04 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US10002233B2 (en) | 2007-05-14 | 2018-06-19 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US20200037874A1 (en) * | 2007-05-18 | 2020-02-06 | Dexcom, Inc. | Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise |
JP5680960B2 (en) | 2007-06-21 | 2015-03-04 | アボット ダイアベティス ケア インコーポレイテッドAbbott Diabetes Care Inc. | Health care device and method |
EP2166928B1 (en) | 2007-06-21 | 2018-09-12 | Abbott Diabetes Care Inc. | Health monitor |
US8641618B2 (en) | 2007-06-27 | 2014-02-04 | Abbott Diabetes Care Inc. | Method and structure for securing a monitoring device element |
US8085151B2 (en) | 2007-06-28 | 2011-12-27 | Abbott Diabetes Care Inc. | Signal converting cradle for medical condition monitoring and management system |
US8160900B2 (en) | 2007-06-29 | 2012-04-17 | Abbott Diabetes Care Inc. | Analyte monitoring and management device and method to analyze the frequency of user interaction with the device |
US8834366B2 (en) | 2007-07-31 | 2014-09-16 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor calibration |
US7768386B2 (en) | 2007-07-31 | 2010-08-03 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
JP2010536373A (en) | 2007-08-23 | 2010-12-02 | イントレキソン コーポレーション | Methods and compositions for diagnosing disease |
CA2715080C (en) | 2007-09-28 | 2021-09-28 | Intrexon Corporation | Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof |
EP4098177A1 (en) | 2007-10-09 | 2022-12-07 | DexCom, Inc. | Integrated insulin delivery system with continuous glucose sensor |
US8377031B2 (en) | 2007-10-23 | 2013-02-19 | Abbott Diabetes Care Inc. | Closed loop control system with safety parameters and methods |
US8216138B1 (en) | 2007-10-23 | 2012-07-10 | Abbott Diabetes Care Inc. | Correlation of alternative site blood and interstitial fluid glucose concentrations to venous glucose concentration |
US8409093B2 (en) | 2007-10-23 | 2013-04-02 | Abbott Diabetes Care Inc. | Assessing measures of glycemic variability |
EP2203741B1 (en) | 2007-10-25 | 2023-05-10 | Dexcom, Inc. | Systems and methods for processing sensor data |
US8417312B2 (en) | 2007-10-25 | 2013-04-09 | Dexcom, Inc. | Systems and methods for processing sensor data |
US20090164239A1 (en) | 2007-12-19 | 2009-06-25 | Abbott Diabetes Care, Inc. | Dynamic Display Of Glucose Information |
WO2009105709A1 (en) | 2008-02-21 | 2009-08-27 | Dexcom, Inc. | Systems and methods for processing, transmitting and displaying sensor data |
US8682408B2 (en) | 2008-03-28 | 2014-03-25 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US8583204B2 (en) | 2008-03-28 | 2013-11-12 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US11730407B2 (en) | 2008-03-28 | 2023-08-22 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US20090247855A1 (en) * | 2008-03-28 | 2009-10-01 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US8252229B2 (en) | 2008-04-10 | 2012-08-28 | Abbott Diabetes Care Inc. | Method and system for sterilizing an analyte sensor |
WO2009126900A1 (en) | 2008-04-11 | 2009-10-15 | Pelikan Technologies, Inc. | Method and apparatus for analyte detecting device |
US7826382B2 (en) | 2008-05-30 | 2010-11-02 | Abbott Diabetes Care Inc. | Close proximity communication device and methods |
US8591410B2 (en) | 2008-05-30 | 2013-11-26 | Abbott Diabetes Care Inc. | Method and apparatus for providing glycemic control |
US8924159B2 (en) | 2008-05-30 | 2014-12-30 | Abbott Diabetes Care Inc. | Method and apparatus for providing glycemic control |
US8876755B2 (en) | 2008-07-14 | 2014-11-04 | Abbott Diabetes Care Inc. | Closed loop control system interface and methods |
US8734422B2 (en) | 2008-08-31 | 2014-05-27 | Abbott Diabetes Care Inc. | Closed loop control with improved alarm functions |
US20100057040A1 (en) | 2008-08-31 | 2010-03-04 | Abbott Diabetes Care, Inc. | Robust Closed Loop Control And Methods |
US8622988B2 (en) | 2008-08-31 | 2014-01-07 | Abbott Diabetes Care Inc. | Variable rate closed loop control and methods |
US9943644B2 (en) | 2008-08-31 | 2018-04-17 | Abbott Diabetes Care Inc. | Closed loop control with reference measurement and methods thereof |
WO2010033724A2 (en) | 2008-09-19 | 2010-03-25 | Dexcom, Inc. | Particle-containing membrane and particulate electrode for analyte sensors |
US8986208B2 (en) | 2008-09-30 | 2015-03-24 | Abbott Diabetes Care Inc. | Analyte sensor sensitivity attenuation mitigation |
US9326707B2 (en) | 2008-11-10 | 2016-05-03 | Abbott Diabetes Care Inc. | Alarm characterization for analyte monitoring devices and systems |
US8103456B2 (en) | 2009-01-29 | 2012-01-24 | Abbott Diabetes Care Inc. | Method and device for early signal attenuation detection using blood glucose measurements |
US9375169B2 (en) | 2009-01-30 | 2016-06-28 | Sanofi-Aventis Deutschland Gmbh | Cam drive for managing disposable penetrating member actions with a single motor and motor and control system |
US8560082B2 (en) | 2009-01-30 | 2013-10-15 | Abbott Diabetes Care Inc. | Computerized determination of insulin pump therapy parameters using real time and retrospective data processing |
EP2419015A4 (en) | 2009-04-16 | 2014-08-20 | Abbott Diabetes Care Inc | Analyte sensor calibration management |
WO2010129375A1 (en) | 2009-04-28 | 2010-11-11 | Abbott Diabetes Care Inc. | Closed loop blood glucose control algorithm analysis |
WO2010127050A1 (en) | 2009-04-28 | 2010-11-04 | Abbott Diabetes Care Inc. | Error detection in critical repeating data in a wireless sensor system |
EP2424426B1 (en) | 2009-04-29 | 2020-01-08 | Abbott Diabetes Care, Inc. | Method and system for providing data communication in continuous glucose monitoring and management system |
US9184490B2 (en) | 2009-05-29 | 2015-11-10 | Abbott Diabetes Care Inc. | Medical device antenna systems having external antenna configurations |
US9517023B2 (en) | 2009-06-01 | 2016-12-13 | Profusa, Inc. | Method and system for directing a localized biological response to an implant |
US8613892B2 (en) | 2009-06-30 | 2013-12-24 | Abbott Diabetes Care Inc. | Analyte meter with a moveable head and methods of using the same |
US20110027458A1 (en) | 2009-07-02 | 2011-02-03 | Dexcom, Inc. | Continuous analyte sensors and methods of making same |
DK3936032T3 (en) | 2009-07-23 | 2024-07-29 | Abbott Diabetes Care Inc | Real-time management of data related to physiological control of glucose levels |
CN104799866A (en) | 2009-07-23 | 2015-07-29 | 雅培糖尿病护理公司 | Analyte monitoring device |
WO2011026148A1 (en) | 2009-08-31 | 2011-03-03 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods for managing power and noise |
US9314195B2 (en) | 2009-08-31 | 2016-04-19 | Abbott Diabetes Care Inc. | Analyte signal processing device and methods |
WO2011041469A1 (en) | 2009-09-29 | 2011-04-07 | Abbott Diabetes Care Inc. | Method and apparatus for providing notification function in analyte monitoring systems |
WO2011053881A1 (en) | 2009-10-30 | 2011-05-05 | Abbott Diabetes Care Inc. | Method and apparatus for detecting false hypoglycemic conditions |
WO2011075575A1 (en) | 2009-12-17 | 2011-06-23 | Bayer Healthcare Llc | Transdermal systems, devices, and methods to optically analyze an analyte |
US8965476B2 (en) | 2010-04-16 | 2015-02-24 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US10010272B2 (en) | 2010-05-27 | 2018-07-03 | Profusa, Inc. | Tissue-integrating electronic apparatus |
US8635046B2 (en) | 2010-06-23 | 2014-01-21 | Abbott Diabetes Care Inc. | Method and system for evaluating analyte sensor response characteristics |
US10092229B2 (en) | 2010-06-29 | 2018-10-09 | Abbott Diabetes Care Inc. | Calibration of analyte measurement system |
EP2600761A4 (en) | 2010-08-06 | 2014-08-13 | Microchips Inc | Biosensor membrane composition, biosensor, and methods for making same |
CA2813041C (en) | 2010-10-06 | 2018-08-21 | Natalie Ann Wisniewski | Tissue-integrating sensors |
WO2012048168A2 (en) | 2010-10-07 | 2012-04-12 | Abbott Diabetes Care Inc. | Analyte monitoring devices and methods |
JP5644447B2 (en) * | 2010-12-06 | 2014-12-24 | ソニー株式会社 | Microscope, region determination method, and program |
EP2680754B1 (en) | 2011-02-28 | 2019-04-24 | Abbott Diabetes Care, Inc. | Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same |
US10136845B2 (en) | 2011-02-28 | 2018-11-27 | Abbott Diabetes Care Inc. | Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same |
PL2697388T3 (en) | 2011-03-28 | 2015-11-30 | Hoffmann La Roche | Improved diffusion layer for an enzymatic in-vivo sensor |
US9002390B2 (en) | 2011-04-08 | 2015-04-07 | Dexcom, Inc. | Systems and methods for processing and transmitting sensor data |
WO2012142502A2 (en) | 2011-04-15 | 2012-10-18 | Dexcom Inc. | Advanced analyte sensor calibration and error detection |
CA2843008A1 (en) | 2011-07-26 | 2013-01-31 | Glysens Incorporated | Tissue implantable sensor with hermetically sealed housing |
US20130053666A1 (en) | 2011-08-26 | 2013-02-28 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
CN111887862B (en) | 2011-09-23 | 2024-10-15 | 德克斯康公司 | System and method for processing and transmitting sensor data |
CN102499696B (en) * | 2011-09-23 | 2015-08-19 | 长沙三诺生物传感技术股份有限公司 | Biological enzyme sensor of a kind of human implantable and preparation method thereof |
US9622691B2 (en) | 2011-10-31 | 2017-04-18 | Abbott Diabetes Care Inc. | Model based variable risk false glucose threshold alarm prevention mechanism |
US9069536B2 (en) | 2011-10-31 | 2015-06-30 | Abbott Diabetes Care Inc. | Electronic devices having integrated reset systems and methods thereof |
CA2840640C (en) | 2011-11-07 | 2020-03-24 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods |
US8710993B2 (en) | 2011-11-23 | 2014-04-29 | Abbott Diabetes Care Inc. | Mitigating single point failure of devices in an analyte monitoring system and methods thereof |
US9317656B2 (en) | 2011-11-23 | 2016-04-19 | Abbott Diabetes Care Inc. | Compatibility mechanisms for devices in a continuous analyte monitoring system and methods thereof |
EP2825096B1 (en) | 2012-03-16 | 2023-04-26 | Dexcom, Inc. | Systems and methods for processing analyte sensor data |
RU2611038C2 (en) * | 2012-03-27 | 2017-02-20 | Ф.Хоффманн-Ля Рош Аг | Improved spacer membrane for enzyme sensor in vivo |
US10561353B2 (en) | 2016-06-01 | 2020-02-18 | Glysens Incorporated | Biocompatible implantable sensor apparatus and methods |
US10660550B2 (en) | 2015-12-29 | 2020-05-26 | Glysens Incorporated | Implantable sensor apparatus and methods |
US10132793B2 (en) | 2012-08-30 | 2018-11-20 | Abbott Diabetes Care Inc. | Dropout detection in continuous analyte monitoring data during data excursions |
US9968306B2 (en) | 2012-09-17 | 2018-05-15 | Abbott Diabetes Care Inc. | Methods and apparatuses for providing adverse condition notification with enhanced wireless communication range in analyte monitoring systems |
US10405961B2 (en) | 2013-03-14 | 2019-09-10 | Cell and Molecular Tissue Engineering, LLC | Coated surgical mesh, and corresponding systems and methods |
US10130288B2 (en) | 2013-03-14 | 2018-11-20 | Cell and Molecular Tissue Engineering, LLC | Coated sensors, and corresponding systems and methods |
US9717583B2 (en) * | 2014-03-13 | 2017-08-01 | Cell and Molecular Tissue Engineering, LLC | Sensors, cannulas, collars and coated surgical mesh, and corresponding systems and methods |
CN105120750B (en) | 2013-03-14 | 2018-01-12 | 普罗菲尤萨股份有限公司 | Method and apparatus for correcting optical signalling |
US10433773B1 (en) | 2013-03-15 | 2019-10-08 | Abbott Diabetes Care Inc. | Noise rejection methods and apparatus for sparsely sampled analyte sensor data |
US8858884B2 (en) | 2013-03-15 | 2014-10-14 | American Sterilizer Company | Coupled enzyme-based method for electronic monitoring of biological indicator |
US10076285B2 (en) | 2013-03-15 | 2018-09-18 | Abbott Diabetes Care Inc. | Sensor fault detection using analyte sensor data pattern comparison |
US9121050B2 (en) | 2013-03-15 | 2015-09-01 | American Sterilizer Company | Non-enzyme based detection method for electronic monitoring of biological indicator |
US9474475B1 (en) | 2013-03-15 | 2016-10-25 | Abbott Diabetes Care Inc. | Multi-rate analyte sensor data collection with sample rate configurable signal processing |
CN111544011B (en) | 2013-06-06 | 2023-06-06 | 普罗菲尤萨股份有限公司 | Apparatus and method for detecting optical signals from implanted sensors |
WO2015102745A1 (en) | 2013-12-31 | 2015-07-09 | Abbott Diabetes Care Inc. | Self-powered analyte sensor and devices using the same |
WO2015153482A1 (en) | 2014-03-30 | 2015-10-08 | Abbott Diabetes Care Inc. | Method and apparatus for determining meal start and peak events in analyte monitoring systems |
US20180368743A1 (en) | 2014-06-12 | 2018-12-27 | The Trustees Of Columbia University In The City Of New New York | Graphene-based nanosensor for identifying target analytes |
WO2016109163A1 (en) | 2014-12-31 | 2016-07-07 | Theranova, Llc | Methods and devices for analyte sensing in potential spaces |
CN113349766A (en) | 2015-07-10 | 2021-09-07 | 雅培糖尿病护理公司 | System, device and method for dynamic glucose curve response to physiological parameters |
US11629368B2 (en) * | 2015-11-27 | 2023-04-18 | Radiometer Medical Aps | Outer layer for enzyme sensors |
WO2017195035A1 (en) | 2016-05-10 | 2017-11-16 | Interface Biologics, Inc. | Implantable glucose sensors having a biostable surface |
US10638962B2 (en) | 2016-06-29 | 2020-05-05 | Glysens Incorporated | Bio-adaptable implantable sensor apparatus and methods |
US11331018B2 (en) | 2016-12-22 | 2022-05-17 | Profusa, Inc. | System and single-channel biosensor for and method of determining analyte value |
EP3600014A4 (en) | 2017-03-21 | 2020-10-21 | Abbott Diabetes Care Inc. | Methods, devices and system for providing diabetic condition diagnosis and therapy |
US10638979B2 (en) | 2017-07-10 | 2020-05-05 | Glysens Incorporated | Analyte sensor data evaluation and error reduction apparatus and methods |
US11643551B2 (en) | 2017-08-28 | 2023-05-09 | Dsm Ip Assets B.V. | Synthetic membrane composition comprising a polyurethane and a polyoxazoline |
EP3675733A1 (en) | 2017-08-28 | 2020-07-08 | DSM IP Assets B.V. | Synthetic membrane composition comprising a fluorinated polyurethane |
CN111148776B (en) * | 2017-08-28 | 2022-06-03 | 帝斯曼知识产权资产管理有限公司 | Synthetic film compositions comprising polyurethane blends |
US11278668B2 (en) * | 2017-12-22 | 2022-03-22 | Glysens Incorporated | Analyte sensor and medicant delivery data evaluation and error reduction apparatus and methods |
US11255839B2 (en) | 2018-01-04 | 2022-02-22 | Glysens Incorporated | Apparatus and methods for analyte sensor mismatch correction |
US20210000393A1 (en) * | 2018-03-13 | 2021-01-07 | Phc Holdings Corporation | Protective film material for biosensor probe |
WO2019195661A1 (en) | 2018-04-06 | 2019-10-10 | Zense-Life Inc. | Continuous glucose monitoring device |
EP4205649B1 (en) | 2018-04-06 | 2024-10-02 | Allez Health Inc. | Method of making an enzyme membrane |
AU2019346733A1 (en) * | 2018-09-27 | 2021-04-08 | I-Sens, Inc. | Polymer blend for controlling blood glucose influx, and continuous glucose monitoring biosensor comprising same |
EP4021287A4 (en) | 2019-08-30 | 2023-10-04 | TT1 Products, Inc. | Biomarker monitoring fitness system |
IL273038B (en) | 2020-03-03 | 2022-02-01 | Ben Zion Karmon | Bone implant |
CN113521399B (en) * | 2020-04-16 | 2022-10-25 | 三诺生物传感股份有限公司 | Biocompatible film, preparation method thereof and implantable biosensor |
US11284818B2 (en) | 2020-08-31 | 2022-03-29 | TT1 Products, Inc. | Glucose exposure diagnostics and therapeutics related thereto |
CN112426896B (en) * | 2020-10-10 | 2022-08-09 | 德莱森(北京)医疗科技有限公司 | Preparation method of porous polymer semipermeable membrane and product thereof |
CN113317785B (en) * | 2021-04-29 | 2022-10-28 | 苏州中星医疗技术有限公司 | Selective-permeation biocompatible membrane and preparation method and application thereof |
CN113311054A (en) * | 2021-04-29 | 2021-08-27 | 苏州中星医疗技术有限公司 | Glucose biosensor |
USD1004777S1 (en) | 2021-09-01 | 2023-11-14 | TT1 Products, Inc. | Wrist reader |
CN113717607B (en) * | 2021-09-02 | 2022-09-13 | 苏州中星医疗技术有限公司 | Biocompatible membrane, block polymer thereof and application |
WO2023152224A1 (en) | 2022-02-10 | 2023-08-17 | Dsm Ip Assets B.V. | Polyurethane membrane for sensor |
CN115651525B (en) * | 2022-12-09 | 2023-03-21 | 乐普(北京)医疗器械股份有限公司 | Glucose diffusion-limited polymer outer membrane and preparation method and application thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4757022A (en) * | 1986-04-15 | 1988-07-12 | Markwell Medical Institute, Inc. | Biological fluid measuring device |
US6200772B1 (en) * | 1997-08-23 | 2001-03-13 | Sensalyse Holdings Limited | Modified polyurethane membrane sensors and analytical methods |
US6702857B2 (en) * | 2001-07-27 | 2004-03-09 | Dexcom, Inc. | Membrane for use with implantable devices |
US20060068208A1 (en) * | 2002-05-22 | 2006-03-30 | Tapsak Mark A | Techniques to improve polyurethane membranes for implantable glucose sensors |
US8050737B2 (en) * | 2007-11-30 | 2011-11-01 | Siemens Aktiengesellschaft | Method and medical apparatus for measuring pulmonary artery blood flow |
Family Cites Families (473)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US538028A (en) * | 1895-04-23 | Apparatus for treatment of bone-black | ||
US947227A (en) * | 1906-07-19 | 1910-01-25 | Victor Talking Machine Co | Sound-reproducing device. |
DE19852258A1 (en) | 1998-11-11 | 2000-05-18 | Agfa Gevaert Ag | Radiation-sensitive recording material for the production of waterless offset printing plates |
US3562352A (en) * | 1968-09-06 | 1971-02-09 | Avco Corp | Polysiloxane-polyurethane block copolymers |
GB1412983A (en) * | 1971-11-30 | 1975-11-05 | Debell & Richardson | Method of producing porous plastic materials |
US3943918A (en) * | 1971-12-02 | 1976-03-16 | Tel-Pac, Inc. | Disposable physiological telemetric device |
US3775182A (en) * | 1972-02-25 | 1973-11-27 | Du Pont | Tubular electrochemical cell with coiled electrodes and compressed central spindle |
GB1442303A (en) | 1972-09-08 | 1976-07-14 | Radiometer As | Cell for electro-chemical analysis |
US3929971A (en) * | 1973-03-30 | 1975-12-30 | Research Corp | Porous biomaterials and method of making same |
US3898984A (en) | 1974-02-04 | 1975-08-12 | Us Navy | Ambulatory patient monitoring system |
US3966580A (en) * | 1974-09-16 | 1976-06-29 | The University Of Utah | Novel protein-immobilizing hydrophobic polymeric membrane, process for producing same and apparatus employing same |
US3979274A (en) * | 1975-09-24 | 1976-09-07 | The Yellow Springs Instrument Company, Inc. | Membrane for enzyme electrodes |
CH591237A5 (en) * | 1975-11-06 | 1977-09-15 | Bbc Brown Boveri & Cie | |
US4040908A (en) * | 1976-03-12 | 1977-08-09 | Children's Hospital Medical Center | Polarographic analysis of cholesterol and other macromolecular substances |
US4136250A (en) * | 1977-07-20 | 1979-01-23 | Ciba-Geigy Corporation | Polysiloxane hydrogels |
JPS5921500B2 (en) * | 1978-01-28 | 1984-05-21 | 東洋紡績株式会社 | Enzyme membrane for oxygen electrode |
US4172770A (en) * | 1978-03-27 | 1979-10-30 | Technicon Instruments Corporation | Flow-through electrochemical system analytical method |
US4255500A (en) * | 1979-03-29 | 1981-03-10 | General Electric Company | Vibration resistant electrochemical cell having deformed casing and method of making same |
US4292423A (en) | 1979-04-19 | 1981-09-29 | Wacker-Chemie Gmbh | Process for the preparation of organopolysiloxanes |
US4253469A (en) * | 1979-04-20 | 1981-03-03 | The Narda Microwave Corporation | Implantable temperature probe |
DE2932761A1 (en) * | 1979-08-13 | 1981-02-26 | Akzo Gmbh | POLYCARBONATE-POLYAETHER-COPOLYMER MEMBRANE |
JPS5627643A (en) * | 1979-08-14 | 1981-03-18 | Toshiba Corp | Electrochemical measuring device |
US4403984A (en) | 1979-12-28 | 1983-09-13 | Biotek, Inc. | System for demand-based adminstration of insulin |
US4686137A (en) | 1980-02-29 | 1987-08-11 | Thoratec Laboratories Corp. | Moisture vapor permeable materials |
US5120813A (en) | 1980-02-29 | 1992-06-09 | Th. Goldschmidt Ag | Moisture vapor permeable materials |
US4861830A (en) * | 1980-02-29 | 1989-08-29 | Th. Goldschmidt Ag | Polymer systems suitable for blood-contacting surfaces of a biomedical device, and methods for forming |
SE419903B (en) * | 1980-03-05 | 1981-08-31 | Enfors Sven Olof | enzyme electrode |
JPS5949803B2 (en) | 1980-04-18 | 1984-12-05 | 日本ステアグライド販売株式会社 | easy chair |
DE3173564D1 (en) * | 1980-09-02 | 1986-03-06 | Medtronic Inc | Subcutaneously implantable lead with drug dispenser means |
IE51643B1 (en) * | 1980-10-15 | 1987-01-21 | Smith & Nephew Ass | Coated articles and materials suitable for coating |
US4353888A (en) * | 1980-12-23 | 1982-10-12 | Sefton Michael V | Encapsulation of live animal cells |
JPS5929693Y2 (en) | 1980-12-25 | 1984-08-25 | オリンパス光学工業株式会社 | Cell collection device for endoscope |
US4436094A (en) * | 1981-03-09 | 1984-03-13 | Evreka, Inc. | Monitor for continuous in vivo measurement of glucose concentration |
JPS57156005A (en) | 1981-03-20 | 1982-09-27 | Nitto Electric Ind Co Ltd | Selective permeable membrane |
JPS57156004A (en) | 1981-03-20 | 1982-09-27 | Nitto Electric Ind Co Ltd | Gas separating membrane |
JPS57156004U (en) | 1981-03-26 | 1982-09-30 | ||
JPS57156005U (en) | 1981-03-26 | 1982-09-30 | ||
JPS5949805B2 (en) | 1981-04-16 | 1984-12-05 | 永大化工株式会社 | Bed sore prevention bed |
EP0078636B2 (en) | 1981-10-23 | 1997-04-02 | MediSense, Inc. | Sensor for components of a liquid mixture |
US4431004A (en) * | 1981-10-27 | 1984-02-14 | Bessman Samuel P | Implantable glucose sensor |
US4418148A (en) * | 1981-11-05 | 1983-11-29 | Miles Laboratories, Inc. | Multilayer enzyme electrode membrane |
US4415666A (en) * | 1981-11-05 | 1983-11-15 | Miles Laboratories, Inc. | Enzyme electrode membrane |
JPS5886172A (en) | 1981-11-18 | 1983-05-23 | テルモ株式会社 | Medical substance moving apparatus |
US4494950A (en) * | 1982-01-19 | 1985-01-22 | The Johns Hopkins University | Plural module medication delivery system |
JPS58163402A (en) | 1982-03-20 | 1983-09-28 | Nitto Electric Ind Co Ltd | Gas separation membrane |
JPS58163403A (en) | 1982-03-23 | 1983-09-28 | Nitto Electric Ind Co Ltd | Gas separation membrane |
US4493714A (en) * | 1982-05-06 | 1985-01-15 | Teijin Limited | Ultrathin film, process for production thereof, and use thereof for concentrating a specified gas in a gaseous mixture |
EP0098592A3 (en) | 1982-07-06 | 1985-08-21 | Fujisawa Pharmaceutical Co., Ltd. | Portable artificial pancreas |
JPS5929693A (en) | 1982-08-10 | 1984-02-16 | Asahi Glass Co Ltd | Fluorine-containing diisocyanate containing siloxane bond |
JPS5949805A (en) | 1982-09-17 | 1984-03-22 | Teijin Ltd | Permselective membrane for separation of gas |
JPS5949803A (en) | 1982-09-17 | 1984-03-22 | Teijin Ltd | Permselective membrane for separation of gas |
JPS5949805U (en) | 1982-09-27 | 1984-04-02 | 株式会社東芝 | High frequency heating cooking device |
JPS5949803U (en) | 1982-09-27 | 1984-04-02 | リンナイ株式会社 | Oven cooking device operating device |
JPS5959221A (en) | 1982-09-29 | 1984-04-05 | Teijin Ltd | Prearation of composite perrmeable membrane for separating gas |
JPS5959221U (en) | 1982-10-12 | 1984-04-18 | 和光産業株式会社 | Plate fixing device in multi-blade fan assembly machine |
JPS591929Y2 (en) | 1982-10-25 | 1984-01-19 | ロ−レルバンクマシン株式会社 | Cumulative coin support rod of coin wrapping machine |
AU573730B2 (en) | 1982-10-25 | 1988-06-23 | Antarctic Pharma Ab | Enzyme composition from euphausiaceae (antarctic krill) as cleaning agent |
JPS5987004A (en) | 1982-11-08 | 1984-05-19 | Nitto Electric Ind Co Ltd | Gas separation membrane |
JPS58163403U (en) | 1982-11-27 | 1983-10-31 | ナイガイ株式会社 | Single drive source packaging machine |
JPS5987004U (en) | 1982-12-01 | 1984-06-12 | 古河電気工業株式会社 | Airtight penetration for optical transmission line |
US5059654A (en) | 1983-02-14 | 1991-10-22 | Cuno Inc. | Affinity matrices of modified polysaccharide supports |
JPS59128406U (en) | 1983-02-19 | 1984-08-29 | 倉敷化工株式会社 | Suspension rubber bushing for automobiles |
US4506680A (en) * | 1983-03-17 | 1985-03-26 | Medtronic, Inc. | Drug dispensing body implantable lead |
CA1226036A (en) | 1983-05-05 | 1987-08-25 | Irving J. Higgins | Analytical equipment and sensor electrodes therefor |
CA1219040A (en) | 1983-05-05 | 1987-03-10 | Elliot V. Plotkin | Measurement of enzyme-catalysed reactions |
JPS59209608A (en) | 1983-05-12 | 1984-11-28 | Teijin Ltd | Permselective membrane |
JPS59209609A (en) | 1983-05-12 | 1984-11-28 | Teijin Ltd | Permselective membrane |
JPS59209610A (en) | 1983-05-12 | 1984-11-28 | Teijin Ltd | Permselective membrane |
US4650547A (en) * | 1983-05-19 | 1987-03-17 | The Regents Of The University Of California | Method and membrane applicable to implantable sensor |
US4484987A (en) * | 1983-05-19 | 1984-11-27 | The Regents Of The University Of California | Method and membrane applicable to implantable sensor |
US4554927A (en) | 1983-08-30 | 1985-11-26 | Thermometrics Inc. | Pressure and temperature sensor |
JPS6084530A (en) | 1983-10-17 | 1985-05-13 | Hitachi Ltd | Liquid crystal display element |
GB2149918A (en) | 1983-11-03 | 1985-06-19 | John Anderson | Sudden infant death syndrome monitor |
JPS60146219A (en) | 1984-01-11 | 1985-08-01 | Toray Ind Inc | Contact lens |
JPS60136214U (en) | 1984-02-23 | 1985-09-10 | いすゞ自動車株式会社 | Height adjustment device for vehicles with air spring suspension |
US4527999A (en) | 1984-03-23 | 1985-07-09 | Abcor, Inc. | Separation membrane and method of preparing and using same |
US4753652A (en) * | 1984-05-04 | 1988-06-28 | Children's Medical Center Corporation | Biomaterial implants which resist calcification |
JPS60245623A (en) | 1984-05-18 | 1985-12-05 | Nippon Yunikaa Kk | Production of flexible polyether-urethane foam of low gas permeability |
US4644046A (en) * | 1984-06-20 | 1987-02-17 | Teijin Limited | Ultrathin film, process for production thereof, and use thereof for concentrating a specific gas from a gas mixture |
CA1258496A (en) | 1984-07-30 | 1989-08-15 | Teruyoshi Uchida | Insulated noble metal wire and porous membrane as po.sub.2 bioelectrode |
US5171689A (en) * | 1984-11-08 | 1992-12-15 | Matsushita Electric Industrial Co., Ltd. | Solid state bio-sensor |
US4602922A (en) | 1984-11-09 | 1986-07-29 | Research Foundation Of State University Of New York | Method of making membranes for gas separation and the composite membranes |
US4702732A (en) * | 1984-12-24 | 1987-10-27 | Trustees Of Boston University | Electrodes, electrode assemblies, methods, and systems for tissue stimulation and transdermal delivery of pharmacologically active ligands |
US4963595A (en) * | 1985-01-04 | 1990-10-16 | Thoratec Laboratories Corporation | Polysiloxane-polylactone block copolymers |
US5235003A (en) | 1985-01-04 | 1993-08-10 | Thoratec Laboratories Corporation | Polysiloxane-polylactone block copolymers |
US4577642A (en) * | 1985-02-27 | 1986-03-25 | Medtronic, Inc. | Drug dispensing body implantable lead employing molecular sieves and methods of fabrication |
JPS61238319A (en) | 1985-04-17 | 1986-10-23 | Dainippon Ink & Chem Inc | Selective gas permeable membrane |
US4781798A (en) * | 1985-04-19 | 1988-11-01 | The Regents Of The University Of California | Transparent multi-oxygen sensor array and method of using same |
GB8514176D0 (en) | 1985-06-05 | 1985-07-10 | Ici Plc | Membrane |
US4671288A (en) * | 1985-06-13 | 1987-06-09 | The Regents Of The University Of California | Electrochemical cell sensor for continuous short-term use in tissues and blood |
US4680268A (en) | 1985-09-18 | 1987-07-14 | Children's Hospital Medical Center | Implantable gas-containing biosensor and method for measuring an analyte such as glucose |
US4890620A (en) * | 1985-09-20 | 1990-01-02 | The Regents Of The University Of California | Two-dimensional diffusion glucose substrate sensing electrode |
JPS6274406A (en) | 1985-09-30 | 1987-04-06 | Teijin Ltd | Separating membrane |
US4689309A (en) * | 1985-09-30 | 1987-08-25 | Miles Laboratories, Inc. | Test device, method of manufacturing same and method of determining a component in a sample |
JPS6283849A (en) | 1985-10-04 | 1987-04-17 | Reiji Yoshinaka | Method of purifying collagen |
JPS6274406U (en) | 1985-10-29 | 1987-05-13 | ||
JPS62102815A (en) | 1985-10-30 | 1987-05-13 | Agency Of Ind Science & Technol | Gas permselective membrane |
US4647643A (en) * | 1985-11-08 | 1987-03-03 | Becton, Dickinson And Company | Soft non-blocking polyurethanes |
US4798876A (en) | 1985-11-12 | 1989-01-17 | Tyndale Plains-Hunter Ltd. | Hydrophilic polyurethane composition |
JPS6283849U (en) | 1985-11-12 | 1987-05-28 | ||
JPH0341047Y2 (en) | 1985-12-19 | 1991-08-29 | ||
US4684538A (en) | 1986-02-21 | 1987-08-04 | Loctite Corporation | Polysiloxane urethane compounds and adhesive compositions, and method of making and using the same |
US4776944A (en) * | 1986-03-20 | 1988-10-11 | Jiri Janata | Chemical selective sensors utilizing admittance modulated membranes |
JPS62225513A (en) * | 1986-03-26 | 1987-10-03 | Shin Etsu Chem Co Ltd | Block-graft copolymer and production thereof |
JPH0696106B2 (en) | 1986-03-31 | 1994-11-30 | 帝人株式会社 | Gas separation membrane |
US4685463A (en) | 1986-04-03 | 1987-08-11 | Williams R Bruce | Device for continuous in vivo measurement of blood glucose concentrations |
US4994167A (en) | 1986-04-15 | 1991-02-19 | Markwell Medical Institute, Inc. | Biological fluid measuring device |
US4909908A (en) * | 1986-04-24 | 1990-03-20 | Pepi Ross | Electrochemical cncentration detector method |
US4795542A (en) * | 1986-04-24 | 1989-01-03 | St. Jude Medical, Inc. | Electrochemical concentration detector device |
US4703756A (en) * | 1986-05-06 | 1987-11-03 | The Regents Of The University Of California | Complete glucose monitoring system with an implantable, telemetered sensor module |
US4731726A (en) * | 1986-05-19 | 1988-03-15 | Healthware Corporation | Patient-operated glucose monitor and diabetes management system |
GB8612861D0 (en) | 1986-05-27 | 1986-07-02 | Cambridge Life Sciences | Immobilised enzyme biosensors |
US4763658A (en) | 1986-06-04 | 1988-08-16 | Solutech, Inc. | Dialysis system 2nd method |
US4726381A (en) * | 1986-06-04 | 1988-02-23 | Solutech, Inc. | Dialysis system and method |
US4781733A (en) | 1986-07-23 | 1988-11-01 | Bend Research, Inc. | Semipermeable thin-film membranes comprising siloxane, alkoxysilyl and aryloxysilyl oligomers and copolymers |
US5002572A (en) | 1986-09-11 | 1991-03-26 | Picha George J | Biological implant with textured surface |
AU617667B2 (en) * | 1986-11-04 | 1991-12-05 | Allergan, Inc. | Open-cell, silicone-elastomer medical implant and method for making |
US5007929B1 (en) | 1986-11-04 | 1994-08-30 | Medical Products Dev | Open-cell silicone-elastomer medical implant |
JPS63130661A (en) | 1986-11-20 | 1988-06-02 | Toppan Printing Co Ltd | Non-porous moisture-permeable waterproof film |
DE3700119A1 (en) | 1987-01-03 | 1988-07-14 | Inst Diabetestechnologie Gemei | IMPLANTABLE ELECTROCHEMICAL SENSOR |
AT391063B (en) | 1987-01-08 | 1990-08-10 | Blum Gmbh Julius | CONNECTING FITTING FOR FASTENING THE RAILING OF A DRAWER |
JPS63130661U (en) | 1987-02-18 | 1988-08-26 | ||
US4935345A (en) * | 1987-04-07 | 1990-06-19 | Arizona Board Of Regents | Implantable microelectronic biochemical sensor incorporating thin film thermopile |
US4759828A (en) * | 1987-04-09 | 1988-07-26 | Nova Biomedical Corporation | Glucose electrode and method of determining glucose |
US5352348A (en) | 1987-04-09 | 1994-10-04 | Nova Biomedical Corporation | Method of using enzyme electrode |
IT1215491B (en) | 1987-05-15 | 1990-02-14 | Enricerche Spa | BIOSENSOR WITH ENZYMATIC MEMBRANE CHEMICALLY CONNECTED TO A SEMICONDUCTIVE DEVICE. |
US4880883A (en) | 1987-06-03 | 1989-11-14 | Wisconsin Alumni Research Foundation | Biocompatible polyurethanes modified with lower alkyl sulfonate and lower alkyl carboxylate |
US5540828A (en) | 1987-06-08 | 1996-07-30 | Yacynych; Alexander | Method for making electrochemical sensors and biosensors having a polymer modified surface |
US5286364A (en) * | 1987-06-08 | 1994-02-15 | Rutgers University | Surface-modified electochemical biosensor |
US4810470A (en) * | 1987-06-19 | 1989-03-07 | Miles Inc. | Volume independent diagnostic device |
US4786657A (en) | 1987-07-02 | 1988-11-22 | Minnesota Mining And Manufacturing Company | Polyurethanes and polyurethane/polyureas crosslinked using 2-glyceryl acrylate or 2-glyceryl methacrylate |
JPH07122624B2 (en) * | 1987-07-06 | 1995-12-25 | ダイキン工業株式会社 | Biosensor |
US4805625A (en) * | 1987-07-08 | 1989-02-21 | Ad-Tech Medical Instrument Corporation | Sphenoidal electrode and insertion method |
FI77569C (en) | 1987-07-13 | 1989-04-10 | Huhtamaeki Oy | ANORDINATION FOR THE PURPOSE OF THE OPERATIONS AND THE OPERATIONS OF ELLER EN VAEVNAD. |
JPH0824830B2 (en) | 1987-07-13 | 1996-03-13 | 帝人株式会社 | Separation membrane |
JPH07114937B2 (en) | 1987-07-13 | 1995-12-13 | 帝人株式会社 | Separation membrane |
DE3725728A1 (en) | 1987-08-04 | 1989-02-16 | Freudenberg Carl Fa | MEDICAL DEVICE AND METHOD FOR THE PRODUCTION THEREOF |
US5221724A (en) | 1987-08-12 | 1993-06-22 | Wisconsin Alumni Research Foundation | Polysiloxane polyurea urethanes |
US4974929A (en) | 1987-09-22 | 1990-12-04 | Baxter International, Inc. | Fiber optical probe connector for physiologic measurement devices |
NL8702370A (en) | 1987-10-05 | 1989-05-01 | Groningen Science Park | METHOD AND SYSTEM FOR GLUCOSE DETERMINATION AND USEABLE MEASURING CELL ASSEMBLY. |
DE3736652A1 (en) | 1987-10-29 | 1989-05-11 | Bayer Ag | PROCESS FOR PREPARING COATINGS |
US5242835A (en) | 1987-11-03 | 1993-09-07 | Radiometer A/S | Method and apparatus for determining the concentration of oxygen |
GB8725936D0 (en) | 1987-11-05 | 1987-12-09 | Genetics Int Inc | Sensing system |
US5128408A (en) | 1987-11-16 | 1992-07-07 | Toyo Boseki Kabushiki Kaisha | Gas-permeable material with excellent compatibility with blood |
US4852573A (en) | 1987-12-04 | 1989-08-01 | Kennedy Philip R | Implantable neural electrode |
US5070169A (en) | 1988-02-26 | 1991-12-03 | Ciba-Geigy Corporation | Wettable, flexible, oxygen permeable contact lens containing block copolymer polysiloxane-polyoxyalkylene backbone units and use thereof |
US4822336A (en) | 1988-03-04 | 1989-04-18 | Ditraglia John | Blood glucose level sensing |
US4951657A (en) | 1988-04-22 | 1990-08-28 | Dow Corning Corporation | Heat sealable membrane for transdermal drug release |
US4793555A (en) | 1988-04-22 | 1988-12-27 | Dow Corning Corporation | Container, method and composition for controlling the release of a volatile liquid from an aqueous mixture |
US5008115A (en) * | 1988-04-22 | 1991-04-16 | Dow Corning Corporation | Matrix for release of active ingredients |
US4908208A (en) * | 1988-04-22 | 1990-03-13 | Dow Corning Corporation | Matrix for release of active ingredients |
US5342693A (en) | 1988-06-08 | 1994-08-30 | Cardiopulmonics, Inc. | Multifunctional thrombo-resistant coating and methods of manufacture |
US4849458A (en) | 1988-06-17 | 1989-07-18 | Matrix Medica, Inc. | Segmented polyether polyurethane |
CA1299653C (en) | 1988-07-07 | 1992-04-28 | Markwell Medical Institute, Inc. | Biological fluid measuring device |
EP0353328A1 (en) | 1988-08-03 | 1990-02-07 | Dräger Nederland B.V. | A polarographic-amperometric three-electrode sensor |
US4983702A (en) | 1988-09-28 | 1991-01-08 | Ciba-Geigy Corporation | Crosslinked siloxane-urethane polymer contact lens |
US5063081A (en) | 1988-11-14 | 1991-11-05 | I-Stat Corporation | Method of manufacturing a plurality of uniform microfabricated sensing devices having an immobilized ligand receptor |
US5212050A (en) | 1988-11-14 | 1993-05-18 | Mier Randall M | Method of forming a permselective layer |
US5200051A (en) | 1988-11-14 | 1993-04-06 | I-Stat Corporation | Wholly microfabricated biosensors and process for the manufacture and use thereof |
US5269891A (en) | 1989-03-09 | 1993-12-14 | Novo Nordisk A/S | Method and apparatus for determination of a constituent in a fluid |
JPH02298855A (en) | 1989-03-20 | 1990-12-11 | Assoc Univ Inc | Electrochemical biosensor using immobilized enzyme and redox polymer |
US4986671A (en) | 1989-04-12 | 1991-01-22 | Luxtron Corporation | Three-parameter optical fiber sensor and system |
US4953552A (en) | 1989-04-21 | 1990-09-04 | Demarzo Arthur P | Blood glucose monitoring system |
US5034461A (en) | 1989-06-07 | 1991-07-23 | Bausch & Lomb Incorporated | Novel prepolymers useful in biomedical devices |
US4927407A (en) * | 1989-06-19 | 1990-05-22 | Regents Of The University Of Minnesota | Cardiac assist pump with steady rate supply of fluid lubricant |
CH677149A5 (en) | 1989-07-07 | 1991-04-15 | Disetronic Ag | |
US5431160A (en) | 1989-07-19 | 1995-07-11 | University Of New Mexico | Miniature implantable refillable glucose sensor and material therefor |
US5264104A (en) | 1989-08-02 | 1993-11-23 | Gregg Brian A | Enzyme electrodes |
US5190041A (en) | 1989-08-11 | 1993-03-02 | Palti Yoram Prof | System for monitoring and controlling blood glucose |
US5101814A (en) | 1989-08-11 | 1992-04-07 | Palti Yoram Prof | System for monitoring and controlling blood glucose |
FR2650756B1 (en) | 1989-08-11 | 1991-10-31 | Inst Francais Du Petrole | GAS SEPARATION MEMBRANE |
US5050612A (en) | 1989-09-12 | 1991-09-24 | Matsumura Kenneth N | Device for computer-assisted monitoring of the body |
US5002590A (en) * | 1989-09-19 | 1991-03-26 | Bend Research, Inc. | Countercurrent dehydration by hollow fibers |
JPH03133440A (en) | 1989-10-18 | 1991-06-06 | Nishitomo:Kk | Clinical thermometer for ladies |
US5140985A (en) | 1989-12-11 | 1992-08-25 | Schroeder Jon M | Noninvasive blood glucose measuring device |
US5985129A (en) | 1989-12-14 | 1999-11-16 | The Regents Of The University Of California | Method for increasing the service life of an implantable sensor |
FR2656423A1 (en) | 1989-12-22 | 1991-06-28 | Rhone Poulenc Chimie | Electrochemical biosensor |
US5183549A (en) * | 1990-01-26 | 1993-02-02 | Commtech International Management Corporation | Multi-analyte sensing electrolytic cell |
US5316008A (en) | 1990-04-06 | 1994-05-31 | Casio Computer Co., Ltd. | Measurement of electrocardiographic wave and sphygmus |
US5165407A (en) | 1990-04-19 | 1992-11-24 | The University Of Kansas | Implantable glucose sensor |
GB9009409D0 (en) | 1990-04-26 | 1990-06-20 | Dow Corning | Film-forming copolymers and their use in water vapour permeable coatings |
US5331555A (en) | 1990-05-11 | 1994-07-19 | Sharp Kabushiki Kaisha | Electronic apparatus |
IT1248934B (en) | 1990-06-01 | 1995-02-11 | Fidia Spa | BIOCOMPATIBLE PERFORATED MEMBRANES, PROCESSES FOR THEIR PREPARATION, THEIR USE AS A SUPPORT FOR THE IN VITRO GROWTH OF EPITHELIAL CELLS, ARTIFICIAL LEATHER THUS OBTAINED AND THEIR USE IN LEATHER TRANSPLANTS |
US5250439A (en) | 1990-07-19 | 1993-10-05 | Miles Inc. | Use of conductive sensors in diagnostic assays |
US5202261A (en) | 1990-07-19 | 1993-04-13 | Miles Inc. | Conductive sensors and their use in diagnostic assays |
US5746898A (en) | 1990-08-10 | 1998-05-05 | Siemens Aktiengesellschaft | Electrochemical-enzymatic sensor |
EP0546021B1 (en) * | 1990-08-28 | 1995-11-08 | Meadox Medicals, Inc. | Self-supporting woven vascular graft |
US5380536A (en) | 1990-10-15 | 1995-01-10 | The Board Of Regents, The University Of Texas System | Biocompatible microcapsules |
US5713888A (en) | 1990-10-31 | 1998-02-03 | Baxter International, Inc. | Tissue implant systems |
ATE138256T1 (en) | 1990-10-31 | 1996-06-15 | Baxter Int | IMPLANT MATERIAL THAT ALLOWS VASCULARIZATION |
US5314471A (en) | 1991-07-24 | 1994-05-24 | Baxter International Inc. | Tissue inplant systems and methods for sustaining viable high cell densities within a host |
US5344454A (en) | 1991-07-24 | 1994-09-06 | Baxter International Inc. | Closed porous chambers for implanting tissue in a host |
US5545223A (en) | 1990-10-31 | 1996-08-13 | Baxter International, Inc. | Ported tissue implant systems and methods of using same |
DE69228957T2 (en) | 1991-01-16 | 1999-10-07 | Toyo Boseki K.K., Osaka | Blood compatible material |
AU1356792A (en) * | 1991-01-25 | 1992-08-27 | Markwell Medical Institute, Inc. | Implantable biological fluid measuring device |
US5348788A (en) | 1991-01-30 | 1994-09-20 | Interpore Orthopaedics, Inc. | Mesh sheet with microscopic projections and holes |
CA2050057A1 (en) | 1991-03-04 | 1992-09-05 | Adam Heller | Interferant eliminating biosensors |
US5593852A (en) | 1993-12-02 | 1997-01-14 | Heller; Adam | Subcutaneous glucose electrode |
JPH08196626A (en) | 1991-04-25 | 1996-08-06 | Toyobo Co Ltd | Blood compatible artificial pulmonary membrane |
US5397848A (en) | 1991-04-25 | 1995-03-14 | Allergan, Inc. | Enhancing the hydrophilicity of silicone polymers |
US5271736A (en) | 1991-05-13 | 1993-12-21 | Applied Medical Research | Collagen disruptive morphology for implants |
JP3118015B2 (en) | 1991-05-17 | 2000-12-18 | アークレイ株式会社 | Biosensor and separation and quantification method using the same |
JP3084642B2 (en) | 1991-05-30 | 2000-09-04 | 株式会社ジェルテック | Pad for dressing and method of manufacturing the same |
US5453278A (en) | 1991-07-24 | 1995-09-26 | Baxter International Inc. | Laminated barriers for tissue implants |
DE4130742A1 (en) | 1991-09-16 | 1993-03-18 | Inst Diabetestechnologie Gemei | METHOD AND ARRANGEMENT FOR DETERMINING THE CONCENTRATION OF INGREDIENTS IN BODY LIQUIDS |
US5322063A (en) * | 1991-10-04 | 1994-06-21 | Eli Lilly And Company | Hydrophilic polyurethane membranes for electrochemical glucose sensors |
US5155149A (en) | 1991-10-10 | 1992-10-13 | Boc Health Care, Inc. | Silicone polyurethane copolymers containing oxygen sensitive phosphorescent dye compounds |
US5866217A (en) | 1991-11-04 | 1999-02-02 | Possis Medical, Inc. | Silicone composite vascular graft |
US5296144A (en) * | 1992-01-02 | 1994-03-22 | World Trade Corporation | Composite membrane of a hydrophilic asymmetric membrane coated with an organosiloxane block copolymer |
JPH07508183A (en) | 1992-02-01 | 1995-09-14 | ザ ヴィクトリア ユニヴァーシティ オヴ マンチェスター | Improvements regarding monitoring system |
NL9200207A (en) | 1992-02-05 | 1993-09-01 | Nedap Nv | IMPLANTABLE BIOMEDICAL SENSOR DEVICE, IN PARTICULAR FOR MEASUREMENT OF THE GLUCOSE CONCENTRATION. |
US5284140A (en) | 1992-02-11 | 1994-02-08 | Eli Lilly And Company | Acrylic copolymer membranes for biosensors |
JPH05279447A (en) | 1992-03-31 | 1993-10-26 | Mitsubishi Rayon Co Ltd | Silicon-based block copolymer and membrane made thereof |
DE69331108T2 (en) | 1992-04-01 | 2002-07-04 | Baxter International Inc. (A Delaware Corporation), Deerfield | SYSTEMS FOR PLANTING VASCULAR TISSUE |
EP0637323B1 (en) * | 1992-04-24 | 1998-08-19 | The Polymer Technology Group, Inc. | Copolymers and non-porous, semi-permeable membrane thereof and its use for permeating molecules of predetermined molecular weight range |
US5589563A (en) | 1992-04-24 | 1996-12-31 | The Polymer Technology Group | Surface-modifying endgroups for biomedical polymers |
GB9211402D0 (en) | 1992-05-29 | 1992-07-15 | Univ Manchester | Sensor devices |
US5208313A (en) | 1992-07-16 | 1993-05-04 | Surface Coatings, Inc. | Waterproof breathable polyurethane membranes and porous substrates protected therewith |
JP2541081B2 (en) | 1992-08-28 | 1996-10-09 | 日本電気株式会社 | Biosensor and method of manufacturing and using biosensor |
EP1104883A3 (en) | 1992-10-01 | 2001-07-18 | Australian Membrane And Biotechnology Research Institute | Improved sensor membranes |
GB9221099D0 (en) * | 1992-10-07 | 1992-11-18 | Ecossensors Ltd | Improvements in and relating to gas permeable membranes for amperometric gas electrodes |
US5387327A (en) | 1992-10-19 | 1995-02-07 | Duquesne University Of The Holy Ghost | Implantable non-enzymatic electrochemical glucose sensor |
US6256522B1 (en) | 1992-11-23 | 2001-07-03 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Sensors for continuous monitoring of biochemicals and related method |
US5299571A (en) | 1993-01-22 | 1994-04-05 | Eli Lilly And Company | Apparatus and method for implantation of sensors |
US5389430A (en) | 1993-02-05 | 1995-02-14 | Th. Goldschmidt Ag | Textiles coated with waterproof, moisture vapor permeable polymers |
DE4329898A1 (en) | 1993-09-04 | 1995-04-06 | Marcus Dr Besson | Wireless medical diagnostic and monitoring device |
CA2148354A1 (en) | 1993-09-24 | 1995-03-30 | Laura A. Martinson | Methods for enhancing vascularization of implant devices |
US5582184A (en) | 1993-10-13 | 1996-12-10 | Integ Incorporated | Interstitial fluid collection and constituent measurement |
US5545220A (en) | 1993-11-04 | 1996-08-13 | Lipomatrix Incorporated | Implantable prosthesis with open cell textured surface and method for forming same |
KR970010981B1 (en) * | 1993-11-04 | 1997-07-05 | 엘지전자 주식회사 | Alcohol concentration measuring bio-sensor, manufacturing method and related apparatus |
US5791344A (en) | 1993-11-19 | 1998-08-11 | Alfred E. Mann Foundation For Scientific Research | Patient monitoring system |
US5497772A (en) * | 1993-11-19 | 1996-03-12 | Alfred E. Mann Foundation For Scientific Research | Glucose monitoring system |
US5443080A (en) | 1993-12-22 | 1995-08-22 | Americate Transtech, Inc. | Integrated system for biological fluid constituent analysis |
US5437824A (en) | 1993-12-23 | 1995-08-01 | Moghan Medical Corp. | Method of forming a molded silicone foam implant having open-celled interstices |
US5549675A (en) | 1994-01-11 | 1996-08-27 | Baxter International, Inc. | Method for implanting tissue in a host |
US5391250A (en) | 1994-03-15 | 1995-02-21 | Minimed Inc. | Method of fabricating thin film sensors |
US5390671A (en) * | 1994-03-15 | 1995-02-21 | Minimed Inc. | Transcutaneous sensor insertion set |
US5569186A (en) | 1994-04-25 | 1996-10-29 | Minimed Inc. | Closed loop infusion pump system with removable glucose sensor |
US5584876A (en) * | 1994-04-29 | 1996-12-17 | W. L. Gore & Associates, Inc. | Cell excluding sheath for vascular grafts |
DE4415896A1 (en) | 1994-05-05 | 1995-11-09 | Boehringer Mannheim Gmbh | Analysis system for monitoring the concentration of an analyte in the blood of a patient |
DE59509994D1 (en) * | 1994-06-03 | 2002-02-21 | Metrohm Ag Herisau | Device for voltammetry, indicator electrode arrangement for such a device, in particular as part of a tape cassette, and row analysis method for voltammetry |
US5494562A (en) * | 1994-06-27 | 1996-02-27 | Ciba Corning Diagnostics Corp. | Electrochemical sensors |
ATE172099T1 (en) | 1994-07-08 | 1998-10-15 | Baxter Int | IMPLANTED TUMOR CELL DEVICE FOR TREATING CANCER |
US6007845A (en) * | 1994-07-22 | 1999-12-28 | Massachusetts Institute Of Technology | Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers |
US5513636A (en) | 1994-08-12 | 1996-05-07 | Cb-Carmel Biotechnology Ltd. | Implantable sensor chip |
US5462051A (en) | 1994-08-31 | 1995-10-31 | Colin Corporation | Medical communication system |
AT402452B (en) * | 1994-09-14 | 1997-05-26 | Avl Verbrennungskraft Messtech | PLANAR SENSOR FOR DETECTING A CHEMICAL PARAMETER OF A SAMPLE |
US5624537A (en) | 1994-09-20 | 1997-04-29 | The University Of British Columbia - University-Industry Liaison Office | Biosensor and interface membrane |
US5807406A (en) | 1994-10-07 | 1998-09-15 | Baxter International Inc. | Porous microfabricated polymer membrane structures |
CA2159052C (en) | 1994-10-28 | 2007-03-06 | Rainer Alex | Injection device |
IE72524B1 (en) | 1994-11-04 | 1997-04-23 | Elan Med Tech | Analyte-controlled liquid delivery device and analyte monitor |
ATE216078T1 (en) * | 1994-11-14 | 2002-04-15 | Bayer Ag | RANDOMLY DISTRIBUTED SEGMENTED THERMOPLASTIC POLYURETHANES AS A MATRIX FOR THE ELECTROCHEMICAL ANALYSIS OF BIVALUENT CALCIUM IONS |
US5837728A (en) * | 1995-01-27 | 1998-11-17 | Molecular Design International | 9-cis retinoic acid esters and amides and uses thereof |
US5697366A (en) | 1995-01-27 | 1997-12-16 | Optical Sensors Incorporated | In situ calibration system for sensors located in a physiologic line |
US5568806A (en) | 1995-02-16 | 1996-10-29 | Minimed Inc. | Transcutaneous sensor insertion set |
US5586553A (en) | 1995-02-16 | 1996-12-24 | Minimed Inc. | Transcutaneous sensor insertion set |
US5786439A (en) | 1996-10-24 | 1998-07-28 | Minimed Inc. | Hydrophilic, swellable coatings for biosensors |
US5882494A (en) | 1995-03-27 | 1999-03-16 | Minimed, Inc. | Polyurethane/polyurea compositions containing silicone for biosensor membranes |
DE29624309U1 (en) * | 1995-04-04 | 2002-01-03 | Commonwealth Scientific And Industrial Research Organisation, Campbell | Duration supporting lenses |
WO1996032076A1 (en) | 1995-04-11 | 1996-10-17 | Baxter Internatonal Inc. | Tissue implant systems |
US5620579A (en) | 1995-05-05 | 1997-04-15 | Bayer Corporation | Apparatus for reduction of bias in amperometric sensors |
US6060640A (en) | 1995-05-19 | 2000-05-09 | Baxter International Inc. | Multiple-layer, formed-in-place immunoisolation membrane structures for implantation of cells in host tissue |
DE69630266T2 (en) | 1995-06-07 | 2004-09-09 | W.L. Gore & Associates, Inc., Newark | IMPLANTABLE RECEIVER FOR A THERAPEUTIC DEVICE |
US5743262A (en) | 1995-06-07 | 1998-04-28 | Masimo Corporation | Blood glucose monitoring system |
US5626561A (en) * | 1995-06-07 | 1997-05-06 | Gore Hybrid Technologies, Inc. | Implantable containment apparatus for a therapeutical device and method for loading and reloading the device therein |
US5656707A (en) | 1995-06-16 | 1997-08-12 | Regents Of The University Of Minnesota | Highly cross-linked polymeric supports |
US5995860A (en) | 1995-07-06 | 1999-11-30 | Thomas Jefferson University | Implantable sensor and system for measurement and control of blood constituent levels |
US5611900A (en) | 1995-07-20 | 1997-03-18 | Michigan State University | Microbiosensor used in-situ |
US5700902A (en) * | 1995-07-27 | 1997-12-23 | Circe Biomedical, Inc. | Block copolymers |
JP2000501069A (en) | 1995-09-21 | 2000-02-02 | ノバルティス・アクチエンゲゼルシャフト | Polymer-bound fluorophores as photoion sensors |
AU699410B2 (en) | 1995-09-26 | 1998-12-03 | Ameron International Corporation | Polysiloxane polyurethane compositions |
US5628890A (en) | 1995-09-27 | 1997-05-13 | Medisense, Inc. | Electrochemical sensor |
US5665222A (en) | 1995-10-11 | 1997-09-09 | E. Heller & Company | Soybean peroxidase electrochemical sensor |
US5972199A (en) | 1995-10-11 | 1999-10-26 | E. Heller & Company | Electrochemical analyte sensors using thermostable peroxidase |
US6689265B2 (en) * | 1995-10-11 | 2004-02-10 | Therasense, Inc. | Electrochemical analyte sensors using thermostable soybean peroxidase |
US5855613A (en) | 1995-10-13 | 1999-01-05 | Islet Sheet Medical, Inc. | Retrievable bioartificial implants having dimensions allowing rapid diffusion of oxygen and rapid biological response to physiological change |
US5711861A (en) | 1995-11-22 | 1998-01-27 | Ward; W. Kenneth | Device for monitoring changes in analyte concentration |
US6002954A (en) | 1995-11-22 | 1999-12-14 | The Regents Of The University Of California | Detection of biological molecules using boronate-based chemical amplification and optical sensors |
EP0862648B1 (en) * | 1995-11-22 | 2004-10-06 | Medtronic MiniMed, Inc. | Detection of biological molecules using chemical amplification and optical sensors |
US6063637A (en) | 1995-12-13 | 2000-05-16 | California Institute Of Technology | Sensors for sugars and other metal binding analytes |
US6271332B1 (en) | 1995-12-22 | 2001-08-07 | Novartis Ag | Polyurethanes made from polysiloxane/polyol macromers |
WO1997024059A1 (en) | 1995-12-28 | 1997-07-10 | Cygnus, Inc. | Continuous monitoring of physiological analyte |
US5795453A (en) | 1996-01-23 | 1998-08-18 | Gilmartin; Markas A. T. | Electrodes and metallo isoindole ringed compounds |
US5833603A (en) * | 1996-03-13 | 1998-11-10 | Lipomatrix, Inc. | Implantable biosensing transponder |
US6407195B2 (en) | 1996-04-25 | 2002-06-18 | 3M Innovative Properties Company | Tackified polydiorganosiloxane oligourea segmented copolymers and a process for making same |
US6022463A (en) * | 1996-05-16 | 2000-02-08 | Sendx Medical, Inc. | Sensors with subminiature through holes |
US5776324A (en) | 1996-05-17 | 1998-07-07 | Encelle, Inc. | Electrochemical biosensors |
US5964261A (en) | 1996-05-29 | 1999-10-12 | Baxter International Inc. | Implantation assembly |
IL127213A (en) * | 1996-07-08 | 2003-09-17 | Animas Corp | Implantable sensor and system for in vivo measurement and control of fluid constituent levels |
JP2943700B2 (en) | 1996-07-10 | 1999-08-30 | 日本電気株式会社 | Biosensor |
US6325978B1 (en) | 1998-08-04 | 2001-12-04 | Ntc Technology Inc. | Oxygen monitoring and apparatus |
US5703359A (en) | 1996-07-29 | 1997-12-30 | Leybold Inficon, Inc. | Composite membrane and support assembly |
US6054142A (en) | 1996-08-01 | 2000-04-25 | Cyto Therapeutics, Inc. | Biocompatible devices with foam scaffolds |
US6018013A (en) | 1996-09-03 | 2000-01-25 | Nkk Corporation | Coating composition and method for producing precoated steel sheets |
DE19642453C2 (en) * | 1996-10-15 | 1998-07-23 | Bosch Gmbh Robert | Arrangement for gas sensor electrodes |
JP4451931B2 (en) * | 1996-11-12 | 2010-04-14 | ホアットマン,インコーポレーテッド | Hydrophilic polymer phase change membrane |
AU5461298A (en) | 1996-12-04 | 1998-06-29 | Enact Health Management Systems | System for downloading and reporting medical information |
US5811487A (en) | 1996-12-16 | 1998-09-22 | Dow Corning Corporation | Thickening silicones with elastomeric silicone polyethers |
US5964993A (en) * | 1996-12-19 | 1999-10-12 | Implanted Biosystems Inc. | Glucose sensor |
US5914026A (en) | 1997-01-06 | 1999-06-22 | Implanted Biosystems Inc. | Implantable sensor employing an auxiliary electrode |
US6093172A (en) | 1997-02-05 | 2000-07-25 | Minimed Inc. | Injector for a subcutaneous insertion set |
US6891317B2 (en) * | 2001-05-22 | 2005-05-10 | Sri International | Rolled electroactive polymers |
US6208894B1 (en) * | 1997-02-26 | 2001-03-27 | Alfred E. Mann Foundation For Scientific Research And Advanced Bionics | System of implantable devices for monitoring and/or affecting body parameters |
US6741877B1 (en) * | 1997-03-04 | 2004-05-25 | Dexcom, Inc. | Device and method for determining analyte levels |
US6001067A (en) | 1997-03-04 | 1999-12-14 | Shults; Mark C. | Device and method for determining analyte levels |
US7657297B2 (en) | 2004-05-03 | 2010-02-02 | Dexcom, Inc. | Implantable analyte sensor |
US7899511B2 (en) | 2004-07-13 | 2011-03-01 | Dexcom, Inc. | Low oxygen in vivo analyte sensor |
US7192450B2 (en) | 2003-05-21 | 2007-03-20 | Dexcom, Inc. | Porous membranes for use with implantable devices |
US6862465B2 (en) | 1997-03-04 | 2005-03-01 | Dexcom, Inc. | Device and method for determining analyte levels |
US6558321B1 (en) * | 1997-03-04 | 2003-05-06 | Dexcom, Inc. | Systems and methods for remote monitoring and modulation of medical devices |
US20050033132A1 (en) * | 1997-03-04 | 2005-02-10 | Shults Mark C. | Analyte measuring device |
US7885697B2 (en) | 2004-07-13 | 2011-02-08 | Dexcom, Inc. | Transcutaneous analyte sensor |
FR2760962B1 (en) | 1997-03-20 | 1999-05-14 | Sillonville Francis Klefstad | REMOTE MEDICAL ASSISTANCE AND SURVEILLANCE SYSTEM |
US6270455B1 (en) | 1997-03-28 | 2001-08-07 | Health Hero Network, Inc. | Networked system for interactive communications and remote monitoring of drug delivery |
US5961451A (en) | 1997-04-07 | 1999-10-05 | Motorola, Inc. | Noninvasive apparatus having a retaining member to retain a removable biosensor |
US6059946A (en) | 1997-04-14 | 2000-05-09 | Matsushita Electric Industrial Co., Ltd. | Biosensor |
US6558351B1 (en) | 1999-06-03 | 2003-05-06 | Medtronic Minimed, Inc. | Closed loop system for controlling insulin infusion |
US6093167A (en) | 1997-06-16 | 2000-07-25 | Medtronic, Inc. | System for pancreatic stimulation and glucose measurement |
CA2294610A1 (en) * | 1997-06-16 | 1998-12-23 | George Moshe Katz | Methods of calibrating and testing a sensor for in vivo measurement of an analyte and devices for use in such methods |
US6013711A (en) | 1997-06-18 | 2000-01-11 | Ck Witco Corporation | Hydrophilic polysiloxane compositions |
US5861019A (en) * | 1997-07-25 | 1999-01-19 | Medtronic Inc. | Implantable medical device microstrip telemetry antenna |
US5871514A (en) | 1997-08-01 | 1999-02-16 | Medtronic, Inc. | Attachment apparatus for an implantable medical device employing ultrasonic energy |
US6259937B1 (en) | 1997-09-12 | 2001-07-10 | Alfred E. Mann Foundation | Implantable substrate sensor |
US5999848A (en) | 1997-09-12 | 1999-12-07 | Alfred E. Mann Foundation | Daisy chainable sensors and stimulators for implantation in living tissue |
US6409674B1 (en) * | 1998-09-24 | 2002-06-25 | Data Sciences International, Inc. | Implantable sensor with wireless communication |
US6088608A (en) | 1997-10-20 | 2000-07-11 | Alfred E. Mann Foundation | Electrochemical sensor and integrity tests therefor |
US6119028A (en) | 1997-10-20 | 2000-09-12 | Alfred E. Mann Foundation | Implantable enzyme-based monitoring systems having improved longevity due to improved exterior surfaces |
US6081736A (en) * | 1997-10-20 | 2000-06-27 | Alfred E. Mann Foundation | Implantable enzyme-based monitoring systems adapted for long term use |
US6030827A (en) * | 1998-01-23 | 2000-02-29 | I-Stat Corporation | Microfabricated aperture-based sensor |
US6134461A (en) | 1998-03-04 | 2000-10-17 | E. Heller & Company | Electrochemical analyte |
US6013113A (en) * | 1998-03-06 | 2000-01-11 | Wilson Greatbatch Ltd. | Slotted insulator for unsealed electrode edges in electrochemical cells |
US5904708A (en) | 1998-03-19 | 1999-05-18 | Medtronic, Inc. | System and method for deriving relative physiologic signals |
GB9805896D0 (en) * | 1998-03-20 | 1998-05-13 | Eglise David | Remote analysis system |
US6091975A (en) | 1998-04-01 | 2000-07-18 | Alza Corporation | Minimally invasive detecting device |
US6537318B1 (en) * | 1998-04-06 | 2003-03-25 | Konjac Technologies, Llc | Use of glucomannan hydrocolloid as filler material in prostheses |
US6241863B1 (en) | 1998-04-27 | 2001-06-05 | Harold G. Monbouquette | Amperometric biosensors based on redox enzymes |
US6949816B2 (en) | 2003-04-21 | 2005-09-27 | Motorola, Inc. | Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same |
US6175752B1 (en) | 1998-04-30 | 2001-01-16 | Therasense, Inc. | Analyte monitoring device and methods of use |
EP1077634B1 (en) | 1998-05-13 | 2003-07-30 | Cygnus, Inc. | Monitoring of physiological analytes |
PT1077636E (en) | 1998-05-13 | 2004-06-30 | Cygnus Therapeutic Systems | SIGNAL PROCESSING FOR PHYSIOLOGICAL ANALYZES MEDICATION |
US6129757A (en) | 1998-05-18 | 2000-10-10 | Scimed Life Systems | Implantable members for receiving therapeutically useful compositions |
US6187062B1 (en) * | 1998-06-16 | 2001-02-13 | Alcatel | Current collection through thermally sprayed tabs at the ends of a spirally wound electrochemical cell |
GB2339912B (en) | 1998-07-20 | 2002-06-05 | Univ Bristol | Apparatus and method for measuring the moisture level within enamel dentine or tooth tissue |
US6248067B1 (en) | 1999-02-05 | 2001-06-19 | Minimed Inc. | Analyte sensor and holter-type monitor system and method of using the same |
PT1108207E (en) * | 1998-08-26 | 2008-08-06 | Sensors For Med & Science Inc | Optical-based sensing devices |
US6201980B1 (en) * | 1998-10-05 | 2001-03-13 | The Regents Of The University Of California | Implantable medical sensor system |
US6338790B1 (en) * | 1998-10-08 | 2002-01-15 | Therasense, Inc. | Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator |
EP1119285A1 (en) | 1998-10-08 | 2001-08-01 | Minimed Inc. | Telemetered characteristic monitor system |
US6016448A (en) * | 1998-10-27 | 2000-01-18 | Medtronic, Inc. | Multilevel ERI for implantable medical devices |
AU762948B2 (en) | 1998-12-02 | 2003-07-10 | Ut-Battelle, Llc | In vivo biosensor apparatus and method of use |
US6447448B1 (en) * | 1998-12-31 | 2002-09-10 | Ball Semiconductor, Inc. | Miniature implanted orthopedic sensors |
US6309384B1 (en) | 1999-02-01 | 2001-10-30 | Adiana, Inc. | Method and apparatus for tubal occlusion |
US6424847B1 (en) | 1999-02-25 | 2002-07-23 | Medtronic Minimed, Inc. | Glucose monitor calibration methods |
US6360888B1 (en) | 1999-02-25 | 2002-03-26 | Minimed Inc. | Glucose sensor package system |
US6230059B1 (en) | 1999-03-17 | 2001-05-08 | Medtronic, Inc. | Implantable monitor |
JP2002541441A (en) | 1999-04-07 | 2002-12-03 | スペクトルクス,インコーポレイティド | Analytical device for continuous measurement of fluid properties |
JP2002542498A (en) * | 1999-04-22 | 2002-12-10 | シグナス, インコーポレイテッド | Methods and devices for removing interfering species |
US6475750B1 (en) | 1999-05-11 | 2002-11-05 | M-Biotech, Inc. | Glucose biosensor |
US6300002B1 (en) * | 1999-05-13 | 2001-10-09 | Moltech Power Systems, Inc. | Notched electrode and method of making same |
US6546268B1 (en) * | 1999-06-02 | 2003-04-08 | Ball Semiconductor, Inc. | Glucose sensor |
EP1192269A2 (en) | 1999-06-18 | 2002-04-03 | Therasense, Inc. | MASS TRANSPORT LIMITED i IN VIVO /i ANALYTE SENSOR |
US6413393B1 (en) | 1999-07-07 | 2002-07-02 | Minimed, Inc. | Sensor including UV-absorbing polymer and method of manufacture |
US6471689B1 (en) | 1999-08-16 | 2002-10-29 | Thomas Jefferson University | Implantable drug delivery catheter system with capillary interface |
US6346583B1 (en) * | 1999-08-25 | 2002-02-12 | General Electric Company | Polar solvent compatible polyethersiloxane elastomers |
US6343225B1 (en) * | 1999-09-14 | 2002-01-29 | Implanted Biosystems, Inc. | Implantable glucose sensor |
AU7582200A (en) | 1999-09-15 | 2001-04-17 | Midtronic Minimed, Inc. | Glucose sensing molecules having selected fluorescent properties |
US6541107B1 (en) * | 1999-10-25 | 2003-04-01 | Dow Corning Corporation | Nanoporous silicone resins having low dielectric constants |
US6527729B1 (en) * | 1999-11-10 | 2003-03-04 | Pacesetter, Inc. | Method for monitoring patient using acoustic sensor |
US6520997B1 (en) * | 1999-12-08 | 2003-02-18 | Baxter International Inc. | Porous three dimensional structure |
US6895263B2 (en) | 2000-02-23 | 2005-05-17 | Medtronic Minimed, Inc. | Real time self-adjusting calibration algorithm |
DE60144142D1 (en) | 2000-03-02 | 2011-04-14 | Microchips Inc | MICROMECHANICAL DEVICES AND METHOD FOR THE STORAGE AND SELECTIVE EXPOSURE OF CHEMICALS |
US6551496B1 (en) * | 2000-03-03 | 2003-04-22 | Ysi Incorporated | Microstructured bilateral sensor |
US6365670B1 (en) | 2000-03-10 | 2002-04-02 | Wacker Silicones Corporation | Organopolysiloxane gels for use in cosmetics |
WO2001088524A1 (en) | 2000-05-12 | 2001-11-22 | Therasense, Inc. | Electrodes with multilayer membranes and methods of using and making the electrodes |
US6442413B1 (en) | 2000-05-15 | 2002-08-27 | James H. Silver | Implantable sensor |
US7769420B2 (en) | 2000-05-15 | 2010-08-03 | Silver James H | Sensors for detecting substances indicative of stroke, ischemia, or myocardial infarction |
US7181261B2 (en) | 2000-05-15 | 2007-02-20 | Silver James H | Implantable, retrievable, thrombus minimizing sensors |
US6395325B1 (en) | 2000-05-16 | 2002-05-28 | Scimed Life Systems, Inc. | Porous membranes |
US6459917B1 (en) | 2000-05-22 | 2002-10-01 | Ashok Gowda | Apparatus for access to interstitial fluid, blood, or blood plasma components |
WO2001090733A1 (en) * | 2000-05-23 | 2001-11-29 | Radiometer Medical A/S | A sensor membrane, a method for the preparation thereof, a sensor and a layered membrane structure for such sensor |
US6991652B2 (en) * | 2000-06-13 | 2006-01-31 | Burg Karen J L | Tissue engineering composite |
US7092014B1 (en) * | 2000-06-28 | 2006-08-15 | Microsoft Corporation | Scene capturing and view rendering based on a longitudinally aligned camera array |
US6400974B1 (en) * | 2000-06-29 | 2002-06-04 | Sensors For Medicine And Science, Inc. | Implanted sensor processing system and method for processing implanted sensor output |
US6477392B1 (en) * | 2000-07-14 | 2002-11-05 | Futrex Inc. | Calibration of near infrared quantitative measurement device using optical measurement cross-products |
US6642015B2 (en) | 2000-12-29 | 2003-11-04 | Minimed Inc. | Hydrophilic polymeric material for coating biosensors |
AU2002239810A1 (en) | 2001-01-02 | 2002-07-16 | The Charles Stark Draper Laboratory, Inc. | Tissue engineering of three-dimensional vascularized using microfabricated polymer assembly technology |
US6547839B2 (en) * | 2001-01-23 | 2003-04-15 | Skc Co., Ltd. | Method of making an electrochemical cell by the application of polysiloxane onto at least one of the cell components |
US7014610B2 (en) | 2001-02-09 | 2006-03-21 | Medtronic, Inc. | Echogenic devices and methods of making and using such devices |
WO2002064027A2 (en) * | 2001-02-15 | 2002-08-22 | The Regents Of The University Of California | Membrane and electrode structure for implantable sensor |
FR2822383B1 (en) | 2001-03-23 | 2004-12-17 | Perouse Lab | PROSTHESIS FOR PLASTIC RECONSTRUCTION WITH IMPROVED HYDROPHILICITY PROPERTIES, AND METHOD FOR OBTAINING SAME |
US6454710B1 (en) * | 2001-04-11 | 2002-09-24 | Motorola, Inc. | Devices and methods for monitoring an analyte |
DE10119036C1 (en) * | 2001-04-18 | 2002-12-12 | Disetronic Licensing Ag | Immersion sensor for measuring the concentration of an analyte using an oxidase |
US20020162792A1 (en) | 2001-05-01 | 2002-11-07 | Zepf Robert F. | Polymer membrane meshes |
US6613379B2 (en) | 2001-05-08 | 2003-09-02 | Isense Corp. | Implantable analyte sensor |
DE60202468T2 (en) | 2001-06-28 | 2006-02-16 | Microchips, Inc., Bedford | METHOD FOR THE HERMETIC SEALING OF MICROCHIP RESERVOIR DEVICES |
US20030032874A1 (en) | 2001-07-27 | 2003-02-13 | Dexcom, Inc. | Sensor head for use with implantable devices |
US6913626B2 (en) * | 2001-08-14 | 2005-07-05 | Mcghan Jim J. | Medical implant having bioabsorbable textured surface |
US7025760B2 (en) | 2001-09-07 | 2006-04-11 | Medtronic Minimed, Inc. | Method and system for non-vascular sensor implantation |
US6809507B2 (en) | 2001-10-23 | 2004-10-26 | Medtronic Minimed, Inc. | Implantable sensor electrodes and electronic circuitry |
US6705833B2 (en) | 2001-11-15 | 2004-03-16 | Hewlett-Packard Development Company, L.P. | Airflow flapper valve |
WO2003051191A1 (en) | 2001-12-17 | 2003-06-26 | Danfoss A/S | Method and device for monitoring analyte concentration by optical detection |
US7018336B2 (en) * | 2001-12-27 | 2006-03-28 | Medtronic Minimed, Inc. | Implantable sensor flush sleeve |
US20050154272A1 (en) | 2002-01-23 | 2005-07-14 | Danfoss A/S | Method and device for monitoring analyte concentration by use of differential osmotic pressure measurement |
US8010174B2 (en) * | 2003-08-22 | 2011-08-30 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
CA2480550C (en) | 2002-03-22 | 2011-07-12 | Cygnus, Inc. | Improving performance of an analyte monitoring device |
US20030228681A1 (en) | 2002-04-05 | 2003-12-11 | Powerzyme, Inc. | Analyte sensor |
US20070227907A1 (en) | 2006-04-04 | 2007-10-04 | Rajiv Shah | Methods and materials for controlling the electrochemistry of analyte sensors |
US7813780B2 (en) | 2005-12-13 | 2010-10-12 | Medtronic Minimed, Inc. | Biosensors and methods for making and using them |
US7008979B2 (en) | 2002-04-30 | 2006-03-07 | Hydromer, Inc. | Coating composition for multiple hydrophilic applications |
SI1501566T1 (en) | 2002-05-09 | 2008-12-31 | Hemoteq Ag | Medical products comprising a haemocompatible coating, production and use thereof |
US7166235B2 (en) | 2002-05-09 | 2007-01-23 | The Procter & Gamble Company | Compositions comprising anionic functionalized polyorganosiloxanes for hydrophobically modifying surfaces and enhancing delivery of active agents to surfaces treated therewith |
US6801041B2 (en) | 2002-05-14 | 2004-10-05 | Abbott Laboratories | Sensor having electrode for determining the rate of flow of a fluid |
US20060258761A1 (en) | 2002-05-22 | 2006-11-16 | Robert Boock | Silicone based membranes for use in implantable glucose sensors |
US20030225324A1 (en) | 2002-06-03 | 2003-12-04 | Anderson Edward J. | Noninvasive detection of a physiologic Parameter within a body tissue of a patient |
US8996090B2 (en) * | 2002-06-03 | 2015-03-31 | Exostat Medical, Inc. | Noninvasive detection of a physiologic parameter within a body tissue of a patient |
US20040063167A1 (en) | 2002-07-12 | 2004-04-01 | Peter Kaastrup | Minimising calibration problems of in vivo glucose sensors |
US20040180391A1 (en) | 2002-10-11 | 2004-09-16 | Miklos Gratzl | Sliver type autonomous biosensors |
US7120483B2 (en) | 2003-01-13 | 2006-10-10 | Isense Corporation | Methods for analyte sensing and measurement |
US7134999B2 (en) * | 2003-04-04 | 2006-11-14 | Dexcom, Inc. | Optimized sensor geometry for an implantable glucose sensor |
US7279174B2 (en) * | 2003-05-08 | 2007-10-09 | Advanced Cardiovascular Systems, Inc. | Stent coatings comprising hydrophilic additives |
JP2007504920A (en) | 2003-05-16 | 2007-03-08 | ブルー メンブレーンス ゲーエムベーハー | Biocompatible coated medical implant |
US7875293B2 (en) | 2003-05-21 | 2011-01-25 | Dexcom, Inc. | Biointerface membranes incorporating bioactive agents |
US7687586B2 (en) | 2003-05-21 | 2010-03-30 | Isense Corporation | Biosensor membrane material |
US20050118344A1 (en) | 2003-12-01 | 2005-06-02 | Pacetti Stephen D. | Temperature controlled crimping |
WO2005010518A1 (en) | 2003-07-23 | 2005-02-03 | Dexcom, Inc. | Rolled electrode array and its method for manufacture |
US7366556B2 (en) | 2003-12-05 | 2008-04-29 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
EP1648298A4 (en) | 2003-07-25 | 2010-01-13 | Dexcom Inc | Oxygen enhancing membrane systems for implantable devices |
US20050176136A1 (en) | 2003-11-19 | 2005-08-11 | Dexcom, Inc. | Afinity domain for analyte sensor |
WO2005012873A2 (en) * | 2003-07-25 | 2005-02-10 | Dexcom, Inc. | Electrode systems for electrochemical sensors |
US8282549B2 (en) | 2003-12-09 | 2012-10-09 | Dexcom, Inc. | Signal processing for continuous analyte sensor |
WO2005019795A2 (en) * | 2003-07-25 | 2005-03-03 | Dexcom, Inc. | Electrochemical sensors including electrode systems with increased oxygen generation |
US7761130B2 (en) | 2003-07-25 | 2010-07-20 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US20050056552A1 (en) | 2003-07-25 | 2005-03-17 | Simpson Peter C. | Increasing bias for oxygen production in an electrode system |
US7591801B2 (en) | 2004-02-26 | 2009-09-22 | Dexcom, Inc. | Integrated delivery device for continuous glucose sensor |
US8060173B2 (en) | 2003-08-01 | 2011-11-15 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US7433727B2 (en) | 2003-09-24 | 2008-10-07 | Legacy Good Samaritan Hospital And Medical Center | Implantable biosensor |
ATE464834T1 (en) * | 2003-09-30 | 2010-05-15 | Hoffmann La Roche | SENSOR WITH IMPROVED BIOCOMPATIBILITY |
US20050090607A1 (en) * | 2003-10-28 | 2005-04-28 | Dexcom, Inc. | Silicone composition for biocompatible membrane |
WO2005051170A2 (en) | 2003-11-19 | 2005-06-09 | Dexcom, Inc. | Integrated receiver for continuous analyte sensor |
EP1711790B1 (en) | 2003-12-05 | 2010-09-08 | DexCom, Inc. | Calibration techniques for a continuous analyte sensor |
DE602004028164D1 (en) | 2003-12-08 | 2010-08-26 | Dexcom Inc | SYSTEMS AND METHOD FOR IMPROVING ELECTROCHEMICAL ANALYTIC SENSORS |
WO2005068528A1 (en) | 2004-01-08 | 2005-07-28 | Dutch Polymer Institute | Polyurethanes, polyurethaneureas and polyureas and use thereof |
US7637868B2 (en) | 2004-01-12 | 2009-12-29 | Dexcom, Inc. | Composite material for implantable device |
US20050182451A1 (en) | 2004-01-12 | 2005-08-18 | Adam Griffin | Implantable device with improved radio frequency capabilities |
WO2005079257A2 (en) * | 2004-02-12 | 2005-09-01 | Dexcom, Inc. | Biointerface with macro- and micro- architecture |
CN101189271A (en) | 2004-02-13 | 2008-05-28 | 北卡罗来纳大学查珀尔希尔分校 | Functional materials and novel methods for the fabrication of microfluidic devices |
WO2005084257A2 (en) | 2004-02-26 | 2005-09-15 | Vpn Solutions, Llc | Composite thin-film glucose sensor |
US8277713B2 (en) * | 2004-05-03 | 2012-10-02 | Dexcom, Inc. | Implantable analyte sensor |
US20050245799A1 (en) * | 2004-05-03 | 2005-11-03 | Dexcom, Inc. | Implantable analyte sensor |
JP4799557B2 (en) | 2004-06-09 | 2011-10-26 | ベクトン・ディキンソン・アンド・カンパニー | Multi-sample sensor |
US20060015020A1 (en) | 2004-07-06 | 2006-01-19 | Dexcom, Inc. | Systems and methods for manufacture of an analyte-measuring device including a membrane system |
US7640048B2 (en) * | 2004-07-13 | 2009-12-29 | Dexcom, Inc. | Analyte sensor |
US7905833B2 (en) * | 2004-07-13 | 2011-03-15 | Dexcom, Inc. | Transcutaneous analyte sensor |
WO2006127023A2 (en) | 2004-08-24 | 2006-11-30 | University Of South Florida | Epoxy enhanced polymer membrane to increase durability of biosensors |
US7244443B2 (en) | 2004-08-31 | 2007-07-17 | Advanced Cardiovascular Systems, Inc. | Polymers of fluorinated monomers and hydrophilic monomers |
US9011831B2 (en) | 2004-09-30 | 2015-04-21 | Advanced Cardiovascular Systems, Inc. | Methacrylate copolymers for medical devices |
US20070299409A1 (en) | 2004-11-09 | 2007-12-27 | Angiotech Biocoatings Corp. | Antimicrobial Needle Coating For Extended Infusion |
CN100367906C (en) * | 2004-12-08 | 2008-02-13 | 圣美迪诺医疗科技(湖州)有限公司 | Endermic implantating biological sensors |
US7604818B2 (en) | 2004-12-22 | 2009-10-20 | Advanced Cardiovascular Systems, Inc. | Polymers of fluorinated monomers and hydrocarbon monomers |
EP1830902A2 (en) | 2004-12-30 | 2007-09-12 | Cinvention Ag | Combination comprising an agent providing a signal, an implant material and a drug |
US20060171980A1 (en) | 2005-02-01 | 2006-08-03 | Helmus Michael N | Implantable or insertable medical devices having optimal surface energy |
WO2006110193A2 (en) | 2005-04-08 | 2006-10-19 | Dexcom, Inc. | Cellulosic-based interference domain for an analyte sensor |
US20060263839A1 (en) | 2005-05-17 | 2006-11-23 | Isense Corporation | Combined drug delivery and analyte sensor apparatus |
US20060275859A1 (en) | 2005-05-17 | 2006-12-07 | Kjaer Thomas | Enzyme sensor including a water-containing spacer layer |
JP4763777B2 (en) | 2005-05-17 | 2011-08-31 | ラジオメーター・メディカル・アー・ペー・エス | Enzyme sensor comprising a cover membrane layer coated with a hydrophilic polymer |
US20070129524A1 (en) | 2005-12-06 | 2007-06-07 | Sunkara Hari B | Thermoplastic polyurethanes comprising polytrimethylene ether soft segments |
WO2007084516A2 (en) | 2006-01-18 | 2007-07-26 | Dexcom, Inc. | Membranes for an analyte sensor |
CA2577760A1 (en) | 2006-02-27 | 2007-08-27 | Tyco Healthcare Group Lp | Pressurized dip coating system |
US20070233013A1 (en) | 2006-03-31 | 2007-10-04 | Schoenberg Stephen J | Covers for tissue engaging members |
US8114023B2 (en) * | 2006-07-28 | 2012-02-14 | Legacy Emanuel Hospital & Health Center | Analyte sensing and response system |
US7871456B2 (en) * | 2006-08-10 | 2011-01-18 | The Regents Of The University Of California | Membranes with controlled permeability to polar and apolar molecules in solution and methods of making same |
WO2008039543A1 (en) | 2006-09-27 | 2008-04-03 | University Of Connecticut | Implantable biosensor and methods of use thereof |
CN101342465B (en) * | 2008-09-01 | 2011-11-09 | 天津工业大学 | Hollow fiber porous film and process for producing same |
-
2002
- 2002-05-22 US US10/153,356 patent/US7226978B2/en not_active Expired - Lifetime
-
2003
- 2003-05-20 AU AU2003229330A patent/AU2003229330A1/en not_active Abandoned
- 2003-05-20 JP JP2004507523A patent/JP4317519B2/en not_active Expired - Fee Related
- 2003-05-20 WO PCT/US2003/015816 patent/WO2003100083A1/en active Application Filing
- 2003-05-20 EP EP20030726922 patent/EP1506307A1/en not_active Withdrawn
-
2005
- 2005-11-16 US US11/280,672 patent/US8050731B2/en active Active
- 2005-11-16 US US11/280,102 patent/US20060068208A1/en not_active Abandoned
-
2010
- 2010-01-15 US US12/688,737 patent/US8053018B2/en not_active Expired - Lifetime
-
2011
- 2011-10-27 US US13/283,397 patent/US20120040101A1/en not_active Abandoned
-
2012
- 2012-09-28 US US13/631,780 patent/US8865249B2/en not_active Expired - Lifetime
-
2014
- 2014-09-10 US US14/482,458 patent/US9179869B2/en not_active Expired - Lifetime
-
2015
- 2015-10-05 US US14/875,539 patent/US9801574B2/en not_active Expired - Lifetime
-
2017
- 2017-09-27 US US15/716,998 patent/US10154807B2/en not_active Expired - Lifetime
-
2018
- 2018-11-09 US US16/185,957 patent/US20190083018A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4757022A (en) * | 1986-04-15 | 1988-07-12 | Markwell Medical Institute, Inc. | Biological fluid measuring device |
US6200772B1 (en) * | 1997-08-23 | 2001-03-13 | Sensalyse Holdings Limited | Modified polyurethane membrane sensors and analytical methods |
US6702857B2 (en) * | 2001-07-27 | 2004-03-09 | Dexcom, Inc. | Membrane for use with implantable devices |
US20060068208A1 (en) * | 2002-05-22 | 2006-03-30 | Tapsak Mark A | Techniques to improve polyurethane membranes for implantable glucose sensors |
US8050737B2 (en) * | 2007-11-30 | 2011-11-01 | Siemens Aktiengesellschaft | Method and medical apparatus for measuring pulmonary artery blood flow |
Cited By (212)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10154807B2 (en) | 2002-05-22 | 2018-12-18 | Dexcom, Inc. | Techniques to improve polyurethane membranes for implantable glucose sensors |
US8865249B2 (en) | 2002-05-22 | 2014-10-21 | Dexcom, Inc. | Techniques to improve polyurethane membranes for implantable glucose sensors |
US9801574B2 (en) | 2002-05-22 | 2017-10-31 | Dexcom, Inc. | Techniques to improve polyurethane membranes for implantable glucose sensors |
US9179869B2 (en) | 2002-05-22 | 2015-11-10 | Dexcom, Inc. | Techniques to improve polyurethane membranes for implantable glucose sensors |
US9980670B2 (en) | 2002-11-05 | 2018-05-29 | Abbott Diabetes Care Inc. | Sensor inserter assembly |
US11141084B2 (en) | 2002-11-05 | 2021-10-12 | Abbott Diabetes Care Inc. | Sensor inserter assembly |
US10973443B2 (en) | 2002-11-05 | 2021-04-13 | Abbott Diabetes Care Inc. | Sensor inserter assembly |
US11116430B2 (en) | 2002-11-05 | 2021-09-14 | Abbott Diabetes Care Inc. | Sensor inserter assembly |
USD914881S1 (en) | 2003-11-05 | 2021-03-30 | Abbott Diabetes Care Inc. | Analyte sensor electronic mount |
USD902408S1 (en) | 2003-11-05 | 2020-11-17 | Abbott Diabetes Care Inc. | Analyte sensor control unit |
US11160475B2 (en) | 2004-12-29 | 2021-11-02 | Abbott Diabetes Care Inc. | Sensor inserter having introducer |
US10226207B2 (en) | 2004-12-29 | 2019-03-12 | Abbott Diabetes Care Inc. | Sensor inserter having introducer |
US8602991B2 (en) | 2005-08-30 | 2013-12-10 | Abbott Diabetes Care Inc. | Analyte sensor introducer and methods of use |
US10342489B2 (en) | 2005-09-30 | 2019-07-09 | Abbott Diabetes Care Inc. | Integrated introducer and transmitter assembly and methods of use |
US9521968B2 (en) | 2005-09-30 | 2016-12-20 | Abbott Diabetes Care Inc. | Analyte sensor retention mechanism and methods of use |
US9775563B2 (en) | 2005-09-30 | 2017-10-03 | Abbott Diabetes Care Inc. | Integrated introducer and transmitter assembly and methods of use |
USD979766S1 (en) | 2005-09-30 | 2023-02-28 | Abbott Diabetes Care Inc. | Analyte sensor device |
US11457869B2 (en) | 2005-09-30 | 2022-10-04 | Abbott Diabetes Care Inc. | Integrated transmitter unit and sensor introducer mechanism and methods of use |
US9480421B2 (en) | 2005-09-30 | 2016-11-01 | Abbott Diabetes Care Inc. | Integrated introducer and transmitter assembly and methods of use |
US9398882B2 (en) | 2005-09-30 | 2016-07-26 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor and data processing device |
US10194863B2 (en) | 2005-09-30 | 2019-02-05 | Abbott Diabetes Care Inc. | Integrated transmitter unit and sensor introducer mechanism and methods of use |
US8512243B2 (en) | 2005-09-30 | 2013-08-20 | Abbott Diabetes Care Inc. | Integrated introducer and transmitter assembly and methods of use |
US10307091B2 (en) | 2005-12-28 | 2019-06-04 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor insertion |
US9795331B2 (en) | 2005-12-28 | 2017-10-24 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor insertion |
US8545403B2 (en) | 2005-12-28 | 2013-10-01 | Abbott Diabetes Care Inc. | Medical device insertion |
US8852101B2 (en) | 2005-12-28 | 2014-10-07 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor insertion |
US11298058B2 (en) | 2005-12-28 | 2022-04-12 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor insertion |
US9332933B2 (en) | 2005-12-28 | 2016-05-10 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor insertion |
USD961778S1 (en) | 2006-02-28 | 2022-08-23 | Abbott Diabetes Care Inc. | Analyte sensor device |
US10028680B2 (en) | 2006-04-28 | 2018-07-24 | Abbott Diabetes Care Inc. | Introducer assembly and methods of use |
US10736547B2 (en) | 2006-04-28 | 2020-08-11 | Abbott Diabetes Care Inc. | Introducer assembly and methods of use |
US8862198B2 (en) | 2006-09-10 | 2014-10-14 | Abbott Diabetes Care Inc. | Method and system for providing an integrated analyte sensor insertion device and data processing unit |
US9808186B2 (en) | 2006-09-10 | 2017-11-07 | Abbott Diabetes Care Inc. | Method and system for providing an integrated analyte sensor insertion device and data processing unit |
US10362972B2 (en) | 2006-09-10 | 2019-07-30 | Abbott Diabetes Care Inc. | Method and system for providing an integrated analyte sensor insertion device and data processing unit |
US10070810B2 (en) | 2006-10-23 | 2018-09-11 | Abbott Diabetes Care Inc. | Sensor insertion devices and methods of use |
US11234621B2 (en) | 2006-10-23 | 2022-02-01 | Abbott Diabetes Care Inc. | Sensor insertion devices and methods of use |
US9788771B2 (en) | 2006-10-23 | 2017-10-17 | Abbott Diabetes Care Inc. | Variable speed sensor insertion devices and methods of use |
US10363363B2 (en) | 2006-10-23 | 2019-07-30 | Abbott Diabetes Care Inc. | Flexible patch for fluid delivery and monitoring body analytes |
US11724029B2 (en) | 2006-10-23 | 2023-08-15 | Abbott Diabetes Care Inc. | Flexible patch for fluid delivery and monitoring body analytes |
US9259175B2 (en) | 2006-10-23 | 2016-02-16 | Abbott Diabetes Care, Inc. | Flexible patch for fluid delivery and monitoring body analytes |
US8613703B2 (en) | 2007-05-31 | 2013-12-24 | Abbott Diabetes Care Inc. | Insertion devices and methods |
US11779248B2 (en) | 2008-03-28 | 2023-10-10 | Abbott Diabetes Care Inc. | Analyte sensor calibration management |
US8718739B2 (en) | 2008-03-28 | 2014-05-06 | Abbott Diabetes Care Inc. | Analyte sensor calibration management |
US9320462B2 (en) | 2008-03-28 | 2016-04-26 | Abbott Diabetes Care Inc. | Analyte sensor calibration management |
US10463288B2 (en) | 2008-03-28 | 2019-11-05 | Abbott Diabetes Care Inc. | Analyte sensor calibration management |
US9730623B2 (en) | 2008-03-28 | 2017-08-15 | Abbott Diabetes Care Inc. | Analyte sensor calibration management |
USD955599S1 (en) | 2009-02-03 | 2022-06-21 | Abbott Diabetes Care Inc. | Analyte sensor inserter |
US11006870B2 (en) | 2009-02-03 | 2021-05-18 | Abbott Diabetes Care Inc. | Analyte sensor and apparatus for insertion of the sensor |
US11006872B2 (en) | 2009-02-03 | 2021-05-18 | Abbott Diabetes Care Inc. | Analyte sensor and apparatus for insertion of the sensor |
US11213229B2 (en) | 2009-02-03 | 2022-01-04 | Abbott Diabetes Care Inc. | Analyte sensor and apparatus for insertion of the sensor |
US11202591B2 (en) | 2009-02-03 | 2021-12-21 | Abbott Diabetes Care Inc. | Analyte sensor and apparatus for insertion of the sensor |
US11006871B2 (en) | 2009-02-03 | 2021-05-18 | Abbott Diabetes Care Inc. | Analyte sensor and apparatus for insertion of the sensor |
USD882432S1 (en) | 2009-02-03 | 2020-04-28 | Abbott Diabetes Care Inc. | Analyte sensor on body unit |
US9636068B2 (en) | 2009-02-03 | 2017-05-02 | Abbott Diabetes Care Inc. | Analyte sensor and apparatus for insertion of the sensor |
USD957643S1 (en) | 2009-02-03 | 2022-07-12 | Abbott Diabetes Care Inc. | Analyte sensor device |
US10786190B2 (en) | 2009-02-03 | 2020-09-29 | Abbott Diabetes Care Inc. | Analyte sensor and apparatus for insertion of the sensor |
US9993188B2 (en) | 2009-02-03 | 2018-06-12 | Abbott Diabetes Care Inc. | Analyte sensor and apparatus for insertion of the sensor |
US11166656B2 (en) | 2009-02-03 | 2021-11-09 | Abbott Diabetes Care Inc. | Analyte sensor and apparatus for insertion of the sensor |
USD957642S1 (en) | 2009-02-03 | 2022-07-12 | Abbott Diabetes Care Inc. | Analyte sensor inserter |
US9402544B2 (en) | 2009-02-03 | 2016-08-02 | Abbott Diabetes Care Inc. | Analyte sensor and apparatus for insertion of the sensor |
US10009244B2 (en) | 2009-04-15 | 2018-06-26 | Abbott Diabetes Care Inc. | Analyte monitoring system having an alert |
US8497777B2 (en) | 2009-04-15 | 2013-07-30 | Abbott Diabetes Care Inc. | Analyte monitoring system having an alert |
US8730058B2 (en) | 2009-04-15 | 2014-05-20 | Abbott Diabetes Care Inc. | Analyte monitoring system having an alert |
US9178752B2 (en) | 2009-04-15 | 2015-11-03 | Abbott Diabetes Care Inc. | Analyte monitoring system having an alert |
US9310230B2 (en) | 2009-04-29 | 2016-04-12 | Abbott Diabetes Care Inc. | Method and system for providing real time analyte sensor calibration with retrospective backfill |
US9186113B2 (en) | 2009-08-31 | 2015-11-17 | Abbott Diabetes Care Inc. | Displays for a medical device |
US11730429B2 (en) | 2009-08-31 | 2023-08-22 | Abbott Diabetes Care Inc. | Displays for a medical device |
US10123752B2 (en) | 2009-08-31 | 2018-11-13 | Abbott Diabetes Care Inc. | Displays for a medical device |
USRE47315E1 (en) | 2009-08-31 | 2019-03-26 | Abbott Diabetes Care Inc. | Displays for a medical device |
US8816862B2 (en) | 2009-08-31 | 2014-08-26 | Abbott Diabetes Care Inc. | Displays for a medical device |
US8514086B2 (en) | 2009-08-31 | 2013-08-20 | Abbott Diabetes Care Inc. | Displays for a medical device |
USD962446S1 (en) | 2009-08-31 | 2022-08-30 | Abbott Diabetes Care, Inc. | Analyte sensor device |
US20110054275A1 (en) * | 2009-08-31 | 2011-03-03 | Abbott Diabetes Care Inc. | Mounting Unit Having a Sensor and Associated Circuitry |
US9549694B2 (en) | 2009-08-31 | 2017-01-24 | Abbott Diabetes Care Inc. | Displays for a medical device |
US10456091B2 (en) | 2009-08-31 | 2019-10-29 | Abbott Diabetes Care Inc. | Displays for a medical device |
US10881355B2 (en) | 2009-08-31 | 2021-01-05 | Abbott Diabetes Care Inc. | Displays for a medical device |
US10772572B2 (en) | 2009-08-31 | 2020-09-15 | Abbott Diabetes Care Inc. | Displays for a medical device |
US11202586B2 (en) | 2009-08-31 | 2021-12-21 | Abbott Diabetes Care Inc. | Displays for a medical device |
US9814416B2 (en) | 2009-08-31 | 2017-11-14 | Abbott Diabetes Care Inc. | Displays for a medical device |
US11241175B2 (en) | 2009-08-31 | 2022-02-08 | Abbott Diabetes Care Inc. | Displays for a medical device |
US10918342B1 (en) | 2009-08-31 | 2021-02-16 | Abbott Diabetes Care Inc. | Displays for a medical device |
US9226714B2 (en) | 2009-08-31 | 2016-01-05 | Abbott Diabetes Care Inc. | Displays for a medical device |
US10765351B2 (en) | 2009-09-30 | 2020-09-08 | Abbott Diabetes Care Inc. | Interconnect for on-body analyte monitoring device |
US11259725B2 (en) | 2009-09-30 | 2022-03-01 | Abbott Diabetes Care Inc. | Interconnect for on-body analyte monitoring device |
US9750444B2 (en) | 2009-09-30 | 2017-09-05 | Abbott Diabetes Care Inc. | Interconnect for on-body analyte monitoring device |
US9351669B2 (en) | 2009-09-30 | 2016-05-31 | Abbott Diabetes Care Inc. | Interconnect for on-body analyte monitoring device |
USD924406S1 (en) | 2010-02-01 | 2021-07-06 | Abbott Diabetes Care Inc. | Analyte sensor inserter |
US10772547B1 (en) | 2010-03-24 | 2020-09-15 | Abbott Diabetes Care Inc. | Medical device inserters and processes of inserting and using medical devices |
US10952657B2 (en) | 2010-03-24 | 2021-03-23 | Abbott Diabetes Care Inc. | Medical device inserters and processes of inserting and using medical devices |
US9186098B2 (en) | 2010-03-24 | 2015-11-17 | Abbott Diabetes Care Inc. | Medical device inserters and processes of inserting and using medical devices |
US9687183B2 (en) | 2010-03-24 | 2017-06-27 | Abbott Diabetes Care Inc. | Medical device inserters and processes of inserting and using medical devices |
US10292632B2 (en) | 2010-03-24 | 2019-05-21 | Abbott Diabetes Care Inc. | Medical device inserters and processes of inserting and using medical devices |
US11013440B2 (en) | 2010-03-24 | 2021-05-25 | Abbott Diabetes Care Inc. | Medical device inserters and processes of inserting and using medical devices |
US9215992B2 (en) | 2010-03-24 | 2015-12-22 | Abbott Diabetes Care Inc. | Medical device inserters and processes of inserting and using medical devices |
US8764657B2 (en) | 2010-03-24 | 2014-07-01 | Abbott Diabetes Care Inc. | Medical device inserters and processes of inserting and using medical devices |
US10881340B2 (en) | 2010-03-24 | 2021-01-05 | Abbott Diabetes Care Inc. | Medical device inserters and processes of inserting and using medical devices |
US10881341B1 (en) | 2010-03-24 | 2021-01-05 | Abbott Diabetes Care Inc. | Medical device inserters and processes of inserting and using medical devices |
US10010280B2 (en) | 2010-03-24 | 2018-07-03 | Abbott Diabetes Care Inc. | Medical device inserters and processes of inserting and using medical devices |
US9265453B2 (en) | 2010-03-24 | 2016-02-23 | Abbott Diabetes Care Inc. | Medical device inserters and processes of inserting and using medical devices |
US11064922B1 (en) | 2010-03-24 | 2021-07-20 | Abbott Diabetes Care Inc. | Medical device inserters and processes of inserting and using medical devices |
USD997362S1 (en) | 2010-03-24 | 2023-08-29 | Abbott Diabetes Care Inc. | Analyte sensor inserter |
US10945649B2 (en) | 2010-03-24 | 2021-03-16 | Abbott Diabetes Care Inc. | Medical device inserters and processes of inserting and using medical devices |
US11000216B2 (en) | 2010-03-24 | 2021-05-11 | Abbott Diabetes Care Inc. | Medical device inserters and processes of inserting and using medical devices |
USD987830S1 (en) | 2010-03-24 | 2023-05-30 | Abbott Diabetes Care Inc. | Analyte sensor inserter |
US11058334B1 (en) | 2010-03-24 | 2021-07-13 | Abbott Diabetes Care Inc. | Medical device inserters and processes of inserting and using medical devices |
US10959654B2 (en) | 2010-03-24 | 2021-03-30 | Abbott Diabetes Care Inc. | Medical device inserters and processes of inserting and using medical devices |
US10959653B2 (en) | 2010-06-29 | 2021-03-30 | Abbott Diabetes Care Inc. | Devices, systems and methods for on-skin or on-body mounting of medical devices |
US10966644B2 (en) | 2010-06-29 | 2021-04-06 | Abbott Diabetes Care Inc. | Devices, systems and methods for on-skin or on-body mounting of medical devices |
US10973449B2 (en) | 2010-06-29 | 2021-04-13 | Abbott Diabetes Care Inc. | Devices, systems and methods for on-skin or on-body mounting of medical devices |
US11064921B2 (en) | 2010-06-29 | 2021-07-20 | Abbott Diabetes Care Inc. | Devices, systems and methods for on-skin or on-body mounting of medical devices |
US9572534B2 (en) | 2010-06-29 | 2017-02-21 | Abbott Diabetes Care Inc. | Devices, systems and methods for on-skin or on-body mounting of medical devices |
US10874338B2 (en) | 2010-06-29 | 2020-12-29 | Abbott Diabetes Care Inc. | Devices, systems and methods for on-skin or on-body mounting of medical devices |
US9743862B2 (en) | 2011-03-31 | 2017-08-29 | Abbott Diabetes Care Inc. | Systems and methods for transcutaneously implanting medical devices |
US9339217B2 (en) | 2011-11-25 | 2016-05-17 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods of use |
US11391723B2 (en) | 2011-11-25 | 2022-07-19 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods of use |
US10082493B2 (en) | 2011-11-25 | 2018-09-25 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods of use |
USD915601S1 (en) | 2011-12-11 | 2021-04-06 | Abbott Diabetes Care Inc. | Analyte sensor device |
US9931066B2 (en) | 2011-12-11 | 2018-04-03 | Abbott Diabetes Care Inc. | Analyte sensor devices, connections, and methods |
USD1036674S1 (en) | 2011-12-11 | 2024-07-23 | Abbott Diabetes Care Inc. | Analyte sensor device |
US9693713B2 (en) | 2011-12-11 | 2017-07-04 | Abbott Diabetes Care Inc. | Analyte sensor devices, connections, and methods |
US9402570B2 (en) | 2011-12-11 | 2016-08-02 | Abbott Diabetes Care Inc. | Analyte sensor devices, connections, and methods |
US11051725B2 (en) | 2011-12-11 | 2021-07-06 | Abbott Diabetes Care Inc. | Analyte sensor devices, connections, and methods |
USD903877S1 (en) | 2011-12-11 | 2020-12-01 | Abbott Diabetes Care Inc. | Analyte sensor device |
US11051724B2 (en) | 2011-12-11 | 2021-07-06 | Abbott Diabetes Care Inc. | Analyte sensor devices, connections, and methods |
USD915602S1 (en) | 2011-12-11 | 2021-04-06 | Abbott Diabetes Care Inc. | Analyte sensor device |
US11179068B2 (en) | 2011-12-11 | 2021-11-23 | Abbott Diabetes Care Inc. | Analyte sensor devices, connections, and methods |
EP4275598A2 (en) | 2012-04-04 | 2023-11-15 | DexCom, Inc. | Applicator and method for applying a transcutaneous analyte sensor |
WO2013152090A2 (en) | 2012-04-04 | 2013-10-10 | Dexcom, Inc. | Transcutaneous analyte sensors, applicators therefor, and associated methods |
WO2013184566A2 (en) | 2012-06-05 | 2013-12-12 | Dexcom, Inc. | Systems and methods for processing analyte data and generating reports |
US11145410B2 (en) | 2012-06-05 | 2021-10-12 | Dexcom, Inc. | Dynamic report building |
US12080414B2 (en) | 2012-06-05 | 2024-09-03 | Dexcom, Inc. | Dynamic report building |
EP3975192A1 (en) | 2012-06-05 | 2022-03-30 | Dexcom, Inc. | Systems and methods for processing analyte data and generating reports |
WO2014004460A1 (en) | 2012-06-29 | 2014-01-03 | Dexcom, Inc. | Use of sensor redundancy to detect sensor failures |
EP4018929A1 (en) | 2012-06-29 | 2022-06-29 | Dexcom, Inc. | Method and system for processing data from a continuous glucose sensor |
US11892426B2 (en) | 2012-06-29 | 2024-02-06 | Dexcom, Inc. | Devices, systems, and methods to compensate for effects of temperature on implantable sensors |
US11737692B2 (en) | 2012-06-29 | 2023-08-29 | Dexcom, Inc. | Implantable sensor devices, systems, and methods |
EP3915465A2 (en) | 2012-06-29 | 2021-12-01 | Dexcom, Inc. | Use of sensor redundancy to detect sensor failures |
EP3767633A1 (en) | 2012-07-09 | 2021-01-20 | Dexcom, Inc. | Systems and methods for leveraging smartphone features in continuous glucose monitoring |
WO2014011488A2 (en) | 2012-07-09 | 2014-01-16 | Dexcom, Inc. | Systems and methods for leveraging smartphone features in continuous glucose monitoring |
EP4075441A1 (en) | 2012-07-09 | 2022-10-19 | Dexcom, Inc. | Systems and methods for leveraging smartphone features in continuous glucose monitoring |
EP4080517A1 (en) | 2012-07-09 | 2022-10-26 | Dexcom, Inc. | Systems and methods for leveraging smartphone features in continuous glucose monitoring |
US11896371B2 (en) | 2012-09-26 | 2024-02-13 | Abbott Diabetes Care Inc. | Method and apparatus for improving lag correction during in vivo measurement of analyte concentration with analyte concentration variability and range data |
US11864891B2 (en) | 2012-09-28 | 2024-01-09 | Dexcom, Inc. | Zwitterion surface modifications for continuous sensors |
EP3782550A1 (en) | 2012-09-28 | 2021-02-24 | Dexcom, Inc. | Zwitterion surface modifications for continuous sensors |
US11179079B2 (en) | 2012-09-28 | 2021-11-23 | Dexcom, Inc. | Zwitterion surface modifications for continuous sensors |
EP4344632A2 (en) | 2012-09-28 | 2024-04-03 | DexCom, Inc. | Zwitterion surface modifications for continuous sensors |
WO2014052080A1 (en) | 2012-09-28 | 2014-04-03 | Dexcom, Inc. | Zwitterion surface modifications for continuous sensors |
EP4231309A2 (en) | 2012-11-07 | 2023-08-23 | DexCom, Inc. | Systems and methods for managing glycemic variability |
EP3654348A1 (en) | 2012-11-07 | 2020-05-20 | Dexcom, Inc. | Systems and methods for managing glycemic variability |
US11744463B2 (en) | 2012-12-31 | 2023-09-05 | Dexcom, Inc. | Remote monitoring of analyte measurements |
US11382508B2 (en) | 2012-12-31 | 2022-07-12 | Dexcom, Inc. | Remote monitoring of analyte measurements |
US10860687B2 (en) | 2012-12-31 | 2020-12-08 | Dexcom, Inc. | Remote monitoring of analyte measurements |
US10869599B2 (en) | 2012-12-31 | 2020-12-22 | Dexcom, Inc. | Remote monitoring of analyte measurements |
US11160452B2 (en) | 2012-12-31 | 2021-11-02 | Dexcom, Inc. | Remote monitoring of analyte measurements |
US10856736B2 (en) | 2012-12-31 | 2020-12-08 | Dexcom, Inc. | Remote monitoring of analyte measurements |
US10993617B2 (en) | 2012-12-31 | 2021-05-04 | Dexcom, Inc. | Remote monitoring of analyte measurements |
US11850020B2 (en) | 2012-12-31 | 2023-12-26 | Dexcom, Inc. | Remote monitoring of analyte measurements |
US11213204B2 (en) | 2012-12-31 | 2022-01-04 | Dexcom, Inc. | Remote monitoring of analyte measurements |
US11109757B2 (en) | 2012-12-31 | 2021-09-07 | Dexcom, Inc. | Remote monitoring of analyte measurements |
US10985804B2 (en) | 2013-03-14 | 2021-04-20 | Dexcom, Inc. | Systems and methods for processing and transmitting sensor data |
EP3401818A1 (en) | 2013-03-14 | 2018-11-14 | Dexcom, Inc. | Systems and methods for processing and transmitting sensor data |
WO2014158405A2 (en) | 2013-03-14 | 2014-10-02 | Dexcom, Inc. | Systems and methods for processing and transmitting sensor data |
EP3806103A1 (en) | 2013-03-14 | 2021-04-14 | Dexcom, Inc. | Advanced calibration for analyte sensors |
EP4220654A1 (en) | 2013-03-14 | 2023-08-02 | Dexcom, Inc. | Systems and methods for processing and transmitting sensor data |
US11677443B1 (en) | 2013-03-14 | 2023-06-13 | Dexcom, Inc. | Systems and methods for processing and transmitting sensor data |
US12052067B2 (en) | 2013-03-14 | 2024-07-30 | Dexcom, Inc. | Systems and methods for processing and transmitting sensor data |
US12081287B2 (en) | 2013-03-14 | 2024-09-03 | Dexcom, Inc. | Systems and methods for processing and transmitting sensor data |
WO2014158327A2 (en) | 2013-03-14 | 2014-10-02 | Dexcom, Inc. | Advanced calibration for analyte sensors |
EP4235684A1 (en) | 2013-03-14 | 2023-08-30 | Dexcom, Inc. | Systems and methods for processing and transmitting sensor data |
US12081288B2 (en) | 2013-03-14 | 2024-09-03 | Dexcom, Inc. | Systems and methods for processing and transmitting sensor data |
US11998329B2 (en) | 2013-03-15 | 2024-06-04 | Dexcom, Inc. | Membrane for continuous analyte sensors |
EP4257044A2 (en) | 2014-04-10 | 2023-10-11 | DexCom, Inc. | Sensor for continuous analyte monitoring |
WO2015156966A1 (en) | 2014-04-10 | 2015-10-15 | Dexcom, Inc. | Sensors for continuous analyte monitoring, and related methods |
US10674944B2 (en) | 2015-05-14 | 2020-06-09 | Abbott Diabetes Care Inc. | Compact medical device inserters and related systems and methods |
USD980986S1 (en) | 2015-05-14 | 2023-03-14 | Abbott Diabetes Care Inc. | Analyte sensor inserter |
US10213139B2 (en) | 2015-05-14 | 2019-02-26 | Abbott Diabetes Care Inc. | Systems, devices, and methods for assembling an applicator and sensor control device |
EP4046571A1 (en) | 2015-10-21 | 2022-08-24 | Dexcom, Inc. | Transcutaneous analyte sensors, applicators therefor, and associated methods |
EP4378390A2 (en) | 2015-10-21 | 2024-06-05 | Dexcom, Inc. | Transcutaneous analyte sensors, applicators therefor, and associated methods |
US11399721B2 (en) | 2015-12-28 | 2022-08-02 | Dexcom, Inc. | Systems and methods for remote and host monitoring communications |
US10932672B2 (en) | 2015-12-28 | 2021-03-02 | Dexcom, Inc. | Systems and methods for remote and host monitoring communications |
EP4324921A2 (en) | 2015-12-30 | 2024-02-21 | Dexcom, Inc. | Biointerface layer for analyte sensors |
EP4292528A1 (en) | 2015-12-30 | 2023-12-20 | Dexcom, Inc. | Membrane layers for analyte sensors |
US11112377B2 (en) | 2015-12-30 | 2021-09-07 | Dexcom, Inc. | Enzyme immobilized adhesive layer for analyte sensors |
EP4253536A2 (en) | 2015-12-30 | 2023-10-04 | DexCom, Inc. | Diffusion resistance layer for analyte sensors |
EP3895614A1 (en) | 2015-12-30 | 2021-10-20 | Dexcom, Inc. | Enzyme immobilized adhesive layer for analyte sensors |
US10980453B2 (en) | 2016-03-31 | 2021-04-20 | Dexcom, Inc. | Systems and methods for display device and sensor electronics unit communication |
US10980450B2 (en) | 2016-03-31 | 2021-04-20 | Dexcom, Inc. | Systems and methods for display device and sensor electronics unit communication |
US10799157B2 (en) | 2016-03-31 | 2020-10-13 | Dexcom, Inc. | Systems and methods for display device and sensor electronics unit communication |
US10881335B2 (en) | 2016-03-31 | 2021-01-05 | Dexcom, Inc. | Systems and methods for display device and sensor electronics unit communication |
US10980451B2 (en) | 2016-03-31 | 2021-04-20 | Dexcom, Inc. | Systems and methods for display device and sensor electronics unit communication |
US10568552B2 (en) | 2016-03-31 | 2020-02-25 | Dexcom, Inc. | Systems and methods for display device and sensor electronics unit communication |
US10561349B2 (en) | 2016-03-31 | 2020-02-18 | Dexcom, Inc. | Systems and methods for display device and sensor electronics unit communication |
US11071478B2 (en) | 2017-01-23 | 2021-07-27 | Abbott Diabetes Care Inc. | Systems, devices and methods for analyte sensor insertion |
EP3928688A1 (en) | 2017-06-23 | 2021-12-29 | Dexcom, Inc. | Transcutaneous analyte sensors, applicators therefor, and associated methods |
US11504063B2 (en) | 2017-06-23 | 2022-11-22 | Dexcom, Inc. | Transcutaneous analyte sensors, applicators therefor, and associated methods |
EP4111949A1 (en) | 2017-06-23 | 2023-01-04 | Dexcom, Inc. | Transcutaneous analyte sensors, applicators therefor, and needle hub comprising anti-rotation feature |
US11395631B2 (en) | 2017-06-23 | 2022-07-26 | Dexcom, Inc. | Transcutaneous analyte sensors, applicators therefor, and associated methods |
US11311241B2 (en) | 2017-06-23 | 2022-04-26 | Dexcom, Inc. | Transcutaneous analyte sensors, applicators therefor, and associated methods |
US11510625B2 (en) | 2017-06-23 | 2022-11-29 | Dexcom, Inc. | Transcutaneous analyte sensors, applicators therefor, and associated methods |
EP4008240A1 (en) | 2017-06-23 | 2022-06-08 | Dexcom, Inc. | Transcutaneous analyte sensors, applicators therefor, and associated methods |
EP3925522A1 (en) | 2017-06-23 | 2021-12-22 | Dexcom, Inc. | Transcutaneous analyte sensors, applicators therefor, and associated methods |
US11706876B2 (en) | 2017-10-24 | 2023-07-18 | Dexcom, Inc. | Pre-connected analyte sensors |
US11943876B2 (en) | 2017-10-24 | 2024-03-26 | Dexcom, Inc. | Pre-connected analyte sensors |
US11382540B2 (en) | 2017-10-24 | 2022-07-12 | Dexcom, Inc. | Pre-connected analyte sensors |
US11350862B2 (en) | 2017-10-24 | 2022-06-07 | Dexcom, Inc. | Pre-connected analyte sensors |
US11331022B2 (en) | 2017-10-24 | 2022-05-17 | Dexcom, Inc. | Pre-connected analyte sensors |
USD1036676S1 (en) | 2018-06-22 | 2024-07-23 | Dexcom, Inc. | Wearable medical monitoring device |
USD1002852S1 (en) | 2019-06-06 | 2023-10-24 | Abbott Diabetes Care Inc. | Analyte sensor device |
USD1006235S1 (en) | 2020-12-21 | 2023-11-28 | Abbott Diabetes Care Inc. | Analyte sensor inserter |
USD999913S1 (en) | 2020-12-21 | 2023-09-26 | Abbott Diabetes Care Inc | Analyte sensor inserter |
USD982762S1 (en) | 2020-12-21 | 2023-04-04 | Abbott Diabetes Care Inc. | Analyte sensor inserter |
US12125588B2 (en) | 2021-04-28 | 2024-10-22 | Dexcom Inc. | Systems and methods for processing and transmitting sensor data |
Also Published As
Publication number | Publication date |
---|---|
JP4317519B2 (en) | 2009-08-19 |
EP1506307A1 (en) | 2005-02-16 |
US8053018B2 (en) | 2011-11-08 |
US20160022186A1 (en) | 2016-01-28 |
US20140378798A1 (en) | 2014-12-25 |
US7226978B2 (en) | 2007-06-05 |
US20100119693A1 (en) | 2010-05-13 |
US20030217966A1 (en) | 2003-11-27 |
US9179869B2 (en) | 2015-11-10 |
US8050731B2 (en) | 2011-11-01 |
WO2003100083A1 (en) | 2003-12-04 |
US20060086624A1 (en) | 2006-04-27 |
AU2003229330A1 (en) | 2003-12-12 |
US8865249B2 (en) | 2014-10-21 |
US9801574B2 (en) | 2017-10-31 |
US20190083018A1 (en) | 2019-03-21 |
US20180014765A1 (en) | 2018-01-18 |
US10154807B2 (en) | 2018-12-18 |
US20130030273A1 (en) | 2013-01-31 |
JP2005531755A (en) | 2005-10-20 |
US20060068208A1 (en) | 2006-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10154807B2 (en) | Techniques to improve polyurethane membranes for implantable glucose sensors | |
US5777060A (en) | Silicon-containing biocompatible membranes | |
US6642015B2 (en) | Hydrophilic polymeric material for coating biosensors | |
CN102762740B (en) | Analyte sensors comprising blended membrane compositions and methods for making and using them | |
AU658450B2 (en) | Hydrophilic polyurethane membranes for electrochemical glucose sensors | |
EP1669022A2 (en) | Sensor head for monitoring glucose for use with implantable devices | |
WO1992013271A1 (en) | Implantable biological fluid measuring device | |
WO2006018425A2 (en) | Multiphase biocompatible semi-permeable membrane for biosensors | |
US20170347933A1 (en) | Polycarbonate urea/urethane polymers for use with analyte sensors | |
US12109023B2 (en) | Thermally stable glucose limiting membrane for glucose sensors | |
WO1998013685A1 (en) | Silicon-containing biocompatible membranes | |
WO2004060297A2 (en) | Hydrophilic cross-linking agents for use in enzymatic sensors | |
JP4098364B2 (en) | Silicon-containing biocompatible membrane | |
CA2238005C (en) | Silicon-containing biocompatible membranes | |
JP2000500691A (en) | Silicon-containing biocompatible membrane |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: DEXCOM, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TAPSAK, MARK A.;RHODES, RATHBUN K.;SHULTS, MARK C.;AND OTHERS;SIGNING DATES FROM 20020516 TO 20020521;REEL/FRAME:027140/0506 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |